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Zusammenfassung 
Das K15 Gen des Kaposi Sarkom-assoziierten Herpesvirus (KSHV) besteht aus acht 
alternativ gespleissten Exons und kann potentiell für Transmembranproteine mit einer 
variablen Anzahl von Membrandomänen und einem cytoplasmatischen C-Terminus kodieren. 
Die C-terminale Domäne weist Bindungsmotive für Proteine mit SH2- und SH3-Domänen, 
und für Tumor Nekrose Faktor Rezeptor-assoziierte Faktoren (TRAFs) auf. Diese 
Eigenschaften erinnern an Transmembranproteine weiterer Vertreter der γ-Herpesviren wie 
Epstein-Barr Virus, Herpesvirus saimiri, Herpesvirus ateles und Rhesus Rhadinovirus. Diese 
γ-Herpesviren kodieren für Membranproteine, die intrazelluläre Signalkaskaden aktivieren 
können. In dieser Arbeit wurden die vom offenen Leserahmen K15 kodierten Proteine 
hinsichtlich ihrer zellulären Lokalisation und Signaleigenschaften charakterisiert. Desweiteren 
wurde die in vivo Expression von K15 Proteinen in einer Reihe von KSHV-infizierten Zell-
Linien untersucht. 
Es wurde gezeigt, dass ein 45 kDa K15 Protein von einem cDNA Konstrukt mit allen acht 
Exons exprimiert wird, das potentiell aus bis zu zwölf Transmembrandomänen besteht. 
Dieses Protein ist membranassoziiert und lokalisiert zum Teil in Membran-Mikrodomänen, 
sogenannten Lipid Rafts. Unter Verwendung von dominant negativen Mutanten und 
chemischen Inhibitoren wurde gezeigt, dass das 45 kDa K15 Protein den AP-1 
Transkriptionsfaktor über den klassischen „Mitogen-activated protein kinase“ (MAPK) 
Signalweg (Ras-Raf-MEK-Erk) aktiviert. Zusätzlich wird die Aktivität der MAP kinase JNK1 
und des Transkriptionsfaktors NF-κB von K15 induziert. Die Mitglieder der Src Familie der 
Protein Tyrosin Kinasen Src, Lck, Yes, Hck und Fyn interagieren mit der cytoplasmatischen 
Domäne des K15 Proteins und phosphorylieren das Y481 des potentiellen SH2-Bindemotives 
Y481EEV. Ein K15 Expressionskonstrukt mit der Punktmutation Y481 zu F481 vermag weder 
die Transkriptionsfaktoren AP-1 und NF-κB, noch die MAP Kinasen Erk2 und JNK1 zu 
aktivieren, was auf eine wichtige Rolle der Phosphorylierung von K15 bei der 
Signaltransduktion hindeutet. Frühere Experimente zeigten, dass K15 mit TRAFs interagiert 
(Glenn et al., 1999). Eine dominant negative TRAF-2 Mutante inhibiert die K15 
Signaltransduktion, was auf eine Rolle von TRAF-2 bei der Signalweiterleitung von K15 
hindeutet. Ferner aktiviert das 45 kDa K15 Protein den Promotor des RTA Proteins von 
KSHV, und diese Aktivierung erfolgt über den Ras/MAPK Signalweg. K15 Spleissvarianten, 
die Proteine mit einer geringeren Anzahl an Transmembrandomänen exprimieren, waren nicht 
in der Lage, die von dem 45 kDa K15 Protein induzierten Signalwege zu aktivieren. Dies 
weist auf eine wichtige Rolle der Transmembrandomänen des K15 Proteins bei der 
Signaltransduktion hin. In KSHV-infizierten B Zellen wurde mit einem Antikörper gegen die 
cytoplasmatische Domäne von K15 ein 23 kDa Protein detektiert. Dieses Protein war jedoch 
nicht mit zellulären Membranen assoziiert. In de novo KSHV-infizierten 293-T Zellen konnte 
erstmals die Expression von K15 Transkripten mittels RT-PCR nachgewiesen werden. 
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Summary 
The K15 gene of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8 
(KSHV/HHV-8), encoded at the right end of the genome, consists of eight alternatively 
spliced exons and is predicted to encode membrane proteins with a variable number of 
transmembrane regions and a common C-terminal cytoplasmic domain with putative binding 
sites for SH2- and SH3- binding domains, as well as for TRAFs. These features are 
reminiscent of the viral terminal membrane proteins of other γ-herpesviruses Epstein-Barr 
virus, Herpesvirus saimiri, Herpesvirus ateles and Rhesus Rhadinovirus. Their terminal 
membrane proteins can activate a number of intracellular signaling pathways. The aim of this 
work was to functionally characterise the proteins derived from the KSHV K15 ORF 
concerning their localisation in transiently transfected cells, their ability to initiate 
intracellular signaling and to analyse K15 protein expression in vivo in KSHV infected cell 
lines. 
A 45 kDa K15 protein derived from all eight K15 exons and containing up to 12 predicted 
transmembrane domains in addition to the cytoplasmic domain was shown to be associated 
with cellular membranes and to localise to lipid rafts. As shown with dominant negative 
mutants and chemical inhibitors, this K15 protein activated the AP-1 transcription factor via 
the classical Mitogen-activated Protein Kinase (MAPK) pathway Ras-Raf-MEK-Erk2 and the 
MAPK JNK1. Furthermore, the eight exon K15 protein activated the transcription factor NF-
κB. Members of the Src family of non-receptor protein tyrosine kinases (PTK) Src, Lck, Yes, 
Hck and Fyn were shown to bind to the cytoplasmic C-terminal domain of K15 and to 
phosphorylate the tyrosine residue in the putative SH2-binding motif Y481EEV. A K15 
construct carrying the point mutation Y481 to F481 was unable to activate the transcription 
factors AP-1 and NF-κB, pointing to a role of tyrosine phosphorylation by PTKs in K15 
signaling. Earlier experiments showed that TRAFs-1, -2 and -3 bind to the cytoplasmic 
domain of K15. A dominant negative TRAF-2 mutant inhibited the K15-mediated activation 
of the Ras/MAPK pathway, suggesting an involvement of TRAF-2 in the inititation of these 
signaling routes. Furthermore, the eight exon K15 protein was shown to activate the promoter 
of the KSHV gene ORF50/Rta, and this involved the Ras/MAPK pathway and TRAF-2. In 
addition to the eight exon K15 isoform, several splice variants are derived from the K15 ORF 
that are predicted to encode proteins with fewer transmembrane domains. These K15 splice 
variants, although containing the intact cytoplasmic domain like the 45 kDa K15 protein, 
activated the MAPK and NF-κB pathways only weakly. Therefore, the transmembrane region 
of K15 seems to be important for efficient signaling. 
In B-cells naturally infected with KSHV, a 23 kDa protein was detected with K15 
antiserum. However, unlike an experimentally generated K15 variant of this size, this protein 
was not associated with cellular membranes. K15 transcripts were also identified by RT-PCR 
in de novo KSHV-infected HEK 293-T cells one day post infection. 
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1 Introduction 
1.1 The Family Herpesviridae 
Herpesviruses are highly disseminated in nature and most animal species have yielded at 
least one but frequently several herpesviruses. Members of the Herpesviridae share a common 
virion morphology and several significant biological properties. A typical herpes virion 
consists of a core containing a double-stranded linear viral DNA, an icosahedral capsid (100-
110 nm in diameter) containing 162 capsomers, the tegument which is surrounding the capsid, 
and an envelope in which viral glycoproteins are embedded (reviewed in Roizman & Pellett 
2002). 
 
Biological properties: 
1. All herpesviruses encode a large array of enzymes involved in nucleic acid metabolism, 
DNA synthesis and processing of proteins. 
2. The synthesis of viral DNA and capsid assembly occurs in the nucleus. 
3. Production of infectious progeny virus is invariably accompanied by the destruction of the 
infected cell (lytic viral life cycle). 
4. Herpesviruses are able to establish a latent infection in their natural hosts. In latently 
infected cells, viral genomes take the form of closed circular molecules (termed episomes), 
and only a small subset of viral genes are expressed (latent viral life cycle). Latent genomes 
retain the capacity to replicate upon reactivation. 
 
Thus far, eight herpesviruses have been isolated from humans (human herpesvirus 1-8 
[HHV-1 to -8]), and they have been categorized into three subfamilies according to their 
pathogenicity, host cells, replication characteristics and nucleotide sequence: 
 
• α-herpesvirinae have a wide host cell range, multiply efficiently, rapidly spread in culture, 
efficiently destroy the cells they infect productively and are capable of establishing latent 
infections primarily but not exclusively in sensory ganglia (Simplexvirus Herpes simplex 
virus I and II [HSV-I, HSV-II], and Varicellovirus Varizella zoster virus [VZV or HHV-3]). 
• β-herpesvirinae show a more restricted host range and grow slowly in cell culture. Infected 
cells become enlarged and carrier cultures are readily established. The virus latently infects 
secretory glands, lymphoreticular cells, kidneys and other tissues (Cytomegalovirus 
Cytomegalovirus [CMV or HHV-5], Roseolovirus HHV-6 and HHV-7). 
• γ-herpesvirinae replicate in lymphoid cells in vitro and in vivo, being either specific for T- 
or B-lymphocytes. Latent virus is frequently demonstrated in lymphoid tissue. This subfamily 
contains two genera: Lymphocryptovirus (Epstein-Barr virus [EBV or HHV-4]) and 
Rhadinovirus (Kaposi´s sarcoma-associated herpesvirus [KSHV or HHV-8]). EBV and 
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KSHV both also infect epithelial cells, and KSHV can be detected in myeloid cells 
(monocytes, macrophages), keratinocytes and endothelial cells in vivo. 
 
Herpesvirions vary in size from 120 to nearly 300 nm, and the viral DNA is variable 
concerning length (120-250 kb), base composition (31-75% total GC content) and copy 
number of terminal and internal reiterated sequences. Most herpesvirus genes contain a 
promoter/regulatory sequence spanning 50-200 bp upstream of a TATA box, a transcription 
initiation site 20-25 bp downstream of the TATA box, a 5´ nontranslated leader sequence of 
30-300 bp, a single open rading frame (ORF), 10-30 bp of 3´ nontranslated sequence and a 
canonical polyadenylation signal. However, exceptions for this genetic architecture exist: 
genes without a TATA box (Chou & Roizman, 1986) and initiation from a second in-frame 
methionine (Markovitz et al., 1999) have been described. In addition, ORFs can be expressed 
that are situated entirely antisense to each other (Lagunoff & Roizman, 1994), gene overlaps 
are common, and each herpesvirus encodes a handful of spliced genes and can encode 
noncoding RNAs (reviewed in Roizman & Pellett 2002). 
Between 70 (smallest genome) and over 200 (largest genome) gene products are encoded by 
Herpesviruses. Herpesvirus proteins frequently have multiple functions. In addition to viral 
proteins being involved in viral replication, establishment/maintenance of latency or 
reactivation from latency, an armamentarium of viral proteins is expressed to fend off the host 
cell defenses to infection (e.g. inhibition of apoptosis, blocking the activation of the interferon 
pathway). 
Herpesviruses encode at least one gene of obvious host origin. In some cases, the host-
acquired genes retain a function similar to their cellular counterparts, in other cases they have 
altered functions. KSHV for example encodes several “captured” cellular genes such as the 
viral G-protein coupled receptor (vGPCR), which is constitutively active and capable of 
transforming cells, or viral cyclin (vcyc) which is homologous to cellular D-type cyclin (see 
1.2). 
1.2 The Kaposi´s sarcoma-associated herpesvirus (KSHV) 
The eighth human herpesvirus, Kaposi´s sarcoma-associated herpesvirus (KSHV or HHV-
8), is the most recently discovered human DNA tumour virus. KSHV was originally isolated 
from Kaposi´s sarcoma (KS) tissues by representional difference analysis in 1994 by Chang et 
al. Today, the available epidemiological and molecular evidence strongly suggests that KSHV 
is the cause of three human neoplastic disorders, namely Kaposi´s sarcoma (Moore & Chang 
1995, reviewed in Schulz 2000), a very rare form of B-cell lymphoma called body cavity-
based lymphoma (BCBL) or primary effusion lymphoma (PEL) (Cesarman et al., 1995) and 
the plasma cell variant of multicentric Castleman´s disease (MCD) (Soulier et al., 1995). 
The KSHV genome consists of a long unique coding region of 140 kb (GC content ~54%), 
which is flanked by 801 bp terminal tandem repeats rich in GC (85%), the so called terminal 
   3
repeats (total length varying between 20-30 kb, see figure 1) (Neipel et al., 1997, Russo et al., 
1996). More than 90 putative KSHV open reading frames are described in the literature today. 
As for other members of the genus rhadinovirus, many KSHV genes have been described 
which show homologies to cellular genes implicated in signal transduction, cell cycle control 
and apoptosis. 
Role of KSHV in neoplastic disease 
Kaposi´s sarcoma 
Kaposi´s sarcoma exclusively develops in KSHV-infected individuals. However, classic KS 
is a rare tumour in immunocompetent KSHV-infected individuals, while KS is much more 
common in immunosuppressed patients, e.g. HIV-infected patients (AIDS-KS) or transplant 
recipients. 
In Africa, endemic KS (i.e. the clinically severe form of KS in HIV negative individuals) is 
mainly found in East and Central Africa, in spite of a high KSHV prevalence in most sub-
Saharan Africa (reviewed in Dedicoat & Newton, 2003), which suggests the existence of 
other co-factors that promote KS development in KSHV positive individuals (reviewed in 
Schulz 2000). 
The natural reservoir for KSHV are endothelial cell-derived spindle cells which are the 
neoplastic components of the KS tumour (Boshoff et al., 1995, Rainbow et al., 1997, 
reviewed in Schulz 2001). In these cells, four latent viral genes are expressed: ORF73/Lana-1, 
ORF K12/kaposin, ORF K13/vFLIP, ORF72/vcyclin (see figure 1 and below). The major 
population of spindle cells harbours viral episomes, however, in some spindle cells KSHV is 
not strictly latent but undergoes lytic replication (Staskus et al., 1997, Katano et al., 2000, 
Parravicini et al., 2000). Whereas other human DNA tumour viruses are thought to use viral 
proteins expressed during latency to induce proliferation and tumourigenesis, it seems that 
KSHV lytic genes, which experimentally appear to have the potential to promote 
tumourigenesis, contribute to the development of KS (see below). 
Primary effusion lymphoma 
Primary effusion lymphoma is a rare lymphoma in AIDS patients, and the presence of 
KSHV is considered an essential criterion for the diagnosis of PEL. In PEL cells, the latent 
genes Lana-1, vFLIP, vcyclin and kaposin are expressed (Rainbow et al., 1997, Parravicini et 
al., 2000, Katano et al., 2000, see figure 1). Lytic gene expression has been detected in a small 
subset of cells: the viral interleukin 6 homologue (vIL-6) was detected in 2-5% of tumour 
cells, whereas viral lytic proteins (see below) K8/kbZIP, the viral membrane glycoprotein 
K8.1, the three viral interferon regulatory factors (vIRF) K9, K10, K11, a viral processivity 
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factor ORF59/PF-8 and the minor capsid protein ORF65 were detected in less than 1% of 
PEL cells (Parravicini et al., 2000, Katano et al., 2000). 
Multicentric Castleman´s diesease 
Compared to PEL and KS tissue, KSHV appears to adopt a less restrictive pattern of gene 
expression in MCD, jugded by the detection of a number of lytic genes in a significant 
number of cells (Parravicini et al., 2000, Katano et al., 2000). This would suggest that MCD 
could represent the active viral lytic replication in lymphoid tissue. 
Epidemiology of KSHV 
Currently available seroepidemiology data indicate that KSHV is relatively rare in most 
northern, western and central European countries, the USA and Asian countries, with less 
than 5% of blood donors having antibodies. KSHV infection is more frequently found in the 
general population in Italy with prevalence rates of 30% in Sicily and south Italy (Calabro et 
al., 1998), Greece, Israel and Spain, but by far the highest frequency is found in most African 
countries, particularly in sub-Saharan Africa. Antibodies to KSHV are detected in 50-60% of 
adults and adolescents in most parts of sub-Saharan Africa investigated so far and 20-40% in 
South Africa. However, endemic KS, the HIV-negative variant of classic KS, appears to be 
more common in East Africa than in other parts of Africa, which implies the role of certain, 
yet unidentified co-factors associated with endemic KS (reviewed in Schulz 2001). 
In western countries, KSHV seroprevalence rates range between 20-40% among 
homosexual men, but are significantly lower (below 5-10%) in HIV-infected intravenous drug 
users, women and patients with hemophilia. KS develops in 50% of KSHV and HIV infected 
homosexual men (Renwick et al., 1998, Jacobsen et al., 2000). In contrast, KSHV infection in 
immunocompotent individuals in Europe is rarely associated with disease, whereas 
occasionally observed in immunosuppressed patients (e.g. transplant patients). Despite a 
KSHV seroprevalence of 30% in Sicily, only very few individuals develop classic KS 
(population based incidence 3/100.000, Calabro et al., 1998). 
Evolution 
Based on sequence information and phylogenetic comparisons, KSHV has been placed with 
the γ2-subfamily of herpesviruses, the rhadinoviruses. Following the discovery of KSHV, 
closely related rhadinoviruses have been identified in many non-human primates. Today, 
three branches of rhadinovirus are described based on phylogenetic analysis of the viral DNA 
polymerase genes, namely rhadinovirus 1 subgroup (RV-1) including KSHV and closely 
related viruses being found in Old World primate species (chimpanzee PanRHV1, gorilla 
GoRHV1, mandrill MnRHV1, African green monkey ChRV1 and macaque RFHVMm, 
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RFHVMn), a second group called RV-2 comprising slightly more distantly related γ2-
herpesviruses (chimpanzee PanRHV2, mandrill MnRHV2, African green monkey ChRV2, 
macaque RRV) and a third branch of the New World primate γ2-herpesviruses Herpesvirus 
saimiri (HVS) and Herpesvirus ateles (HVA) (reviewed in Greensill & Schulz, 2000). 
The study of genomic variation of KSHV isolates has revealed the existence of particular 
KSHV variants in certain geographic regions, suggesting that KSHV has co-evolved with 
human populations. This is best illustrated by the pattern of variability found in the K1 gene 
at the left side of the KSHV genome (see figures 1 and 2), and today K1 variants are grouped 
into four or five major clades designated A-E (see 1.3.5). In addition, two highly diverged 
alternative allelic forms of the ORF K15 region, located at the right end of the KSHV 
genome, have been identified. They are referred to as predominant K15 (K15-P) and minor 
K15 (K15-M). K15-P and K15-M only share 33% identity at the amino acid level (see 1.3.6 
and figures 1-3 and 5, Poole et al., 1999). It seems probable that the 33% identity between 
K15-P and K15-M represents a level of evolutionary divergence that is consistent with an 
origin for one of them by recombination with a related virus from another great ape, another 
Old World primate species, or even a more distant host species. 
Transmission 
KSHV can be efficiently transmitted in childhood (Mayama et al., 1998, Gessain et al., 
1999, Andreoni et al., 1999, Plancoulaine et al., 2000, Bourboulia et al., 1998), and given the 
excretion of KSHV in saliva, it is conceivable, but not yet proven, that KSHV can be 
transmitted by saliva from mother to child or sibling to sibling (Andreoni et al., 2002). Recent 
findings demonstrate an association between high viral DNA copy number in maternal saliva 
and transmission to her child (Dedicoat et al., 2004). While in endemic countries or 
populations the majority of infections appears to occur before puberty, transmission during 
adulthood accounts for most infections in non-endemic countries. Several studies indicate 
sexual contact being an important route of infection, especially among homosexual men. 
Parenteral transmission is discussed controversely, but among transplant patients, KSHV 
transmission through transplanted organs has been clearly documented (Regamey et al., 1998, 
Luppi et al., 2000). However, most cases of transplant KS appear to be due to reactivation of a 
pre-existing KSHV infection (reviewed in Luppi et al., 2002). 
Virus culture 
Several groups succeeded in establishing persistently infected PEL cell lines, which are 
infected with KSHV only or co-infected with EBV. In some PEL cell lines, only latent genes 
are expressed (e.g. BCP-1, BCBL-1), but in others KSHV will spontaneously switch into the 
lytic cycle (Jsc-1, ISI). The lytic viral replication cycle can also be artificially induced by the 
addition of the phorbol esters 12-O-tetradecanoylphorbol-13-acetate (TPA) or n-butyrate 
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(Miller et al., 1997a, Renne et al., 1996). A major drawback is the little in vitro infectivity of 
KSHV obtained from lytically induced PEL cell lines and the lack of an animal model. 
However, investigators succeeded in infecting the epithelial cell line 293 (Foreman et al., 
1997, Renne et al., 1998), primary endothelial cell cultures (Cannon et al., 2000, Ciufo et al., 
2001), endothelial cell lines immortalised by either human papillomavirus E6/E7 proteins 
(Moses et al., 1999) or telomerase (TIME cells; Lagunoff et al., 2002), human and murine 
fibroblasts, HeLa and the endothelial SLK cell line (Bechtel et al., 2003). Intriguingly, 
successful infection of human lymphoblastoid cells has not been achieved by some (Bechtel et 
al., 2003), whereas others have reported successful infection of primary B-cells which were 
simultaneously exposed to EBV and KSHV (Kliche et al., 1998). Infectious KSHV can be 
produced from 293 and TIME cells being provided in trans with a plasmid coding for the 
viral lytic transactivator RTA (regulator of transcriptional activation, see below; Bechtel et al., 
2003). 
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Figure 1: Schematic presentation of the KSHV genome. The long unique region, which codes for more than 
90 open reading frames, encompasses 140 kb and is flanked by terminal repeat regions which consist of several 
803 bp repeat subunits. The total length of the TR region of KSHV comprises 20-30 kbp. Boxes I – IV” indicate 
conserved genes within the group of herpesviruses. ORFs are colour-coded to distinguish between genes 
expressed during the latent or lytic viral life cycle. ORFs unique for KSHV are designated with the prefix “K” 
(K1-K15). 
Pathogenesis 
KSHV has the capacity to interfere with the control of cellular proliferation and to fend off 
the immune response. The next section will focus on the biochemical and cell biological 
features of individual KSHV proteins involved in cell entry, latent and lytic replication, 
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regulation of the cell cycle and apoptosis, angiogenesis, B-cell proliferation, and manipulation 
of the host immune system. Several KSHV proteins, as for example LANA-1 and vIRFs, play 
multiple roles in the manipulation of cellular functions. 
Cell entry 
KSHV shows a wide tropism in vitro (Vieira et al., 2001, Renne et al., 1998, Cerimele et al., 
2001, Flore et al., 1998, Lagunoff et al., 2002, Moses et al., 1999), which may be due to its 
interaction with the ubiquitous host cell surface molecule heparan sulfate via viral 
glycoproteins gB and gK8.1 (Akula et al., 2001a, b, Birkmann et al., 2001, Wang et al., 
2001). In addition, KSHV gB contains an RGD (arg-gly-asp) motif which binds specifically 
to α3β1 integrin, which is also broadly expressed and has been detected on all cells susceptible 
to infection with KSHV (Akula et al., 2002, Wang et al., 2003a). Upon infection, the integrin-
mediated activation of focal adhesion kinase (FAK) is induced, implicating a role for integrin 
not solely as a receptor for KSHV but also in the induction of signaling pathways inducing 
morphological changes and cytoskeletal rearrangements allowing entry of the virus (Naranatt 
et al., 2003). FAK phosphorylation appears to be induced by gB (Akula et al., 2002, Naranatt 
et al., 2003). In early stages of cell entry, cellular phosphatidylinositol 3-kinase (PI3K) seems 
to play a role, and cellular kinases protein kinase C-ζ (PKC-ζ) and Erk (extracellular signal 
regulated kinase) are involved in later stages of entry (Naranatt et al., 2003). Two reports 
described KSHV entry into epithelial 293-T cells (Inoue et al., 2003) and fibroblasts (Akula et 
al., 2003) to occur via endocytosis. However, in 293-T cells endocytosis of KSHV seems to 
be neither clathrin nor caveolae-dependent, whereas KSHV uses clathrin-mediated 
endocytosis for its entry into fibroblasts. The modulation of host cell gene expression after 
KSHV entry is diverse, with obvious differences in endothelial versus B-cells (Naranatt et al., 
2004). 
Latent replication 
Latency is defined by the presence of episomal, extrachromosomal viral DNA in the cell 
nucleus with a restricted pattern of gene expression and absence of virion production (Judde 
et al., 2000). Five viral genes have been described to be expressed during KSHV latency, 
(colour coded in red in figure 1): the latency-associated nuclear antigen 1 (Lana-1/ORF73), 
the viral homologue of a D-type cyclin viral cyclin (vcyc/ORF72), a homologue of the FLICE 
(Fas-associated death domain-like IL-1-converting enzyme) apoptosis complex viral FLIP 
(viral FLICE inhibitory protein vFLIP/ORF71, K13), a group of membrane-associated 
proteins called kaposin A, B and C (K12) and an interferon regulatory factor (IRF) 
homologue designated Lana-2 (vIRF3/K10.5) (Jenner et al., 2001, Rivas et al., 2001). Among 
the proteins encoded by these five genes, only Lana-1 has been detected in all KSHV-infected 
cells (Rainbow et al., 1997, Katano et al., 2000). LANA-2 protein has only been detected in 
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infected B-cells in vivo and in vitro, suggesting a tissue-specific latency pattern for B-cells 
(Rivas et al., 2001). 
Lana-1 is required for the persistence of the viral episome. It tethers viral episomes to host 
chromatin by binding to two motifs of 16 nucleotides within the terminal repeat subunits via 
its C-terminal region and to heterochromatin via its N-terminus (Garber et al., 2002, Ballestas 
et al., 1999, Viejo-Borbolla et al., 2003). In addition, LANA-1 has a role in the replication of 
latent episomes (Garber et al., 2002, reviewed in Viejo-Borbolla & Schulz 2003), and binds to 
p53 and retinoblastoma protein, thereby inhibiting activation of p53-dependent promoters and 
inducing activation of E2F-dependent genes (Friborg et al., 1999, Radkov et al., 2000). 
Furthermore, LANA-1 acts as a transcriptional activator and repressor (Garber et al., 2001, 
2002, Renne et al., 2001, Hyun et al., 2001, Radkov et al., 2000, Groves et al., 2001, An et al., 
2002, Krithivas et al., 2000, Schwam et al., 2000, Jeong et al., 2001, reviewed in Viejo-
Borbolla & Schulz 2003) and interacts with RING3 (Platt et al., 1999) and other members of 
the BET family of cellular proteins. Two members of the BET family are known to be 
involved in cell cycle regulation. In addition, LANA-1 promotes S-phase entry probably by 
its interaction with the kinase GSK-3β (Fujimoro et al., 2003). Lana-1 has been shown to 
induce expression of cellular IL-6, which is a growth factor for KSHV-associated disease 
(Asou et al., 1998, Screpanti et al., 1996), in an AP-1 (activator protein 1) dependent fashion 
via interaction with the transcription factor c-jun, a member of the AP-1 family (An et al., 
2002, 2004).  
Lytic viral replication 
During the lytic viral life cycle, viral particles are produced and released, resulting in the 
death of the host cell. Several observations suggest that a few viral proteins expressed during 
the lytic cycle (called immediate early, early and late lytic proteins according to the time point 
they are expressed after reactivation, see figure 1) have autocrine or paracrine effects and 
thereby might play a role in KSHV-related malignancies (reviewed in Schulz 2001 and Viejo-
Borbolla & Schulz 2003). In EBV, two proteins synergistically mediate activation of the lytic 
cycle, termed EBV-RTA and ZTA. However, reactivation in KSHV is solely dependent on 
ORF50/RTA, which functions as a transcriptional activator of the early and late genes of 
KSHV. Ectopic expression of RTA triggers the lytic cycle (Sun et al., 1998) and dominant-
negative ORF50 mutants were shown to inhibit reactivation in the KSHV positive PEL cell 
line BCBL-1 (Lukac et al., 1998, 1999). RTA can avtivate its own promoter, lytic viral genes 
and cellular genes through binding to specific DNA sequences and by interacting with cellular 
transcription factors (Deng et al., 2000, Chang et al., 2002, Gwack et al., 2002, Liang et al., 
2002, Byun et al., 2002, Wang et al., 2003b, c). RTA also seems to be involved in promoting 
cell proliferation by suppressing p53-mediated apoptosis and by interacting with the 
transcription factor signal transducer and activator of transcription 3 (STAT3) (Gwack et al., 
2003). The KSHV ZTA homologue termed kbZIP (ORF K8) cannot reactivate KSHV from 
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latency on its own, but has been shown to be a coregulator of RTA (Izumiya et al., 2003), to 
upregulate both CCAAT/enhancer-binding protein-α (C/EBPα) and p21CIP-1 expression (Wu 
et al., 2003, Wang et al., 2003b, c) and repress p53 transcriptional activity (Park et al., 2000). 
Cell cycle manipulation 
Like its cellular homologue, viral cyclin (vcyc) mediates phosphorylation and thereby 
inactivation of the retinoblastoma protein (Rb) through association with the cyclin dependent 
kinase 6 (CDK6) (Swanton et al., 1997, Ellis et al., 1999). Vcyc might play a role in 
carcinogenesis, since it can promote the progression of resting cells into the S phase (Swanton 
et al., 1997, Ellis et al., 1999, Lundquist et al., 2003). This might occur by its inactivation of 
STAT 3, preventing growth-suppressive effects (Lundquist et al., 2003) or its activation of the 
cyclin A promoter, a regulator of S phase entry (Duro et al., 1999). Besides vcyc, Lana-1 is 
able to promote entry into S-phase (Fujimoro et al., 2003). 
Angiogenesis and B-cell proliferation: vIL-6, vGPCR and vMIP I, II, III 
The KSHV counterpart of the human cytokine IL-6, vIL-6, is able to support growth of IL-
6-dependent B-cells in vitro (Moore et al., 1996) and mediates STAT and mitogen-activated 
protein kinase (MAPK) signaling pathways (Molden et al., 1997, Osborne et al., 1999). vIL-6 
has been reported to support PEL growth in culture, to promote growth of transformed cells in 
mice, and vIL-6-induced VEGF is essential for tumour growth and dissemination in PEL 
inoculated mice (Aoki et al., 1999a, b, Jones et al., 1999). In all KSHV-associated disorders, 
high levels of vascular endothelial growth factor (VEGF) and its receptor kinase insert 
domain containing receptor (KDR) which induces angiogenesis have been detected (reviewed 
in Hayward, 2003). 
The early lytic viral G protein-coupled receptor (vGPCR) is homologous to the human 
chemokine Interleukin 8 (IL-8) receptor, with the difference of being ligand-independent and 
thereby constitutively active (Cesarman et al., 1996, Arvanitakis et al., 1997). Depending on 
the cell type, vGPCR signals constitutively via multiple G protein subtypes. In endothelial 
cells for example, vGPCR signals via G protein subtype Gi and leads to increased cell 
survival (Montaner et al., 2001, Couty et al., 2001). In certain models, vGPCR activates the 
transcriptional potential of NF-κB and AP-1, signals via MAPKs, activates PI3K-Akt and 
induces secretion of VEGF (Arvanitakis et al., 1997, Bais et al., 1998, Burger et al., 1999, 
Couty et al., 2001, Schwarz & Murphy 2001, Montaner et al., 2001, Pati et al., 2001, Sodhi et 
al., 2000, Smit et al., 2002). In PEL cells, expression of vGPCR from an inducible plasmid 
led to induction of MAPKs Erk1/2 and p38, an increase of transcription of reporter genes 
under control of AP-1, NF-κB, CREB, NFAT and viral ORFs 50 and 57, and production of 
VEGF and vIL-6 (Cannon et al., 2003). An elegant study by Cannon & Cesarman (2004) 
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showed that AP-1 and CREB activation by vGPCR is mediated cooperatively by a Gq-Erk1/2 
and a Gi-PI3K/Akt-Src (Lyn) axis in PEL cells. 
vGPCR was shown to transform murine fibroblasts (NIH 3T3 cells) and can cause vascular 
KS-like lesions in vGPCR-transgenic mice (Yang et al., 2000a). Induction of 
proinflammatory cytokines and growth factors such as IL-2, IL-8, TNF-α, enhanced 
production of VEGF in the presence of vGPCR and the fact that only a few cells (e.g. 10% of 
KS cells) express vGPCR suggest that the angiogenic and tumourigenic activity of vGPCR is 
mediated by paracrine effects on surrounding cells (Shepard et al., 2001, reviewed in Schulz 
2001). 
The three chemokine homologues vMIP-I, -II, and –III, members of the macrophage 
inflammatory protein (MIP) family, are encoded by ORFs K6, K4 and K4.1 (figure 1), 
respectively, and seem to play a role in promoting leukocyte chemotaxis, eosinophil 
migration, angiogenesis (vMIP-I induced VEGF expression in PEL cell lines), inhibition of 
apoptosis and evasion of the immune response (Boshoff et al., 1997, Nicholas et al., 1997, Liu 
et al., 2001, reviewed in Schulz, 2001). 
Inhibition of apoptosis 
Inhibition of apoptosis is a hallmark of tumour cells. One cellular defense mechanism 
against viral infection is the induction of apoptosis, and viruses have successfully evolved 
strategies to interfere with apoptotic pathways, allowing them to prolong the life of virus-
infected cells and consequently the time for replication and virus spread. Two apoptotic 
pathways exist in mammalian cells: the extrinsic pathway in which death receptors such as 
TNFR1 (tumour necrosis factor receptor) or Fas recruit intracellular adaptor molecules such 
as FADD (Fas-associated death domain), TRADD (TNFR-associated death domain) or RIP 
(receptor interacting protein) via death domain interactions, which then subsequently 
associate with and activate the upstream caspases (8 or 10) through death effector domain 
(DED) interactions leading to activation of the downstream caspases, and the intrinsic 
pathway in which mitochondria release caspase-activating enzymes (reviewed in Teodoro & 
Branton 1997). The observation that inhibition of NF-κB in PEL cell lines leads to apoptosis 
(Keller et al., 2000) and that a number of KSHV proteins can induce the NF-κB pathway 
which is known to have an antiapoptotic effect, suggests that some KSHV proteins could 
contribute to the protection against apoptosis. KSHV proteins vFLIP, K7/survivin, vBcl-2, 
vIRF-1, -2 and -3 have been shown to inhibit apoptosis, thereby possibly contributing to 
tumourigenesis.  
vFLIP/ORF K13 [viral FLICE (FADD-like IL-1-converting enzyme)-inhibitory protein] 
contains two DEDs as cellular cFLIP proteins. cFLIPs are antiapoptotic proteins that prevent 
the association of the upstream caspases 8 and 10 with the adaptor molecules through DED-
DED interactions (Irmler et al., 1997). vFLIP has been shown to block Fas-induced apoptosis 
and it has been postulated to act as a tumour progression factor by interfering with apoptotic 
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signals induced by virus-specific T killer cells (Thome et al., 1997, Djerbi et al., 1999, 
Belanger et al., 2001). vFLIP can modulate the NF-κB pathway, which may also play an 
antiapoptotic role, and physically interacts with signaling proteins such as TRAF-2, RIP and 
IκB kinase (IKK) (Chaudhary et al., 1999, Liu et al., 2002). Furthermore, vFLIP has been 
reported to induce cellular IL-6 expression via NF-κB and AP-1 pathways (An et al. 2003). 
vFLIP is transcribed from a polycistronic transcript together with vcyc and LANA-1 (Talbot 
et al., 1999), and translation of vFLIP is regulated by an internal ribosome entry site (IRES) 
(Low et al., 2001, Bieleski & Talbot 2001). 
K7/survivin is a glycoprotein related to human survivin (a member of the inhibitor-of-
apoptosis family) and seems to be an adaptor molecule bringing together Bcl-2 and effector 
caspases, allowing inhibition of the latter by Bcl-2 (Wang et al., 2002). The viral homologue 
of human Bcl-2, vBcl-2, may inhibit apoptosis, but biochemical studies showed that the 
mechanisms of action of the two proteins differ (Cheng et al., 1997, Sarid et al., 1997, 
reviewed in Schulz 2001). 
The initial immune response against viral infection is regulated by interferon regulatory 
factors (IRFs) which are a family of interferon-responsive transcription factors that regulate 
by binding to interferon-stimulated response elements in the promoters of interferon-
responsive genes. Hence, IRFs regulate expression of genes involved in e.g. pathogen 
response and cell proliferation. KSHV vIRF-1 (K9) and vIRF-2 (K11) inhibit interferon 
signaling and subsequently prevent induction of apoptosis (Gao et al., 1997, Kirchhoff et al., 
2002). vIRF-1 and vIRF-3 (LANA-2, K10.5) were shown to inhibit the activation of p53-
dependent promoters (Seo et al., 2001, Rivas et al., 2001). 
Transforming and signaling KSHV proteins: kaposin, vIRF-1, vGPCR, K1 and K15 
ORF K12/kaposin gives rise to three proteins named kaposin A, B and C (Sadler et al., 
1999). Kaposin A, a type II membrane protein, can transform rodent fibroblasts to 
tumourigenicity and induces lymphocyte aggregation and adhesion (Kliche et al., 2001, 
Muralidhar et al., 1998). Kaposin A protein expression has been shown in PEL cells 
(Muralidhar et al., 2000, Kliche et al., 2001). vIRF-1 can transform NIH 3T3 cells (Gao et al., 
1997) and the vGPCR causes tumours in transgenic mice and excerts a number of signaling 
activities e.g. activation of MAPK and NF-κB pathways (see above). Signaling activities of 
terminal membrane proteins K1 and K15 are described below in detail. Lana-1 has been found 
to transform rodent cells when co-transfected with constitutively active H-Ras (Radkov et al., 
2000). 
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Mechanisms of immune evasion 
Many viruses manage to fend off the host cell immune system. Especially herpesviruses that 
can establish long term infections are experts in outwitting the immune response. One escape 
mechanism realised by herpesviruses and also adenoviruses is to downregulate the number of 
major histocompatibility class (MHC) I proteins on the surface of the infected cells, hence 
antigens will not be presented efficiently and the cytotoxic T lymphocytes recognise the 
infected cell less efficiently. In addition, herpesviruses express a very limited number of 
proteins during latency to minimize the immune response. KSHV expresses two type III 
transmembrane proteins, K3 and K5, that have been shown to downregulate MHC class I 
molecules (with different specificities concerning HLA allotypes) by enhancing their 
endocytosis and degradation rate (Coscoy & Ganem, 2000, Means et al., 2002, Ishido et al., 
2000a, Sanchez et al., 2002, Lorenzo et al., 2002). The K5 protein also downregulates ICAM-
1 (intracellular adhesion molecule) and B7-2, molecules that promote cell-cell contact to 
ensure efficient killing, and this results in the inhibition of NK-cell mediated cytotoxicity 
(Ishido et al., 2000b, Coscoy & Ganem 2001). K5 seems to act like a membrane bound E3 
ubiquitin ligase, and influences trafficking of host cell membrane proteins by ubiquitination 
(Coscoy & Ganem 2001). Both K3 and K5 transcripts are expressed immediately after viral 
reactivation (Haque et al., 2000, Rimessi et al., 2001) and both proteins localise to the 
endoplasmatic reticulum (Coscoy & Ganem, 2000). To adress the issue how KSHV 
suppresses the immune response during latency, Tomescu et al. (2003) analysed the 
expression of endothelial cell surface proteins after infection with KSHV and found MHC 
class I, ICAM-1 and PE-CAM (CD31) to be downregulated. 
KSHV vIRF-1 and -2 (see above) can inhibit interferon signal transduction by direct binding 
to cellular IRFs, the CREB binding protein and other transcription factors (Burysek et al., 
1999, Li et al., 2000, Lin et al., 2001, Seo et al., 2000). vMIP-I and –II can bind to chemokine 
receptors and act as chemoattractants for monocytes and Th2 cells, but not for Th1, NK or 
dendritic cells (Kledal et al., 1997, Boshoff et al., 1997, Endres et al., 1999, Dairaghi et al., 
1999, Sozzani et al., 1998, Weber et al., 2001). Finally, three transcripts generated by 
alternative splicing are derived from KSHV ORF4 (KCP) that shows homology to cellular 
complement control proteins. All three protein isoforms are able to inhibit the complement 
component of the innate immune system, pointing to a role in evading complement attack 
during viral replication or persistence (Spiller et al., 2003). 
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1.3 Signaling activity of terminal membrane proteins of γ-herpesviridae: 
 common strategies and differences 
The analysis of the genomes of the human γ1-herpesvirus/lymphocryptovirus Epstein-Barr 
virus (EBV; Baer et al., 1984) and the human γ2-herpesvirus/rhadinovirus Kaposis´s sarcoma-
associated herpesvirus (KSHV; Russo et al., 1996), as well as the genomes of monkey 
rhadinoviruses Rhesus rhadinovirus (RRV; Alexander et al., 2000, Searles et al., 1999), 
Herpesvirus saimiri (HVS; Albrecht et al., 1992) and Herpesvirus ateles (HVA; Albrecht et 
al., 2000) revealed that they all code for terminal membrane proteins (TMPs) adjacent to the 
terminal repeat region of the herpesvirus genomes. In the genome orientation preferred in the 
γ2-herpesvirus field, EBV codes for the latent membrane protein 1 (LMP1), KSHV for K1, 
RRV for R1, HVS for saimiri-transforming proteins (Stp) A, B or C and tyrosine kinase-
interacting protein (Tip), and HVA for the two-in-one protein Tio at the far left side of the 
long unique region (figure 2). At the opposite side of the long unique region, the tumour 
viruses KSHV, EBV and RRV additionally code for multiply spliced genes: ORF K15, latent 
membrane proteins 2A/2B (LMP2A/B) and a hitherto unannotated predicted gene between 
ORF75 and the terminal repeats, R15, respectively (figure 2). All of these viral terminal 
membrane proteins have a cytoplasmic domain with motifs allowing interaction with cellular 
effector molecules, and are capable of initiating cellular signaling cascades involved in 
normal B-cell or T-cell signaling or cellular growth control (figures 3, 4 and 6). 
The TMPs of the γ–herpesviruses have been reported to directly interact with a variety of 
cellular signaling molecules such as non-receptor protein tyrosine kinases (PTK), tumour-
necrosis factor receptor-associated factors (TRAFs), Ras or Janus kinase (JAK), thereby 
initiating further downstream signaling cascades as for example the MAPK or PI3K/Akt 
pathway. Several transcription factors were found to be activated by the viral TMPs, such as 
NFAT, Oct-2, AP-1, NF-κB or STAT. An overview of the signaling activities of the different 
viral TMPs presented here are summarised in table 1 and figure 6. The transforming potential 
of LMP1, K1, R1, Stp and Tip has been clearly demonstrated in a variety of experimental 
settings (table 1). However, the specific contributions of many signaling cascades to the 
oncogenic properties remain to be elucidated. LMP2A, K1 and Tip have been shown to exert 
dominant negative effects on cellular B or T lymphocyte signaling via the B-cell and T cell 
antigen receptors. 
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Figure 2: Genomic localisation of viral terminal membrane proteins of HVS, HVA, RRV, KSHV and 
EBV. At the “left” end of their genomes, monkey γ-herpesviruses HVS, HVA and RRV and human γ-
herpesviruses KSHV and EBV code for membrane proteins with signaling activities and transforming potential. 
ORFs equivalent to R15, K15 or LMP2A/LMP2B, located at the “right” end of the viral genomes of RRV, 
KSHV and EBV, respectively, have not been identified so far in the genomes of HVA or HVS. The length of the 
terminal repeats flanking the long unique region (LUR) varies between the different herpesviruses (not to scale). 
1.3.1 Epstein-Barr virus (EBV) and latent membrane proteins LMP1 and LMP2A 
EBV, the only human member of the genus γ1-herpesvirus/lymphocryptovirus, is associated 
with infectious mononucleosis and a variety of malignant diseases including African endemic 
Burkitt´s lymphoma (BL), Hodgkin´s disease, and lymphoproliferative disorders in 
immunodeficient individuals (reviewed in Rickinson & Kieff 2001). EBV is also associated 
with two epithelial malignancies: nasopharyngeal carcinoma (endemic in China) and oral 
hairy leukoplakia in AIDS patients (reviewed in Rickinson & Kieff 2001). In vitro, EBV can 
infect and efficiently transform and immortalize primary human B lymphocytes leading to the 
outgrowth of transformed and immortalized lymphoblastoid cell lines (LCLs) displaying 
elevated levels of several cellular activation antigens and adhesion molecules (reviewed in 
Rickinson & Kieff 2001). In LCLs, viral gene expression is restricted to a small subset of 
latent genes that encode six Epstein-Barr nuclear antigens (EBNA1, 2, 3A, 3B, 3C, and LP), 
three integral membrane proteins (LMP1, LMP2A, LMP2B), and two small nuclear RNAs 
   15
(reviewed in Farrell 1995). Five of these, namely EBNA1, 2, 3A, 3C, and LMP1, have been 
shown to be essential for the process of B-cell immortalization (reviewed in Izumi 2001). 
1.3.1.1 LMP1 
LMP1 has oncogenic properties 
The latent membrane protein 1 (LMP1) is expressed in several EBV-associated 
malignancies, and this led to the suggestion that this protein contributes to tumourigenesis. 
The role of LMP1 as an oncoprotein has been clearly demonstrated in a variety of cell 
systems: LMP1 has transforming effects in rodent fibroblast cell lines, and Rat-1 cells 
expressing LMP1 are tumourigenic in nude mice (Baichwal & Sugden, 1988, Moorthy & 
Thorley-Lawson, 1993a, Wang et al., 1985, 1988b). In Rat-1 cells, LMP1 can induce loss of 
contact inhibition (Moorthy & Thorley-Lawson, 1993a, Wang et al., 1985). LMP1 alters the 
growth of EBV-negative Burkitt lymphoma lymphoblasts and of primary B lymphopcytes and 
induces many of the changes usually associated with EBV infection of primary B 
lymphocytes (Birkenbach et al., 1989, Peng & Lundgren, 1993, 1992, Peng-Pilon et al., 1995, 
Rowe et al., 1994, Wang et al., 1988a, 1990). LMP1 increases plasma membrane expression 
of adhesion molecules, induces higher levels of the lymphocyte function-associated antigen 
(LFA-1) mRNA and functionally activates adhesion (Wang et al., 1988a, b). 
LMP1 expression can alter cell growth and gene expression in hematopoietic stem cells and 
epithelial cells (Dawson et al., 1990, Fahraeus et al., 1990, Fairbairn et al., 1993, Hu et al., 
1993). Targeted expression of LMP1 in the skin or B-cell compartment of transgenic mice 
leads to the induction of epithelial hyperproliferation and lymphomagenesis, respectively 
(Kulwichit et al., 1998, Wilson et al., 1990). In monolayer cultures, LMP1 alters keratinocyte 
morphology and cytokeratin expression (Fahraeus et al., 1990), and cell differentiation is 
inhibited by LMP1 in raft cultures of immortalized human epithelial cell lines (Dawson et al., 
1990). It has also recently been shown that LMP1 is critical for rendering LCLs tumourigenic 
in SCID mice (Dirmeier et al., 2003). 
LMP1 is composed of six transmembrane domains and a cytoplasmic C-terminus with two 
distinct signaling regions termed CTAR-1/TES-1 and CTAR-2/TES-2 
LMP1 contains a 24 aa arginine- and proline-rich hydrophilic N-terminus, followed by six 
transmembrane domains separated by five 8-10 aa long turns, and a 200 aa C-terminus rich in 
acidic residues (figure 3). LMP1, which has an apparent mass of 63 kDa, can be cleaved near 
the beginning of the C-terminal cytoplasmic domain (L242), resulting in a soluble C-terminal 
domain of 25 kDa (Moorthy & Thorley-Lawson, 1990, 1993b). In addition, in the late lytic 
viral life cycle a lytic LMP1 protein is expressed that consists of transmembrane domains 5 
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and 6 and the C-terminal domain (Hudson et al., 1985), which does not have transforming 
capabilities (Baichwal & Sugden, 1989, Liebowitz et al., 1992). 
Two regions in the C-terminal cytoplasmic domain of LMP1 have been defined to be 
critical for the contribution of LMP1 to the conversion of primary B lymphocytes to LCLs, 
and were therefore termed transformation effector sites (TES) 1 (aa 187-231) and 2 (aa 352-
386) (Kaye et al., 1993, 1995, 1999, Izumi et al., 1997, 1999, Izumi & Kieff, 1997). Nearly 
the same regions were identified to be essential for the ability of LMP1 to activate the 
transcription factor NF-κB (Hammerskjold & Simurda, 1992, Laherty et al., 1992), and were 
therefore termed CTAR-1 (aa 194-232) and CTAR-2 (aa 351-386) for C-terminal NF-κB 
activating region (figure 3; Huen et al., 1995, Mitchell & Sugden, 1995, Floettmann & Rowe, 
1997). NF-κB plays a key role in most of LMP1-stimulated gene expression (Devergne et al., 
1998, He et al., 2000, Mehl et al., 2001, Zhang et al., 2001), and activation of the NF-κB 
pathway is linked to LMP1-induced immortalization of human primary B lymphocytes 
(Devergne et al., 1996, Izumi & Kieff, 1997, Cahir McFarland et al., 1999) and tumourigenic 
transformation of cultured rodent cells (He et al., 2000, Xin et al., 2001). 
LMP1 induces the canonical and non-canonical NF-κB pathways 
The mammalian NF-κB transcription factor is composed of dimers of p50 (precursor = 
p105), p52 (precursor = p100), p65/RelA, RelB and cRel that are complexed to inhibitor 
proteins called IκB. This leads to the retention of NF-κB in the cytoplasm in an inactive state. 
Two NF-κB pathways are described in the literature: the canonical (figure 35; reviewed in 
Ghosh & Karin 2002) and the very recently identified non-canonical/alternative pathway 
(figure 35; reviewed in Pomerantz & Baltimore 2002). The canonical pathway is triggered by 
inflammatory stimuli such as TNF-α, IL-1, double-stranded RNA and LPS. Upon stimulation, 
the IκB kinase (IKK) complex, consisting of the two catalytic subunits IKKα and IKKβ and 
the regulatory subunit IKKγ/NEMO, is activated and specifically phosphorylates the IκB 
proteins. Phosphorylation of IκB proteins leads to their ubiquitination and subsequent 
degradation by the proteasome, resulting in the release of NF-κB dimers (predominantly 
p50/RelA) and their translocation to the nucleus, where they act as transcription factors. This 
pathway depends on the IKK subunits IKKβ and IKKγ. 
Only three cellular receptors have so far been described to signal via the non-canonical NF-
κB pathway: CD40, B-cell activating factor receptor and lymphotoxin β-receptor (reviewed in 
Pomerantz & Baltimore 2002). This pathway involves the proteasome-mediated processing of 
the p52 precursor p100 to produce p52 and requires the MAP3K NIK and IKKα but is 
independent of IKKγ. Processing of p100 to p52 leads to the nuclear translocation of 
p52/RelB dimers. It is firmly established that LMP1 activates the canonical NF-κB pathway 
(see below). Very recently, three independent reports described the non-canonical NF-κB 
pathway to be targeted by LMP1 in fibroblast cell lines (Saito et al., 2003), in epithelial and 
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B-cells (Atkinson et al., 2003) and tumour tissue biopsies (Eliopoulos et al., 2003a). Thereby, 
LMP1 seems to activate the non-canonical pathway via CTAR-1 to induce processing of p100 
to p52, resulting in the nuclear localisation of p52/RelB dimers, whereas it triggers the 
canonical pathway via CTAR-2 to induce p100 production (Saito et al., 2003, Atkinson et al., 
2003). 
LMP1 mimics cellular activated tumour necrosis factor receptors – interaction with TRAFs 
Concerning the interaction of LMP1 with cellular effector proteins and downstream 
signaling effects, LMP1 mimics aspects of constitutively active tumour necrosis factor 
receptors (TNFR) such as CD40 or TNFR-1 (Brodeur et al., 1997, Devergne et al., 1996, 
1998, Eliopoulos et al., 1999a,b, 1996, 1997, 1998, Floettmann et al., 1998, Franken et al., 
1996, Hatzivassiliou et al., 1998, Kaye et al., 1996, Kilger et al., 1998, Miller et al., 1997b, 
Puls et al., 1999, Sandberg et al., 1997, Sylla et al., 1998, Uchida et al., 1999, Gires et al., 
1997). Both LMP1 and activated CD40 receptor initiate overlapping signaling pathways that 
regulate major cell fate decisions including proliferation, differentiation, and apoptosis 
(reviewed in Baker & Reddy 1996). In LMP1 expressing transgenic mice for example, LMP1 
can mimic CD40 signals to induce extrafollicular B-cell differentiation and blocks germinal 
center formation (Uchida et al., 1999). 
LMP1 and CD40 share a PxQxT motif (figure 3; Devergne et al., 1996, Franken et al., 1996, 
Eliopoulos et al., 1997) that has been shown to be a binding site for TNFR-associated factors 
(TRAFs) (Ye et al., 1999, 2000). The PxQxT motif P204QQAT of LMP1 is located to its 
CTAR-1 region (see figure 3). TRAFs are crucial downstream effector molecules of CD40 
and other members of the TNFR family (Cheng et al., 1995, Hu et al., 1994, Rothe et al., 
1994, Takeuchi et al., 1996). Whereas CD40 recruits TRAF molecules upon binding of CD40 
ligand and receptor aggregation, LMP1 constitutively binds TRAFs through its CTAR-1 
region. The binding affinity of the P204xQxT motif of LMP1 is higher for TRAF-1 and -3 than 
for TRAF-2 and -5 (Mosialos et al., 1995, Brodeur et al., 1997, Devergne et al., 1996, 1998, 
Sandberg et al., 1997). TRAF-3 is discussed to act as a negative modulator by displacing 
TRAF-1 and TRAF-2 from CTAR-1 (Devergne et al., 1996, Kaye et al., 1996, Miller et al., 
1997b). 
LMP1 activates NF-κB via its CTAR-1 and CTAR-2 regions by directly interacting with 
TRAFs and TRADD 
LMP1 is a potent activator of the transcription factor NF-κB. However, mutations in CTAR-
1 that disrupt association with TRAF-2, -3 and -5 have little effect on NF-κB activation 
(Sandberg et al., 1997, Brodeur et al., 1997, Kieser et al., 1997, Devergne et al., 1998, Huen et 
al., 1995, Mitchell & Sugden, 1995). Via its CTAR-2 region, LMP1 directly associates with 
two proteins involved in apoptosis, TNFR-associated death domain (TRADD) and receptor 
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interacting protein (RIP) (Izumi & Kieff, 1997; see 1.2 and figure 3). However, unlike TNFR-
1, LMP1 does not contain a death domain, nor does it induce cell death. In contrast, LMP1 
signals via TRADD and RIP to TRAFs, which are known to mediate non-death signals from 
TRADD and RIP (Izumi & Kieff, 1997, Izumi et al., 1999a). A direct interaction of TRAFs 
and the CTAR-2 region of LMP1 has not been shown, but experiments with dominant 
negative TRAF-2 suggest that LMP1 and TRAF-2 might interact indirectly via this region 
(Kaye et al., 1996). A dominant negative mutant of TRAF-2 blocks NF-κB activation from 
CTAR-1 and CTAR-2, as do dominant negative mutants of the NF-κB-inducing kinase (NIK) 
or of IκB kinases (IKK) α and β (Kaye et al., 1996, Sylla et al., 1998). However, NIK may 
not be essential for NF-κB activation by LMP1 (Luftig et al., 2001). 
An LMP1 CTAR-2 double mutant (Y384I, Y385I) that fails to interact with TRADD is 
defective in NF-κB activation and in B lymphocyte transformation (Izumi & Kieff, 1997), 
whereas RIP is not required for NF-κB activation (Izumi et al., 1999a). Although CTAR-1 is 
a weak NF-κB activator, it is sufficient for initial transformation, whereas CTAR-2, being the 
major NF-κB activating region, is insufficient for transformation in the absence of CTAR-1 
(Izumi et al., 1997). 
LMP1 has been reported to interact with HOS (homologue of slimb), a receptor for the 
SCFβ-TrCP/HOS ubiquitin protein ligase (E3) that is involved in targeting the NF-κB inhibitory 
protein IκB for degradation thereby allowing NF-κB dependent transcription (Tang et al., 
2003 and references therein). Based on the observation that mutations in the potential HOS 
binding site of LMP1 that abrogate HOS binding result in a more tumourigenic LMP1 variant, 
Tang et al. (2003) suggest that the extent of LMP1-induced NF-κB signaling could be 
restricted by its interaction with HOS. 
In epithelial cells, LMP1 may enhance proliferative signals and protect cells from apoptosis 
by inducing the expression of the epidermal growth factor receptor (EGFR) and the 
antiapoptotic protein A20 (Miller et al., 1995a, Fries et al., 1996). TRAF binding to the 
P204xQxT motif of LMP1 was shown to be nonessential in upregulating expression of CD40, 
Fas, adhesion molecules ICAM-1 and LFA-3, but critical in upregulating TRAF-1 and the 
EGFR (Devergne et al., 1998, Miller et al., 1998). However, Mehl et al. (2001) found NF-κB 
to be critical for ICAM-1 upregulation by LMP1. 
LMP1 signals via MAPK pathways 
Since LMP1 is able to transform Balb 3T3 cells without inducing NF-κB (Baichwal & 
Sugden, 1988, Martin et al., 1993, Mitchell & Sugden 1995), its transforming potential seems 
not to depend on NF-κB alone. Both AP-1 (activator protein 1) and NF-κB family members 
are proto-oncogenes, whose aberrant activation contributes to tumour formation (reviewed in 
Baeuerle & Baltimore 1996 and Karin et al., 1997). LMP1 has been shown to activate the 
transcription factor AP-1 via mitogen-activated protein kinases (MAPKs) c-jun N-terminal 
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kinase 1 (JNK1) and p38 in B-cells and epithelial cells (figure 6; Eliopoulos & Young 1998, 
Eliopoulos et al., 1999a, b, Kieser et al., 1997). In 293 epithelial cells, activation of JNK was 
dependent on aa 379-384 overlapping the CTAR-2 domain and TRADD binding domain, but 
not on CTAR-1 (Eliopoulos & Young 1998, Kieser et al., 1997, Eliopoulos et al., 1999b, 
Kieser et al., 1999). However, a subsequent study showed that expression of the LMP1 
CTAR-1 domain may result in JNK activation in cell lines expressing TRAF-1, and TRAF-1 
and TRAF-2 were demonstrated to be critical modulators of JNK signaling by the CTAR-1 
region of LMP1 (Eliopoulos et al., 2003b). 
Filopodia formation promoted by LMP1 in fibroblasts and cells of epithelial and B-cell 
origin (reviewed in Eliopoulos & Young, 2001) was shown to be mediated by the small 
GTPase Cdc42, independently of TRADD and TRAF-2 (Puls et al., 1999). Whereas CTAR-2 
mediated NF-κB activation involves TRADD and TRAF-2, LMP1 signaling to JNK1 is 
independent of TRADD, RIP and the p21 Rho-like GTPases Rac1 and Cdc42 (Kieser et al., 
1999, Wan et al., 2004). A recent study employing embryonic fibroblasts from different 
knockout mice and the small interfering RNA technique revealed that LMP1 activates JNK1 
via TRAF-6, the mitogen-activated protein kinase kinase kinase (MAPK3K) TAK1, and the 
c-jun N-terminal kinase kinases (JNKK) 1 and 2 (Wan et al., 2004). In lymphoid cells, 
CTAR-2 mediated JNK activation does not involve TRAF-1 but partially depends on TRAF-2 
(Eliopoulos et al., 2003b). 
Furthermore, LMP1 activates the MAPK p38 through CTAR-1 and -2, which seems to 
involve TRAF-6 downstream of the P204xQxT motif in CTAR-1 and TRADD (Eliopoulos et 
al., 1999a, Schultheiss et al., 2001). In epithelial cells, TRAF-6 is recruited to LMP1 
complexes in the plasma membrane, but binding to LMP1 seems to be indirect (Schultheiss et 
al., 2001). p38 has been shown to mediate cytokine induction by LMP1 (Eliopoulos et al., 
1999a, Vockerodt et al., 2001). In Rat-1 fibroblasts, LMP1 induces the MAPKs extracellular 
signal-regulated kinases 1 and 2 (Erk1/2) via Ras, and co-transfection of a dominant negative 
Ras mutant impaired the ability of LMP1 to induce transformation (Roberts & Cooper, 1998). 
However, Kieser et al. (1997) did not see any activation of Erk2 by LMP1 in epithelial cells. 
Eliopoulos et al. (2002) identified the oncogenic serine/threonine kinase Tpl-2 as a component 
of LMP1-induced NF-κB signaling in epithelial cells. Tpl-2 is activated upon LMP1 
expression, interacts with TRAF-2 and expression of a catalytically inactive Tpl-2 mutant 
inhibited LMP1-induced NF-κB activation (Eliopoulos et al., 2002). Tpl-2 has been shown to 
interact with and activate NIK (Lin et al., 1999), and is also critical for activation of MAPKs 
Erk (Dumitru et al., 2000, Hagemann et al., 1999, Patriotis et al., 1994) and JNK (Salmeron et 
al., 1996). 
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The region between CTAR-1 and CTAR-2: aa 233-350 
The region between CTAR-1 and -2 (aa 233-350) includes four direct imperfect repeats of a 
conserved PQDPDNTDDNG sequence, a PPQLT sequence (aa 320-324) that resembles a 
PxQxT/S TRAF binding core but does not function as one, a protease cleavage site (between 
aa 241 and 242), 19 potential serine or threonine phosphorylation sites and sequences that 
vary in human isolates and have been reported to affect the ability of LMP1 to transform 
immortalized rodent fibroblasts (Fennewald et al., 1984, Hu et al., 1991, Li et al., 1996, Mehl 
et al., 1998). The region encompassing aa 233-350 is not critical for B lymphocyte growth 
transformation (Izumi et al., 1999b). 
LMP1 is phosphorylated at residues serine (S313) and threonine (T324), but not on tyrosine 
residues, and phosphorylation was shown not to be crucial for the transforming activity of 
LMP1 (Baichwal & Sugden 1987, Mann & Thorley-Lawson 1987, Moorthy & Thorley-
Lawson 1993b). The N-terminus and phosphorylation seem to be important for the 
degradation of LMP1 by the proteasome (Aviel et al., 2000). 
LMP1 interacts with Janus kinase (JAK) 3 and activates STATs 
Constitutively active STATs have been found in a variety of human cancers (reviewed in 
Bowman et al., 2000) as well as in a variety of EBV-associated malignancies (Weber-Nordt et 
al., 1996, Chen et al., 2001, Kube et al., 2001). In epithelial cells, LMP1 expression was 
associated with an increase in activated STAT-3 and -5, and expression of constitutively 
activated STAT-3 upregulated LMP1 protein expression, suggesting a positive feedback loop 
between LMP1 and STAT-3 (Chen et al., 1999, 2001a, 2003). 
One group demonstrated that LMP1 interacts with the Janus kinase (JAK) 3 in epithelial and 
EBV immortalized B-cells via the region between CTAR-1 and CTAR-2 and activates JAK 3 
and STAT-1 and -3 (Gires et al., 1999). Another group did confirm JAK3 binding to LMP1, 
but not via aa 233-352, and did not find LMP1 induced activation of JAK3 or STAT-3 in B 
lymphoma or LCLs (Higuchi et al., 2002). 
LMP1 signaling leads to activation or repression of several factors implicated in the control 
of cellular proliferation and apoptosis 
The suppression of apoptotic death is a function of LMP1 that contributes to its 
oncogenicity. One well characterised mechanism by which LMP1 protects against apoptosis 
is the upregulation of the expression of several antiapoptotic proteins such as Bcl-2, A20 and 
Mcl-1 (Fries et al., 1996, Henderson et al., 1991, Gregory et al., 1991, Martin et al., 1993, 
Laherty et al., 1992, Milner et al., 1992, Rowe et al., 1994, Wang et al., 1996). The promoter 
activity of the Bcl-2 family member Bfl-1, which has been shown to possess cell proliferation 
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and transforming activities in vitro, is stimulated by LMP1 in EBV-negative BL-derived cell 
lines through TRAF-2 and NF-κB (D´Souza et al., 2004). 
Transforming growth factor (TGF) β, a tumour suppressor cytokine that inhibits cell 
proliferation due to cell cycle arrest in the G1 phase (reviewed in Massague 2000), as well as 
Smad-mediated transcriptional responses are inhibited by LMP1 in epithelial cells and 
fibroblasts, depending on NF-κB induction by LMP1 (Prokova et al., 2002). However, 
whereas one study showed that LMP1 also causes loss of TGF β-mediated growth inhibition 
in B lymphocytes (Arvanitakis et al., 1995), this observation was not confirmed by another 
study (Inman & Allday, 2000). 
LMP1 represses the expression of E-cadherin, an invasion-suppressor gene, and triggers the 
invasive potential of cells (Fahraeus et al., 1992, Kim et al., 2000). The repression of E-
cadherin gene expression seems to be mediated by activation of cellular DNA 
methyltransferases by LMP1 (Tsai et al., 2002). 
Furthermore, LMP1 induces the antiapoptotic PI3K/Akt pathway to promote cell survival 
and to induce actin remodelling via its P204xQxT motif (Dawson et al., 2003), downregulates 
transcriptional expression of the metastasis suppressor gene RECK via the MAPK Erk in an 
EBV negative nasopharyngeal carcinoma cell line (Liu et al., 2003), prevents Ras-induced 
senescence in human fibroblasts and blocks expression of the p16INK4a tumour suppressor 
gene (Yang et al., 2000b). 
The p16INK4a-Retinoblastoma protein pathway plays a critical role in preventing 
inappropiate cell proliferation, and recently it has been shown that LMP1 inactivates the 
transcription factor Ets2, known to induce p16INK4a expression in Ras-induced senescence 
(Ohtani et al., 2001), by promoting the intracellular redistribution of Ets2 from the nucleus 
into the cytoplasm (Ohtani et al., 2003). In addition, LMP1 inactivates the downstream 
mediators of the p16INK4a-RB growth arrest pathway, E2F4 and E2F5 (Gaubatz et al., 2000, 
Ohtani et al., 2003). Manipulation of E2F4 seems to depend on both CTAR regions and 
involves the MAPK Erk pathway. 
The LMP1 transmembrane domains are essential for signaling and localisation to lipid rafts 
Besides the C-terminal domain of LMP1, its aminoterminal and transmembrane regions 
play a pivotal role in efficient signaling. The LMP1 N-terminus is crucial for the correct 
orientation of the transmembrane domains in the membrane (Coffin et al., 2001). LMP1 is 
able to form aggregates via its transmembrane domains, apparent by the formation of patches 
in the plasma membrane (Hennessy et al., 1984, Liebowitz et al., 1986, 1987). LMP1 mutants 
lacking parts of the N-terminal transmembrane domains localise to the plasma membrane in 
Balb/c 3T3 cells or LCLs, but do not form aggregates, show no transforming activity and are 
not able to induce cellular gene expression (Baichwal & Sugden et al., 1989, Wang et al., 
1988a, Martin & Sugden, 1991, Kaye et al., 1993, Liebowitz et al., 1992, Devergne et al., 
1998). 
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A chimeric protein composed of the six transmembrane domains of LMP2A (see 1.3.1.2) 
and the C-terminal domain of LMP1 was not able to activate NF-κB (Kaykas et al., 2002). 
The capacity of LMP1 to signal constitutively in the absence of any ligand is mediated by its 
transmembrane domains, since a chimeric protein composed of the N-terminus and 
transmembrane domains of LMP1 and the C-terminal part of CD40 can signal in the absence 
of CD40 ligand (Floettmann & Rowe, 1997, Gires et al., 1997, Hatzivassiliou et al., 1998). 
LMP1 also localises to intracellular membranes and the cytoskeleton and is associated with 
lipid rafts (Ardila-Osorio et al., 1999, Liebowitz et al., 1986, 1987, Mann & Thorley-Lawson, 
1987, Moorthy & Thorley-Lawson, 1990, 1993b, Clausse et al., 1997, Kaykas et al., 2000, 
Higuchi et al., 2001). Transmembrane domains 1 and 2 were shown to be sufficient for lipid 
raft association (Coffin et al., 2003). 
CD40, which translocates to lipid rafts upon activation with CD40 ligand, as well as LMP1 
recruit TRAF-3 to lipid rafts, and efficient signaling of LMP1 from lipid rafts is only achieved 
by the full length LMP1 protein (Kaykas et al., 2001, Brown et al., 2001). Interestingly, 
TRAF-3 was found to be degraded after CD40 signaling, but not after LMP1 signaling 
(Brown et al., 2001). However, whereas activated CD40 signals as a trimeric form, neither the 
structure nor the extent to which LMP1 aggregates is known (Kaykas et al., 2001). 
Lam & Sugden (2003) observed that the majority of LMP1 is localised to and signals from 
lipid rafts of intracellular membranes in the EBV-immortalized lymphoblastic cell line 721 
and 293 cells, and is only detected at low levels at the plasma membrane. In intracellular 
compartments, LMP1 was shown to associate with TRADD and to actively recruit TRAF 
molecules (Lam & Sugden 2003). LMP1 protein expression was also observed in 
extracellular vesicles (Vazirabadi et al., 2003, Flanagan et al., 2003). 
When LMP1 is expressed in a variety of cells it inhibits their proliferation by the induction 
of cytostasis (Cuomo et al., 1992, Floettmann et al., 1996, Hammerschmidt et al., 1989), and 
this ability has been attributed to its amino terminus and its transmembrane domains (Kaykas 
& Sugden 2000). 
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Figure 3: Structures of viral terminal membrane proteins LMP1, LMP2A and K15. EBV LMP1 is a potent 
inducer of the NF-κB and MAPK pathways and has transforming properties. It interacts via its C-terminal 
activator regions (CTAR-1 aa 194-232, CTAR-2 aa 351-386) with a variety of cellular proteins, including 
TRAFs, TRADD and RIP (see text and figure 6). Both regions activate the IκB kinases causing phosphorylation 
of IκB, IκB degradation and NF-κB activation, and also activate MAPKs JNK1 and p38 (see figure 35). The six 
transmembrane domains enable LMP1 to aggregate in the plasma membrane. Both the transmembrane domains 
and the cytoplasmic C-terminus are essential for primary B lymphocyte growth formation. EBV LMP2A 
contains 12 transmembrane domains and interacts with protein tyrosine kinases Lyn and Syk via SH2-B domains 
located in its amino-terminal cytoplasmic tail, thereby blocking signaling of the B-cell antigen receptor in vitro. 
KSHV K15 is, in terms of structural organization and genomic localisation (see figure 5), very similar to the 
EBV LMP2A protein and contains, as LMP2A, putative SH2-B motifs. The presence of motifs that are 
reminiscent of TRAF binding sites in the K15 cytoplasmic C-terminus indicate that K15 could share functional 
features with EBV LMP1. 
1.3.1.2 LMP2A 
The LMP2 genes code for proteins with multiple transmembrane domains 
The two LMP2 genes LMP2A and LMP2B are transcribed into two mRNAs across the 
circularized viral genome (i.e. across the terminal repeats) from two spatially distinct 
promoter elements. Both transcripts are multiply spliced, and exons 2-9 are shared by both 
mRNAs (see figures 2 and 5). Exon 1 of LMP2A codes for a 119 aa hydrophilic N-terminal 
cytoplasmic domain, whereas exon 1 of LMP2B is noncoding with translation beginning in 
the common exon 2 before the first transmembrane sequence (figures 2 and 5; Laux et al., 
1988, 1989, Sample et al., 1989). The remaining exons are encoding twelve transmembrane 
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domains and a 27 aa hydrophilic C-terminus (figure 3). LMP2A (497 aa) and LMP2B (378 
aa) form patches in the plasma membrane of latently EBV infected B lymphocytes, and 
LMP2A patches colocalise with LMP1 (Longnecker et al., 1991, Longnecker & Kieff 1990). 
In transfected B-cells and epithelial cells LMP2A and B have been described to colocalise in 
perinuclear regions/the trans-Golgi network (Lynch et al., 2002). 
The LMP2A N-terminus contains potential SH2-B motifs, two of which compose an ITAM 
The LMP2A 119 aa N-terminal cytoplasmic domain includes eight tyrosines (depicted in 
figure 3), some of which are constitutively phosphorylated (Longnecker et al., 1991). Each of 
these phosphorylated tyrosines is situated in a context suitable for interaction with Src-
homology 2 domain (SH2) containing proteins (depicted in figure 3; reviewed in Longnecker 
2000). Many cellular signaling proteins (e.g. lymphocyte receptors, adaptor proteins, protein 
kinases, transcription factors) contain SH2-binding (SH2-B) domains of the consensus 
sequence YXXL/I/V. When these domains are tyrosine phosphorylated, direct binding of SH2 
domain containing proteins such as non-receptor protein tyrosine kinases (PTKs) and 
phosphatidylinositol-3 kinase (PI3K) can occur (reviewed in Pawson & Scott 1997). Motifs of 
the consensus YXXA/P/T also have been described as being SH2-B sites, and the Y112EEA 
motif, the site of Lyn PTK binding in LMP2A (Fruehling et al., 1998), is clearly homologous 
to the Src family PTK preferred SH2-B motif YEEI (Songyang et al., 1993, 1994). Except for 
Y64 and Y23, contained in tyrosine motifs that have no predicted specificity to any identified 
SH2 domain, all tyrosines were found to be highly conserved between LMP2A genes of 
different virus isolates (reviewed in Longnecker 2000). Tyrosine residues Y74 and Y85 
(Y74QPL and Y85LGL) of LMP2A form an immunoreceptor tyrosine-based activation motif 
(ITAM; consensus sequence: stretch of negatively charged aa followed by two SH2-B motifs 
spaced 7-10 aa apart [(D/E)X7(D/E)X2YX2LX7-10YX2L/I], figure 3). 
ITAMs are present in a variety of cellular immunoreceptors such as the B-cell and T-cell 
antigen receptors (BCR, TCR), and it has been shown that ITAMs play a central role in signal 
transduction of these receptors. In primary B lymphocytes, activation of the BCR leads to an 
intricate signal cascade: initially, Src family PTKs are recruited and activated, followed by 
recruitment and activation of Syk PTK and binding of the B-cell linker protein SLP-65, the 
phospholipase PLCγ, the Vav guanine nucleotide exchange factor, PI3K, and the Grb2 and 
Nck adaptor proteins (Fu et al., 1998, Ishiai et al., 1999, Wienands et al., 1998). These initial 
interactions lead to further downstream signals such as mobilization of calcium and activation 
of the Ras/MAPK pathway and protein kinase C (PKC), subsequently resulting in 
transcriptional activation of genes associated with B-cell activation (Buhl et al., 1997, 
reviewed in Cambier et al., 1994 and Benschop & Cambier 1999). 
Furthermore, serine residues in the amino terminal domain of LMP2A are situated in 
contexts that could serve as potential recognition motifs for serine-threonine kinases 
(Songyang et al., 1996): AGPPS15PGGD and PPPYS102PRDD for MAP kinases and 
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EERES52NEEP for Casein kinase II. Indeed, LMP2A has been shown to be phosphorylated in 
vivo on serine and threonine residues (Longnecker et al., 1991), and to be associated in vivo 
with the MAPK Erk1, which can phosphorylate LMP2A at residues S15 and S102 in vitro 
(Panousis & Rowe 1997). 
LMP2A blocks BCR signaling in LCLs and maintains viral latency 
Normal BCR signal transduction following BCR cross-linking is blocked in LCLs generated 
with wildtype EBV as measured by calcium mobilization, cellular kinase activation, induction 
of tyrosine phosphorylation and activation of gene transcription. In contrast, BCR signal 
transduction was found to be normal in LCLs infected with a recombinant EBV from which 
LMP2A had been deleted (Miller et al., 1993, 1995b). From these experiments it is concluded 
that LMP2A is sufficient to block BCR signaling in LCLs. 
In these LCLs, the N-terminal region of LMP2A was found to be constitutively tyrosine 
phosphorylated and to be stably associated with Src family PTKs (Lyn and Fyn) and the Syk 
PTK (Burkhardt et al., 1992, Miller et al., 1995b). The Y112 of the SH2-B motif Y112EEA 
essential for Lyn binding, and Y74 and Y85 of the ITAM mediating Syk binding, were both 
required for blocking BCR signaling (Fruehling et al., 1996, 1998, Fruehling & Longnecker 
1997). In contrast, tyrosine residues Y23, Y31, Y60, Y64 and Y101 were shown to be not required 
for this purpose (Fruehling et al., 1996, Swart et al., 1999). 
LMP2A/B do not affect EBV transformation of primary B lymphocytes into LCLs, LCL 
survival or viral replication (Kim & Yates 1993, Longnecker et al., 1992, 1993a,b, Rochford 
et al., 1997, Speck et al., 1999). These studies with EBV recombinants revealed that BCR 
cross-linking on LCLs with null mutations in LMP2A results in normal BCR signal 
transduction and activation of the lytic viral life cycle of EBV, whereas in the presence of 
LMP2A, lytic infection is blocked. This block can be bypassed by raising intracellular free 
calcium levels by phorbol ester treatment (Miller et al., 1994a, b). Hence, since LMP2A is 
expressed in most latently infected B lymphocytes in vivo, it is postulated to have a role in 
maintaining viral latency. 
LMP2A interacts with ubiquitin ligases via its PPPPY motifs and localises to lipid rafts 
The N-terminal domain of LMP2A includes several proline-rich motifs reminiscent of SH3-
binding (SH3-B) domains (reviewed in Pawson & Gish 1992) and WW domain interaction 
sites (reviewed in Sudol 1996). SH3-B domains are proline-rich regions recognized by 
proteins carrying noncatalytic SH3 domains. Many cellular kinases and adaptor proteins that 
are essential for diverse signal transduction pathways linking cellular receptors to downstream 
signaling events carry such SH3 domains. WW domains consist of paired tryptophane 
residues separated by 20-22 aa and specifically bind to the motif XPPXY (reviewed in Sudol 
1996), of which LMP2A has two (PPPPY60 and PPPPY101). However, no SH3 domain 
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containing proteins have been reported to interact with LMP2A via its potential SH3-B 
domain so far, but LMP2A has recently been shown to bind to several members of the Nedd4-
like ubiquitin protein ligase family via its PPPPY motifs. This interaction results in 
ubiquitination and degradation of LMP2A and LMP2A-associated proteins such as Lyn and 
Syk (Longnecker et al., 2000, Ikeda et al., 2000, 2001, 2002, Winberg et al., 2000). 
One model proposes that LMP2A, acting as an activated BCR, exerts its dominant negative 
effect on BCR signaling by withdrawing Src family PTKs and Syk from the BCR and targets 
them for degradation by its association with ubiquitin ligases. However, the PPPPY motifs of 
LMP2A do not seem to be essential for blocking BCR signaling in LCLs (Ikeda et al., 2001), 
which argues against this model. The dominant negative effect of LMP2A on BCR signaling 
could be mediated by its localisation to lipid rafts in LCLs: LMP2A was shown to exclude the 
BCR from entering lipid rafts where the BCR would otherwise initiate normal B-cell 
signaling (Dykstra et al., 2001). A C-terminal motif of LMP2A seems to mediate physical 
interaction of LMP2A with heterologous transmembrane molecules or between LMP2A 
molecules (Matskova et al., 2001), but the relevance of this observation for LMP2A function 
has not been investigated so far. 
LMP2A drives B-cell development in vivo 
In strong contrast to the data obtained with EBV transformed LCLs, LMP2A was shown to 
provide survival and development signals in an LMP2A transgenic mouse cell line with B-
cell specific expression of LMP2A (Caldwell et al., 1998). Interestingly, this LMP2A 
transgenic mouse line showed a reduction in the number of BCR-positive B-cells. Contrary to 
expectations, even BCR-negative cells were capable of progressing out of the bone marrow 
and entering the peripheral immune system where they subsequently persist. Further, LMP2A 
is able to drive B-cell development when this LMP2A mouse line is crossed into a 
recombinase-activating gene (RAG) null background (Caldwell et al., 2000). In wild type 
mice, cells either lacking the BCR or B-cells of RAG knockout mice would not be able to 
proceed with normal B-cell development. The ITAM motif was proven to be critical for this 
LMP2A function (Merchant et al., 2000). 
One in vivo downstream effector of LMP2A in B-cells of LMP2A transgenic mice was 
identified to be the adaptor protein SLP65 (SH2-domain containing leukocyte protein) 
(Engels et al., 2001). Studies with LMP2A transgenic mice indicate that Nedd4 ubiquitin 
ligases downregulate LMP2A activity in B-cells in vivo (Ikeda et al., 2003). 
DNA microarrays of primary B-cells from LMP2A transgenic mice, LMP2A-expressing 
human B-cell lines and LMP2A-positive and -negative LCLs revealed that LMP2A has 
multiple effects on global gene expression. It increases expression of genes associated with 
cell cycle induction and inhibition of apoptosis, alters the expression of genes involved in 
DNA and RNA metabolism and decreases expression of B-cell specific factors and genes 
associated with immunity (Portis & Longnecker 2003, 2004, Portis et al., 2003). Notably, 
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these alterations mirror those described for Hodgkin/Reed-Sternberg cells present in Hodgkin 
lymphoma, in which LMP2A transcripts have been identified (Portis et al., 2003, reviewed in 
Thorley-Lawson 2001). 
The function of LMP2A in epithelial cells differs from its function in B-cells 
In epithelial cells, LMP2A function might differ from that in B-cells. Tyrosine 
phosphorylation of LMP2A in epithelial cells was triggered by cell adhesion to extracellular 
matrix proteins and was not mediated by Src PTKs but by the C-terminal Src kinase (Csk, a 
negative regulator of Src) in vivo and in vitro, with the ITAM being the major site of in vitro 
phosphorylation (Scholle et al., 1999, 2001). Most notably, LMP2A has transforming 
capabilities and inhibits cell differentiation in the human keratinocyte cell line HaCaT 
(Scholle et al., 2000). In HaCaT cells and in telomerase-immortalized human foreskin 
fibroblasts (HFK), LMP2A activated the serine/threonine kinase Akt (but not MAPK activity) 
(Scholle et al., 2000, Morrison et al., 2003). Akt is implicated in the inhibition of apoptosis 
and is physiologically activated upon BCR crosslinking via the PI3K signaling pathway. 
Activation of Akt seemed to be responsible for cellular transformation induced by LMP2A in 
HaCaT cells (Scholle et al., 2000). 
In HFK cells, Akt activation by LMP2A leads to phosphorylation and inhibition of the pro-
apoptotic forkhead transcription factor (FKHR) and of the glycogen synthase kinase 3 β 
(GSK-3β). Inhibition of GSK-3β by LMP2A results in the stabilization of the proto-oncogene 
β-catenin (Morrison et al., 2003). In B-cells, LMP2A expression also mediates constitutive 
activation of Akt via PI3K, depending on Syk and Lyn, but in the absence of a survival 
phenotype (Miller et al., 1995b, Swart et al., 2000). However, transgenic expression of 
LMP2A in mouse epithelium showed no effect on epithelial differentiation and survival 
(Longan & Longnecker 2000). 
In 293 epithelial cells stably transfected with LMP2A, MAPKs Erk2 and JNK, but not p38 
were found to be activated, and activation of the Erk pathway was implicated in LMP2A-
mediated cell migration (Chen et al., 2002). Interestingly, cross-linking of the BCR of EBV 
transformed LCLs failed to induce MAPK activity, but treatment with phorbol esters could 
bypass this block (Panousis & Rowe, 1997). In epithelial cells, LMP2A localised to internal 
membranes but did not colocalise with LMP1 (Dawson et al., 2001). LMP2A, but not 
LMP2B, was able to augment LMP1-mediated signal transduction by prolonging its half-life 
in epithelial cells (Dawson et al., 2001). 
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1.3.2 R1 and R15 of Rhesus rhadinovirus (RRV) 
RRV has been isolated three years after the discovery of KSHV (Desrosiers et al., 1997) and 
two viral isolates have been completely sequenced, RRV 17577 (Searles et al., 1999, 
AF083501) and RRV 26-95 (Alexander et al., 2000, AF210726). RRV belongs to the old 
world RV-2 lineage of γ2-herpesviruses and has been predominantly detected in B 
lymphocytes (Mansfield et al., 1999). Genomic analysis revealed the existence of an ORF at 
the left hand side of the long unique region that codes for a membrane protein which was 
termed R1 due to its resemblance to KSHV K1 (see 1.3.5; Alexander et al., 2000, Searles et 
al., 1999). 
The right hand side of the long unique region of RRV, between ORF75 and the terminal 
repeat region, has the potential to encode an ORF reminiscent of EBV LMP2A and KSHV 
K15 (see figure 2, 1.3.1.2 and 1.3.6). This ORF was therefore termed R15 for RRV 26-95 by 
Alexander et al. (2000). R15 has not been experimentally analysed, but computational 
analysis of the region between ORF75 and the terminal repeats revealed an ORF with a 
potential splicing pattern strikingly similar to K15 and LMP2A (our observations, see figure 
2). This ORF has the potential to encode a transmembrane protein composed of 11 
transmembrane domains joined to a cytoplasmic C-terminus (our observations, see chapter 3.1 
and figure 9). The cytoplasmic domain would be predicted to contain several SH3-B motifs 
and motifs suitable for phosphorylation by cellular kinases (our observations). 
R1 is a type I transmembrane protein 
The ORF R1, located at the left side of the RRV genome (figure 2), codes for a type I 
transmembrane protein of 423 aa (figure 4) with a predicted molecular mass of 48 kDa 
(Damania et al., 1999). R1 has an apparent mass of 70 kDa in SDS-PAGE and is 
glycosylated, most likely at its N-terminal extracellular domain (aa 1-224) where it carries 
eight potential N-linked glycosylation sites (NXT or NXS). With respect to its N-terminal 
extracellular domain, R1 shares 27% identity (40% similarity) with the K1 protein of KSHV 
(see 1.3.5) and shows homology to a human immunoglobulin G receptor CD16 (Damania et 
al., 1999). The extracellular domains of K1 and R1 contain cysteine residues that may form 
disulfide linkages similar to members of the immunoglobulin receptor superfamily. 
Immunofluorescence studies with C-terminally tagged full length R1 protein revealed that it 
localises to the cytoplasm, and the authors proposed a possible endosomal localisation since 
R1 contains Y-X2-hydrophobic motifs that have been shown to serve as internalization signals 
of plasma membrane proteins (reviewed in Trowbridge et al., 1993), and a dileucine repeat 
(aa 318 and 319) which may also act as an endocytosis signal (Damania et al., 1999). 
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R1 contains several potential SH2-binding motifs and elicits B-cell activation signals 
The single transmembrane domain of R1 is succeeded by a long cytoplasmic C-terminal 
domain of 170 aa (aa 253-423), which contains a number of potential SH2-binding (SH2-B) 
domains (depicted in figure 4). The five distal SH2-B motifs are of the consensus sequence 
YXXL and of these, motifs Y394HGL and Y407NHL or Y407NHL and Y419DWL could 
potentially resemble an ITAM motif, but there is no evidence so far for this potential ITAM to 
be functional. The five membrane proximal motifs are of the consensus YXXA/P/T/V, which 
also have the potential to bind to SH2 domain containing proteins (Damania et al., 1999). Full 
length R1 directly interacts with the PTK Syk but not Src, and is in vitro and in vivo 
phosphorylated by Syk (Damania et al., 2000a). 
A chimeric protein consisting of the extracellular and transmembrane domain of the CD8 
receptor fused to the cytoplasmic tail of R1 is capable of eliciting intracellular calcium 
mobilization in B-cells and cellular tyrosine phosphorylation upon stimulation with an α-CD8 
antibody (Damania et al., 2000a). Furthermore, this chimera induces the activity of the B- and 
T-cell specific transcription factor NFAT (nuclear factor of activated T-lymphocytes) upon α-
CD8 stimulation in reporter assays in stably transfected and sorted B-cells, but also full length 
R1 was able to do so without stimulation in transiently transfected B-cells, but to a lower 
extent (Damania et al., 2000a). These results show that R1 is capable of inducing events 
leading to B-lymphocyte activation, however, attempts to define the domains in the 
cytoplasmic tail of R1 being crucial for these activities failed so far. 
R1 shows oncogenic properties 
The oncogenic potential of R1 was shown in two different systems: Expression of R1 in 
rodent fibroblasts (Rat-1) induces morphological changes and focus formation, and injection 
of R1 expressing Rat-1 cells into nude mice results in formation of multifocal tumours 
(Damania et al., 1999). When the Stp (saimiri-transforming protein, see 1.3.3) gene in the 
HVS genome was replaced with either the R1 or K1 (see 1.3.5) gene under control of the Stp 
promoter, these recombinant viruses could immortalize T lymphocytes from common 
marmosets to IL-2 independent growth, similar to wildtype HVS containing the oncogenic 
Stp protein (see 1.3.3; Damania et al., 1999). 
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1.3.3 Saimiri transforming protein (Stp) and tyrosine kinase interacting protein (Tip) of 
Herpesvirus saimiri (HVS) 
The simian herpesviruses HVS and Herpesvirus ateles (see 1.3.4) are unique in their ability 
to induce T-cell lymphomas and leukemias in several primate species (Daniel et al., 1974, 
Melendez et al., 1969a, b, reviewed in Fickenscher & Fleckenstein 2001). HVS, a T-cell 
specific virus, naturally persists in squirrel monkeys without causing disease (Melendez et al., 
1968, Falk et al., 1972). The far left end of the HVS genome was found to be highly variable, 
and HVS strains were therefore classified into the three subgroups A, B and C which differ 
with respect to their oncogenic potential (Medveczky et al., 1984, 1989, Desrosiers & Falk 
1982). Strains of all subgroups are able to induce T-cell lymphomas in cottontop marmosets, 
but only members of subgroup A and C cause disease in common marmosets (Duboise et al., 
1998a). 
HVS strains A and C immortalize common marmoset T-lymphocytes to IL-2 independent 
growth, and the most highly oncogenic HVS strain C can also immortalize human, rabbit and 
rhesus monkey lymphocytes and cause fulminant lymphoma in rhesus monkeys and New 
World primates (Desrosiers et al., 1986, Szomolanyi et al., 1987, Broker et al., 1993, 
Biesinger et al., 1990, 1992). Among HVS C strains, isolate HVS C-488 is more transforming 
than isolates HVS C-484 and C-139 (Fickenscher et al., 1997). 
These biological differences have been assigned to the genes encoded at the left end of the 
long unique regions of HVS, localised at the equivalent position as EBV LMP1, KSHV K1 
and RRV R1. The HVS TMPs encoded by this region were termed saimiri transforming 
proteins (Stp) A, B or C (figure 2). HVS strain C encodes an additional TMP at the left end of 
its genome termed Tyrosine kinase interacting protein (Tip) (figure 2). A TMP encoded at the 
far right end of the HVS genome has not been described. 
StpA and StpC-Tip are recquired for the oncogenic potential of HVS strains A and C 
At the left end of the HVS genome, ORF 1 of strain A11 codes for the oncogenic StpA 
protein (164 aa) (Murthy et al., 1989) and of strain B (SMHI) for the StpB protein (171 aa, 
Choi et al., 2000b, Hor et al., 2001), whereas two highly oncogenic proteins are derived from 
a bicistronic transcript of HVS strain C-488 termed StpC (ORF2) and Tip (ORF1; Biesinger 
et al., 1990, 1995, Jung et al., 1991, Fickenscher et al., 1997, Lund et al., 1995, 1996; figure 
2). StpA has been shown to be required for in vitro T-cell transformation and in vivo 
leukemogenesis (Desrosiers et al., 1985, 1986, Murthy et al, 1989). StpC and Tip have clearly 
been shown to be responsible for the oncogenic potential of HVS strain C (Medveczky et al., 
1993b, Duboise et al., 1998a). Recombinant HVS either lacking StpC or Tip are neither able 
to immortalize T lymphocytes in vitro to IL-2 independent growth nor to produce fatal 
lymphomas in infected common marmosets as wildtype HVS, but StpC and Tip are 
dispensible for replication and persistence (Duboise et al., 1998a). However, Tip expression 
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alone is not sufficient for oncogenic transformation in rodent fibroblasts (Jung et al., 1991), 
but it induces T-cell lymphomas in transgenic mice (Wehner et al., 2001) and rabbits infected 
with a HVS Tip-484 deletion mutant survive (Lund et al., 1997a). In contrast to StpB, StpA 
and StpC transform rodent fibroblasts (Jung et al., 1991) and transgenic mice expressing 
StpC-488 or StpA-11 develop tumours (Murphy et al., 1994, Kretschmer et al., 1996). 
StpA and StpC are structurally similar 
Although StpA, B and C show an extensive sequence divergence (StpB is 28% identical to 
StpA and 22% identical to StpC), they show structural similarities. The structure of both StpA 
and C comprises a highly acidic N-terminus followed by collagen-like repeats (Gly-X-Y, with 
X or Y being a proline residue) and a hydrophobic membrane anchor, whereas StpB is lacking 
the collagen-like cluster (figure 4; Jung & Desrosiers 1991, 1994, Lee et al., 1997). The net 
negative charge in the first 17 aa of the N-terminus of StpC-488 was found to be important for 
protein structure and transformation (Jung & Desrosiers 1994). 
StpC-488 is membrane bound and localises primarily to perinuclear compartments in rodent 
fibroblasts, and the hydrophobic C-terminal region has been shown to be critical for 
membrane localisation (Jung & Desrosiers 1991, 1994). Whereas the predicted mass for StpC 
(102 aa) is 9.9 kDa, it has an apparent mass of 20 kDa and 22 kDa, with the 22 kDa form 
being phosphorylated in vivo at serine residue S3 (Jung & Desrosiers, 1991, 1992, Jung et al., 
1991). While StpC has 18 direct uninterrupted repeats of a collagen motif (G-P-P or G-P-Q 
encompassing 54 aa) in its N-terminus, StpA has only nine that are not directly repeated 
(figure 4; Biesinger et al., 1990, Geck et al., 1990, Lee et al., 1997). 
Several lines of evidence point to an important role of the collagen repeats of StpA and 
StpC in transformation. First, StpB, which is not capable to transform rodent fibroblasts, lacks 
collagen repeats, but when 18 collagen repeat sequences are introduced into its N-terminus, it 
is able to oligomerize, activate NF-κB and transform rodent fibroblasts (Choi et al., 2000b). 
Second, a mutation disrupting the collagen repeats has been shown to abolish the 
transforming activity of StpC-488 (Jung & Desrosiers 1994). 
Stp A, B and C interact with TRAFs, but only StpA and StpB bind PTKs 
StpA and B both contain SH2-B motifs of the consensus YAEV/I and all three Stp proteins 
have TRAF-binding sites (consensus PXQXT/S, see below). The SH2-B motif Y115AEV of 
StpA is preceded by negatively charged aa, matching well with the consensus binding 
sequence for SH2 domains for Src family PTKs (EEXXYEEV/I) (Songyang et al., 1993, 
1994). Y115 of the StpA Y115AEV motif has been shown to be crucial for binding to Src and 
was reported to be phosphorylated by Src in vitro (Lee et al., 1997). Tyrosine phosphorylation 
of StpA by Src (in vivo) leads to subsequent binding of Lck and Fyn in vitro (Lee et al., 
1997). The SH2-B motif Y118AEI of Stp-B is not preceeded by negatively charged residues, 
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and substitution to negatively charged amino acids resulted in stronger binding to Src, but 
activation of Src kinase activity by StpB in 293-T cells was not observed by Choi et al. 
(2000b). In contrast, another group reported that StpB was, like StpA, phosphorylated in vitro 
and in vivo in the presence of Src in cos cells (Hor et al., 2001). Furthermore, Hor et al. 
(2001) showed that Src binding to StpB was abolished when Y118 was mutated, and that Src 
binding to StpA and StpB seems to occur via the SH2 domain of Src. 
StpC activates the transcription factor NF-κB and interacts with cellular Ras 
Although StpA-11 and StpC-488 were shown to bind to TRAFs-1, -2 and -3 via their TRAF 
binding sites (see below), and StpB to interact with TRAF-1 and -2, StpA and StpB were not 
able to activate the transcription factor NF-κB (Lee et al., 1999, Choi et al., 2000b). In 
contrast, activation of NF-κB by StpC in epithelial cells is dependent on an intact TRAF 
binding motif (residues P10 or I11, Lee et al., 1999) and the presence of functional TRAFs 
(Sorokina et al., 2004). 
 
  TRAF-binding motif:  P   XQXT/S 
  StpA-11   P60 VQES 
  StpB SMHI   P41 TQHT and P84 VQET 
  StpC-488   P10 IEET 
  LMP1    P204QQAT 
  CD40    P   VQET 
 
Interestingly, studies with recombinant HVS carrying the StpC gene with a P10→R10 point 
mutation showed that loss of TRAF interaction and NF-κB activation by StpC is not essential 
for transformation of common marmosets T lymphocytes in vitro and in vivo, but crucial for 
immortalization of primary human T lymphocytes (Lee et al., 1999). Stable expression of 
StpC-488 and a dominant negative TRAF-2 mutant in Rat-1 cells drastically suppressed NF-
κB activity and the transformation of Rat-1 cells by StpC (Lee et al., 1999). These data 
suggest that binding to TRAFs seems to be a major component of the oncogenic potential of 
StpC, reminiscent of the LMP1 protein of EBV, but TRAFs seem not to be the only effectors 
for StpC-associated oncogenicity. 
 
As an additional interaction partner of StpC, cellular Ras has been identified. StpC is able to 
activate the Ras signaling pathway, indicated by a 2-4 fold increase in the ratio of Ras-GTP 
(active form) to Ras-GDP and constitutive activation of the MAPK Erk2 (Jung & Desrosiers 
1995). Ras binding to StpC was reported to be abolished with StpC mutants showing no or 
reduced transforming potential (Jung & Desrosiers 1994, 1995). In addition, StpC-488 is 
capable of competing with Raf-1, the downstream effector of Ras, for binding to Ras (Jung & 
Desrosiers 1995). Experiments with recombinant HVS in which the StpC gene was replaced 
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by cellular or viral oncogenic Ras showed that Ras could substitute the StpC-488 protein in 
lymphocyte transformation, but with lower efficiency (Guo et al., 1998). 
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Figure 4: Structure of viral terminal membrane proteins K1, R1, StpC, Tip and Tio. The type I membrane 
proteins K1 and R1 consist of an N-terminal extracellular domain, one transmembrane domain and a cytoplasmic 
C-terminal domain with potential SH2-B motifs. StpC, Tip and Tio are type II membrane proteins with their N-
terminus located in the cytoplasm. The Tio protein of HVA is 33% identical to Tip in its C-terminal part, 
whereas it shares 36% identity with StpC in its N-terminal part. The consensus motif for an ITAM is 
(D/E)X7(D/E)X2YX2LX7-10YX2L/I and for TRAF binding PXQXT/S. 
(ITAM = immuno receptor tyrosine-based activation motif, X = any amino acid, TRAF = tumour necrosis factor 
receptor-associated factor, TM= transmembrane, C1, C2 = conserved regions 1 and 2, V1, V2 = variable regions 
1 and 2, * = aa 37-79 of Tip-488 are absent in Tip-484, CSKH = C-terminal Src-related kinase homology). 
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The Tip protein interacts with Lck, a major T-cell protein tyrosine kinase 
Two different variants of the Tip protein have been described in the literature, Tip-484 of 
HVS strain 484 (ORF2, 214 aa; Geck et al., 1990, Lund et al., 1995) and Tip-488 of HVS 
strain 488 (ORF1, 256 aa; Biesinger et al., 1990, 1995). They show 71% aa identity, with Tip-
484 lacking 42 aa (aa 37-79 of Tip-488) in its N-terminal domain (figure 4). Both Tip proteins 
can form stable complexes with Lck, a major T-cell kinase that physiologically interacts with 
the T-cell antigen receptor (TCR), CD4, CD8 and IL-2 receptors (Biesinger et al., 1995, Lund 
et al., 1996). 
The binding domain for the Lck kinase has been mapped to (i) a region encompassing the 
potential Tip SH3-B motif (10 aa) that has been shown to bind to the SH3 domain of Lck, (ii) 
a CSKH (C-terminal Src related kinase homology) domain (10 aa) which mediates binding to 
the C-terminal half of Lck and (iii) the 18 aa region between those two motifs (figure 4; Jung 
et al., 1995b, Lund et al., 1996, Hartley et al., 2000, further details in Schweimer et al., 2002). 
The Lck binding domain of Tip-484 is sufficient for activation of Lck in vitro and in vivo and 
also for in vitro STAT-3 binding and activation if expressed in T-cells (Lund et al., 1999). 
Maximal activation of Lck was shown to require simultaneous binding of both Lck domains 
to Tip-484 (Hartley et al., 2000). 
Furthermore, Tip can be phosphorylated in vitro by Lck (Biesinger et al., 1995, Jung et al., 
1995a, b). Further evidence for Tip interaction with PTKs was provided by fluorescence 
spectroscopy studies showing that Tip-peptides bound to the SH3 domains of Src, Lck, Hck, 
Lyn, Fyn and Yes, with highest affinity for Lyn, Hck and Lck (Schweimer et al., 2002). 
The effect of Tip on Lck kinase activity 
It is a contentious issue whether Tip binding to Lck results in an increase or decrease of Lck 
kinase activity (reviewed in Isakov & Biesinger 2000). In T-cells and 293 cells transfected 
with Tip-484 (Lund et al., 1997a, Hartley et al., 1999, 2000) and in HVS-484 infected human 
peripheral blood T lymphocytes (Lund et al., 1997a), Lck kinase activity was found to be 
elevated. Expression of Tip-488 was also reported to enhance Lck kinase activity in T-cells 
(Wiese et al., 1996). Interestingly, in vivo and in vitro activation of Lck kinase activity by 
Tip-484 seemed not to involve the known regulatory sites within Lck (Hartley et al., 1999). 
Others observed downregulation of cellular tyrosine phosphorylation and suppression of 
Lck and Zap-70 activity in Tip-488 stably transfected T-cells (Jung et al., 1995a). In addition, 
the transformed phenotype of NIH 3T3 fibroblasts expressing activated Lck kinase was 
suppressed by coexpression of Tip 488 (Jung et al., 1995a). However, in one study (Kjellen et 
al., 2002) Tip-484 and -488 were analysed in parallel and both were able to stimulate Lck 
kinase activity in vivo and in vitro. Mutation of Y114 in Tip-488 was found to enhance the 
suppression of cellular tyrosine phosphorylation and to increase Lck binding activity 
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compared to wildtype Tip (Guo et al., 1997). In contrast, Kjellen et al. (2002) found that 
mutant Tip-488 Y114F could stimulate Lck activity as well as wildtype Tip. 
Studies with Tip-488 in the context of the complete HVS genome showed that a Tip protein 
in which the prolines in the SH3-B motif have been substituted by alanines (HVS-Tip∆SH3-
B) was unable to bind Lck but was still able to immortalize common marmoset T 
lymphocytes in vitro and in vivo (Duboise et al., 1998b, Yoon et al., 1997), suggesting that 
Lck binding to Tip is not essential for immortalization. However, abrogation of Lck binding 
to Tip resulted in altered characteristics of the transformed cells/lymphomas (Duboise et al., 
1998b). T-cells transformed with HVS-Tip∆SH3-B also showed an increased NF-κB activity 
and upregulated expression of TRAFs-1,-2 and -3, but the relevance of this observation is not 
yet clear. 
Tip activates the transcription factors NFAT, NF-κB, STAT-1 and -3 
Tip-484 induction of DNA-binding of STAT-1 and -3 was shown to be dependent on Lck in 
T-cells (Lund et al., 1997b, 1999). Tip-484 is phosphorylated by Lck at Y72 (= Y114 in Tip-
488) of the Y72XPQ motif, and subsequently STAT-1 and -3 are phosphorylated and STAT 
dependent transcription is induced in 293-T cells (Hartley & Cooper 2000, Kjellen et al., 
2002). STAT-3 can be phosphorylated in vitro by a complex of GST-Tip and Lck, and T-cells 
infected with recombinant HVS or expressing recombinant Tip showed significant increase of 
DNA-binding activity of STAT-1 and -3 and increased in vivo phosphorylation of STAT-3 in 
the presence of Lck (Lund et al., 1997b). Transient expression of Tip-484 in T-cells was 
found to stimulate STAT-3- and NFAT-dependent transcription, and this required both Lck 
binding domains of Tip (Hartely et al., 2000). Tip-484 and -488 were shown to stimulate 
NFAT and STAT-3 dependent transcription in T-cells (Kjellen et al., 2002). 
Furthermore, Tip-488 interacts with the nuclear RNA export factor Tap (Tip-associated 
factor) and co-expression of Tip and Tap in T-cells results in upregulated surface expression 
of adhesion molecules and activation of NF-κB. However, the role of Tap in Tip signaling is 
not clear yet (Yoon et al., 1997). 
Tip has an effect on the TCR and localises to lipid rafts 
Tip-488 interacts with a WD repeat domain containing endosomal protein termed p80. This 
interaction was reported to lead to lysosomal vesicle formation and subsequent targeting of 
the Lck kinase into lysosomes for degradation. Furthermore, Tip interaction with p80 and Lck 
resulted in the downregulation of TCR and CD4 surface expression, respectively (Park et al., 
2002). 
Tip localises to lipid rafts in transfected T-cells and HVS-C488 transformed common 
marmoset T-cells (Park et al., 2003). While lipid raft association of p80 depended on co-
expression of Tip in transfected 293 cells, interaction of Tip and Lck was required for the 
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recruitment of the TCR to lipid rafts (Park et al., 2003). Based on these results and the 
observation that expression of Tip in human T-cells suppresses cellular tyrosine 
phosphorylation and surface expression of lymphocyte antigens (Jung et al., 1995a), Park et 
al. (2003) postulate that Tip might mediate TCR downregulation and thereby interfere with 
the host´s immune control in the following scenario: Upon Tip and Lck interaction, TCR 
complexes would be recruited to lipid rafts and subsequently, Tip would interact with p80 and 
initiate aggregation and internalization of the lipid raft domain, leading to downregulation of 
the TCR complex. 
1.3.4 The Herpesvirus ateles (HVA) two-in-one (Tio) protein 
Herpesvirus ateles (HVA) causes fulminant lymphomas in various New World primates and 
is most closely related to Herpesvirus saimiri (Melendez et al., 1972a). The natural host of 
HVA is the spider monkey (Melendez et al., 1972b). HVA isolates from two strains (810 and 
73) have been described to transform monkey T-cells to permanent growth in vitro and in 
vivo (Hunt et al., 1972, Laufs & Melendez, 1973, Melendez et al., 1973). 
Tio shares sequence similarity with StpC and Tip of HVS 
In transformed monkey T-cells, a single spliced mRNA derived from the highly variable left 
region of the HVA genome (strain 73) is transcribed and gives rise to a protein of 269 aa with 
a predicted mass of 29 kDa (Albrecht et al., 1999, 2000). The term “Two-in-one” (Tio) for 
this protein is derived from its sequence similarity to HVS strain C oncogenic proteins StpC 
and Tip (figure 4). Tio shares 36% aa identity in its N-terminal third with StpC, whereas its 
C-terminal two thirds are 33% identical to Tip (figure 4; Albrecht et al., 1999). However, the 
collagen repeats (Gly-X-Y, with X or Y being a proline residue) of which StpC has 18 in a 
perfect repetetive order are fewer in number (4) and interrupted by proline rich regions in the 
Tio protein (figure 4). 
Tio and Tip share a CSKH motif which is homologous to the αI helix of Src (Xu et al., 
1997), a conserved SH3-B domain (P187PPQLPPR) and a serine rich motif of unknown 
function (figure 4; Albrecht et al., 1999). Tyrosine residues of motifs Y136IPW (Y127TTF in 
Tip) and Y167PKN (Y155PPD in Tip) are conserved between Tip and Tio, whereas the tyrosine 
residue of the putative SH2-B motif of Tio, Y171KKL, is not conserved (figure 4). 
Tio interacts with and is phosphorylated by PTKs 
In lysates of transformed monkey T-cells and in 293-T cells transfected with recombinant 
Tio, protein bands of 43 and 46 kDa are detected. Additionally, a homodimeric form of Tio is 
observed in 293-T cells (Albrecht et al., 1999). When co-transfected in 293-T cells with Src 
family members of PTKs Lck, Src and Fyn, a tagged Tio protein is in vivo phosphorylated on 
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tyrosine and directly binds to Lck, Src and Fyn. Fluorescence spectrometry assays performed 
with a Tio peptide encompassing its SH3-B domain revealed that this binds to GST-SH3 
domain fusion proteins of Lyn, Hck, Lck, Fyn, Src and Yes, but not of Abl, the p85α subunit 
of PI3K or Grb2 (Albrecht et al., 1999). However, a direct binding assay with the complete 
Tio protein was only performed with the SH3 domain of Lck and confirms the peptide 
approach. 
Direct binding of Tio to the SH2 domains of Lck, Src and Fyn is only observed when Tio is 
tyrosine phosphorylated (Albrecht et al., 1999). Interaction of Tio with SH2-domains seems 
to be specific for members of the Src familiy of PTKs, since binding of Tio to SH2 domains 
of Abl, Vav, Grb2 and phospholipase γ was not observed. 
 
Thus, Tio combines functions of Tip regarding its interaction with PTKs of the Src family 
via its SH3-B motif and with StpA/B with respect to binding to Lck, Src and Fyn via its SH2-
B motif in a phosphotyrosine dependent manner. However, despite of the structural 
similarities of Tio and the oncoprotein StpC, no functionally related features have been 
identified so far. The only data indicating that Tio might be an oncoprotein is its similarity to 
the oncoproteins StpC and Tip of HVS regarding its structure and genomic localisation, its 
ability to interact with members of the Src familiy of PTKs and its expression in virus-
transformed monkey T-cells. 
1.3.5 The KSHV K1 protein 
KSHV encodes a 46 kDa type I transmembrane glycoprotein (289 aa) known as K1 at the 
left end of its genome (Russo et al., 1996, Lagunoff & Ganem 1997, Lee et al., 1998a) in a 
position similar to that of the Stp gene of HVS, the R1 gene of RRV and Tio of HVA (figures 
1 and 2). 
The extracellular domain of K1 is structurally similar to that of the R1 protein, but shows no 
similarity to Stp, Tip or Tio regarding aa sequence or structure (figure 4). The K1 protein has 
transforming capabilities in so far as it can induce morphological changes and focus formation 
in rodent fibroblasts (Lee et al., 1998a). In addition, K1 can functionally substitute the StpC 
gene in the context of the HVS genome with regard to immortalization of common marmoset 
T-lymphocytes to interleukin-2-independent growth and the induction of lymphomas (Lee et 
al., 1998a). 
K1 displays high sequence divergence in its extracellular domain 
K1 is composed of an N-terminal domain exposed to the extracellular matrix, a single 
transmembrane domain and a cytoplasmic C-terminal domain of 38 aa (figure 4). The N-
terminal domain of K1, especially the variable regions 1 and 2 (V1, V2), displays high levels 
of genetic variability between different KSHV isolates (except for 12 conserved cysteine 
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residues), with 15-30% divergence at the aa level. This led to the definition of four to five 
major subtypes of K1 (A-E) and 13 distinct variants plus several clades (Nicholas et al., 1998, 
Cook et al., 1999, Cook et al., 2002, Hayward 1999, Lacoste et al., 2000, Zong et al., 1999). 
Different V1 and V2 regions seem to correspond to different geographic areas. For example, 
K1 subtype B is found in KS patients from Africa, whereas subtype C2 is found in classic KS 
in the Middle East, Asia, Europe and USA, and AIDS KS samples from USA predominantly 
have A1, A4 and C3 K1 variants (Cook et al., 1999, Hayward 1999, Kasolo et al., 1998, 
Lacoste et al., 2000, Zong et al., 1999). Notably, the R1 protein of different macaque species 
shows much less amino acid sequence divergence (1-7%) than K1 (Damania et al., 1999). K1 
has been shown to oligomerize, most probably via disulfide linkage of its N-terminal domain 
(figure 6; Lee et al., 1998a, Lagunoff et al., 1999) and contains several N-glycosylation sites 
in its extracellular domain. 
K1 is a lytic protein 
K1 is predominantly expressed during the lytic phase of the viral life cycle (Lagunoff & 
Ganem 1997). A 1.3 kb K1 transcript was detected in BCBL-1 cells induced with TPA 
(Lagunoff & Ganem, 1997), whereas a 1.3 kb and 3 kb K1 transcript were expressed in 
uninduced BC-3 cells, with both transcripts being upregulated in TPA-induced BC-3 cells 
(Samaniego et al., 2001). However, K1 transcripts detected during latency could represent K1 
transcription from the ~5% of BCBL-1 cells undergoing spontaneous lytic replication (Renne 
et al., 1996, 1998), and gene array studies indicate that K1 is a lytic rather than a latent gene 
(Jenner et al., 2001, Paulose-Murphy et al., 2001, Nakamura et al., 2003). It is nevertheless 
possible that there is minimal K1 expression during the latent viral life cycle. Studies with 
monoclonal antibodies raised against the N-terminal domain of K1 showed that K1 protein is 
expressed during the early lytic viral life cycle in PEL cell lines BCBL-1, BC-1 and Jsc-1 
(with little if any expression in unstimulated cells) and MCD tissue but not in KS lesions (Lee 
et al., 2003). By RT-PCR, Samaniego et al. (2001) identified K1 transcripts in KS lesions. 
The K1 promoter element from BCBL-1 cells contains binding sites for transcription factors 
SP-1, NF-1, AP-2 and myc-max and seems to be conserved between different K1 subtypes 
(Bowser et al., 2002). The K1 promoter was proven to be active in 293, KSHV negative 
(BJAB) and positive (BCBL-1) B-cells and KS tumour-derived endothelial cells (SLK-KS-). 
Ectopic expression of the major lytic switch protein of KSHV, ORF50/RTA, could further 
activate the K1 promoter element in 293, BJAB and BCBL-1, but not in SLK-KS- cells 
(Bowser et al., 2002), suggesting that K1 expression may be regulated differently in 
endothelial cells. 
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K1 contains a functional ITAM and signals B-cell activation 
The cytoplasmic tail of K1 contains an immunoreceptor tyrosine-based activation motif 
(ITAM), which is highly conserved between different K1 subtypes and is also present in 
LMP2A, but with the rightmost leucine of the second SH2-B motif (consensus YXXL/I) 
being substituted by proline in the K1 ITAM (Lee et al., 1998b): 
 
   LMP2A: DY74 QPLGTGDQSLY85 LGL 
   K1:  DY271YSLHDLCTEDY282TQP 
 
Studies in KSHV negative B-cells (BJAB cells) stably transfected with a chimeric protein 
consisting of the extracellular and transmembrane domain of CD8 fused to the cytoplasmic C-
terminus of K1 showed that the CD8-K1 chimera induced cellular tyrosine phosphorylation 
and calcium mobilisation upon stimulation with a α-CD8 antibody (Lee et al., 1998b). In this 
system, a single motif of the ITAM (Y271YSL or Y282TQP) was shown to be sufficient for 
induction of cellular tyrosine phosphorylation, but both were important for mobilisation of 
intracellular calcium. 
K1 binds several kinases and is tyrosine phosphorylated at its ITAM motif 
In BJAB cells, the CD8-K1 chimera is predominantly phosphorylated upon α-CD8 
stimulation at Y271 of K1, and also but to a lesser extent at Y282 of the ITAM motif (see figure 
4). Co-transfection studies in cos1 cells indicate that Syk could be a kinase responsible for 
this phosphorylation (Lee et al., 1998b). Phosphorylation of the CD8-K1 ITAM allowed 
subsequent binding of SH2 proteins Syk, Vav and PI3K. Phosphorylated forms of Syk, Cbl 
and PI3K, but not of Vav and Blk, were detected in antibody stimulated CD8-K1 expressing 
BJAB cells. Phosphorylated Syk kinase and phosphorylated phosholipase C-γ2 (PLC-γ2) were 
also detected in KSHV negative/EBV positive B-cells (Raji cells) transfected with full length 
K1, depending on an intact ITAM (Lagunoff et al., 1999). 
Co-transfection experiments in cos1 cells demonstrated that phosphorylated Syk but not Src 
interacted with CD8-K1, however, both kinases could phosphorylate the K1 ITAM motif, 
whereas only a weak phosphorylation was observed with Lyn and ZAP70 and none with Lck 
and Fyn (Lee et al., 1998b). Syk interaction was also observed with a K1 ITAM peptide 
phosphorylated on both tyrosines, but interaction of Syk with full length K1 has not been 
demonstrated yet (Lagunoff et al., 1999). In line with these data, signal transduction of full 
length K1 is impaired in a Syk deficient cell line, pointing to a role of this PTK in 
downstream signaling events of K1 (Lagunoff et al., 1999). 
Interestingly, K1 signaling was found to be quite different in KSHV positive BCBL-1 cells 
versus KSHV negative B-cells. In BCBL-1 cells, transfected K1 was no longer able to induce 
intracellular calcium mobilization or NFAT activation upon antibody stimulation and was 
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impaired in its ability to induce cellular tyrosine phosphorylation (Lee et al., 2002). However, 
Syk was activated, and Syk and Lyn expression levels were equal in both cell lines, but 
expression of PLC-γ2 and Cbl was weak in BCBL-1-K1 compared to BJAB-K1 cells (Lee et 
al., 2002). 
K1 activates the transcription factor NFAT and the PI3K/Akt pathway 
Full length K1 is able to activate the transcription factor NFAT in KSHV negative B-cells 
(Raji). This occurred in the absence of any cross-linking ligand, and was not completely 
abolished with a K1 double mutant (ITAM: Y271F, Y282F), indicating that flanking sequences 
of the two SH2-B motifs of the K1 ITAM are important for efficient signal transduction 
(Lagunoff et al., 1999). Constitutive signaling of K1 is attributed to its extracellular domain, 
that, when transferred to other consensus ITAMs, was able to induce constitutive signaling 
(Lagunoff et al., 1999). K1 signal transduction induced by antibody stimulation with K1 
monoclonal antibodies raised to the N-terminal domain required both the ITAM and the 
authentic conformation of the extracellular domain (Lee et al., 2003). K1 monoclonal 
antibodies recognizing aa 92-125 (encompassing the C2 and Ig-like region, see figure 4) 
could efficiently induce an increase in intracellular calcium concentration and cellular 
tyrosine phosphorylation in B-cells stably transfected with K1 (Lee et al., 2003). 
In B-cells, K1 was found to enhance the phosphorylation of the p85 subunit of PI3K and the 
kinase Akt, thereby activating them, and to enhance the phosphorylation of the regulator of 
the PI3K/Akt pathway, PTEN, thereby inactivating it (Tomlinson & Damania 2004). 
Therefore, K1 seems to signal via the PI3K/Akt pathway, and the K1 ITAM was shown to be 
essential for this feature. Activated Akt phosphorylates and thereby inactivates pro-apoptotic 
factors such as caspase 9, GSK3-β, Bad and members of the FKHR family of transcription 
factors, which results in cell survival. K1 expressing cells showed increased phosphorylation 
of FKHR, but not of Bad, caspase 9 or GSK3-β, and K1 was shown to be able to protect cells 
from FKHR- and Fas-mediated apoptosis (Tomlinson & Damania 2004). 
K1 activates the transcription factors NF-κB and AP-1 and affects cytokine expression 
In the context of KSHV tumourgenicity, it has been postulated that lytic viral proteins (e.g. 
vGPCR) may contribute to tumourigenicity by exerting paracrine effects. In reporter assays, 
K1 was reported to activate the transcription factor AP-1 eight fold in BJAB cells (Lagunoff 
et al., 2001) and to activate the transcription factor NF-κB four fold and AP-1 two fold when 
transiently expressed in cos1 cells (Samaniego et al. 2001). In our hands, K1 did not activate 
the AP-1 transcription factor in reporter assays in 293-T cells (unpublished results). 
In KS endothelial cells and B-cells transfected with K1, NF-κB-dependent promoter activity 
was induced. In addition, in KS cells expressing K1, the induction of secretion of 
inflammatory cytokines implicated in KS lesion formation such as IL-6, IL-12 and 
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granulocyte macrophage colony stimulating factor was observed, but not of RANTES, MIP-I 
or –II (Samaniego et al., 2001, Prakash et al., 2002). This would indicate that K1 could 
contribute to spindle cell formation in KS lesions, but further experiments are needed to 
support this notion. 
However, in K1 transgenic mice, serum IL-12 levels were severely impaired, and basic 
fibroblast growth factor (bFGF) expression was upregulated in lymphocytes and tumours (2 
of 13 mice developed tumours) of K1 mice (Prakash et al., 2002). bFGF is an autocrine 
growth factor for endothelial cells that promotes growth and angiogenesis of AIDS-KS cells 
(Samaniego et al., 1995). B lymphocytes of K1 transgenic mice showed constitutive 
activation of transcription factors NF-κB and Oct-2, increased tyrosine phosphorylation and 
activity of the B-cell specific PTK Lyn (Prakash et al., 2002). 
K1 can downregulate BCR surface expression 
Apart from the induction of signaling events from the plasma membrane, full length K1 was 
reported to downregulate the expression of the BCR complex at the cell surface of BJAB 
cells, thereby potentially inhibiting B-cell activation and allowing a long term survival 
advantage for KSHV infected cells (Lee et al., 2000). Based on studies with different CD8-K1 
chimeric proteins, the N-terminal domain of K1 was proven to be required for BCR surface 
downregulation, and not an intact ITAM. The N-terminal domain of K1 was shown to interact 
with the µ chains of the BCR complex, which probably leads to the retention of BCR subunits 
in the ER (Lee et al., 2000). The physiological interaction of BCR subunits Igα and Igβ with 
µ chains results in the direction of the BCR to the cell surface, so it seems that K1, showing 
structural homology to Igα and Igβ, may act as a dominant negative protein (Lee et al., 2000). 
Inhibition of BCR signaling is reminiscent of the LMP2A protein of EBV, which also 
contains an ITAM motif and interferes with BCR signaling. 
K1 has an effect on the viral life cycle 
K1 expression cannot by itself initiate viral replication (Lukac et al., 1998), but recent data 
suggest that K1 may augment reactivation of KSHV from its latent state and play a role in 
lytic gene expression (Lagunoff et al., 2001). When dominant negative K1 mutants (lacking 
the ITAM motif and shown to inhibit K1, Syk and PLC-γ2 phosphorylation) were expressed 
in the KSHV positive PEL cell line BCBL-1 together with an expression vector for the viral 
transactivator ORF50/RTA, gene expression of ORF59, which is an early lytic gene, was 
reduced by 80%. However, a mild decrease of ORF59 expression was also observed when K1 
wildtype was expressed instead of K1 dominant negative mutants (Lagunoff et al., 2001). 
Notably, the block in lytic replication induced by K1 dominant negative mutants could be 
overcome by TPA treatment (Lagunoff et al., 2001). This result would argue for the notion 
that K1 might signal via a pathway that can be bypassed by TPA treatment. TPA has 
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pleiotropic effects on B-cells, e.g. the induction of AP-1 activity via the Ras-Raf-MEK-Erk 
pathway. Whereas the calcineurin inhibitor FK506 could efficiently block NFAT activation 
by wildtype K1 in BJAB cells, and a dominant negative Ras mutant (Ras N17) could block 
K1 induced AP-1 activity, both FK506 and RasN17 did not have any effect on ORF59 
expression in BCBL-1 cells transfected with ORF50/RTA. This would suggest that K1, if it 
augments lytic reactivation, does not achieve this via these two pathways (Lagunoff et al., 
2001). 
In contrast to the observations made by Lagunoff et al. (2001), Lee et al. (2002) observed 
that K1 was able to suppress lytic KSHV reactivation induced by TPA but not by ORF50 
ectopic expression. A KSHV microarray (established by Paulose-Murphy et al., 2001) showed 
that the majority of viral genes was downregulated in BCBL-1-K1 cells treated with TPA 
(exceptions: levels of ORF48, K1 and K15 were upregulated, Lana and vFLIP not affected), 
including the viral transactivator ORF50/RTA (Lee et al., 2002). Expression of the late lytic 
glycoprotein K8.1 was not enhanced in BCBL-1-K1 cells treated with TPA, and this 
depended on a functional ITAM of K1 (Lee et al., 2002). Furthermore, TPA-induced 
activation of transcription factors AP-1, NF-κB and Oct-1 activities were diminished in 
BCBL-1 cells stably transfected with the CD8-K1 chimera, but not of NFAT, AP-2 and SP-1 
(Lee et al., 2002). 
Whereas the results by Lee et al. (2002) would suggest that K1, as EBV LMP2A and HVS 
Tip, may play a role in maintaining viral latency, the observations made by Lagunoff et al. 
(2001) would rather point to a role of K1 in augmenting the viral lytic cycle. 
1.3.6 The K15 open reading frame of KSHV 
The K15 ORF shows striking similarities to the EBV ORF LMP2A (see figure 5, K15 ex1-8 
M- and P-type). Both genes are located at exactly the same genomic position between the 
viral terminal repeat region and ORF75 (ORF75/BNRF1 in EBV) (see figures 2 and 5). K15 
and LMP2A genes show a complex, very similar splicing pattern concerning number and 
length of introns and exons (figure 5) and structural similarities (figure 3), although they are 
not homologous at the aa level. Furthermore, both ORFs code for membrane proteins with up 
to 12 transmembrane domains and a cytoplasmic domain (see figure 3; Glenn et al., 1999, 
Poole et al., 1999, Choi et al., 2000a). Whereas LMP2A has a long amino-terminal domain 
encoded by exon 1 and 2 with signaling motifs such as SH2-B and SH3-B sites and an ITAM 
motif, putative signaling motifs of K15 are located in its cytoplasmic C-terminus encoded by 
exon 8 (figures 3 and 5). 
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Figure 5: Splicing pattern of KSHV ORF K15 and EBV ORF LMP2A/B. Two K15 alleles, termed K15-P 
(predominant) and K15-M (minor) have been identified in different KSHV isolates. K15-P, K15-M and 
LMP2A/B show a highly similar splicing pattern and are both localised at the “right” end (in the orientation of 
the genome usually used in the γ2-herpesvirus field) of the respective viral genomes upstream of ORF75 (BNFR1 
in EBV). Whereas LMP2A has a long amino terminal domain encoded by exon 1 and 2 with signaling motifs 
such as SH2-B and SH3-B sites, putative signaling motifs of K15 are located in its cytoplasmic C-terminus 
encoded by exon 8. Splicing forms of K15 identified to date vary in the number of transmembrane domains, but 
all code for the cytoplasmic domain. The white/grey boxes indicate non-coding exons of LMP2 (ex1 of LMP2B, 
ex9 of LMP2A/B). as = alternative splice (see text for further details). 
K15 is multiply spliced and gives rise to proteins with different numbers of transmembrane 
domains and a putatively cytoplasmic C-terminus 
Expression of K15 transcripts was identified in unstimulated KSHV positive PEL cells (K15 
P-type: in BCP-1 and BCBL-1 cells; K15 M-type in Hbl-6 cells) and found to be upregulated 
upon lytic cycle induction (Glenn et al., 1999, Poole et al., 199, Choi et al., 2000a). Multiple 
alternatively spliced transcripts are generated from the K15 gene (exemplary transcripts are 
depicted in figure 5) with the most prominent transcript containing eight exons (figure 5, K15 
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ex1-8). The sequences of all K15 cDNA clones isolated so far are predicted to contain a 
common C-terminal cytoplasmic region (encoded by exon 8) linked to a variable number of 
transmembrane domains (figure 5). The eight exons are positioned such that any combination 
of exons identified to date would be in the same open reading frame (e.g. K15 ex1/6-8 
depicted in figure 5). Several splice variants identified (e.g. K15 ex1 as/4-8 and K15 ex1 as/6-
8) use an alternative splice donor and start codon in exon 1, which would be predicted to join 
a part of exon 1 out of frame with the other exons, resulting in an alternative six aa at the N-
terminus of the resulting protein (figure 5; Glenn et al., 1999, Choi et al., 2000a). This is 
reminiscent of LMP2, which also alternatively uses exon 1 resulting in two proteins LMP2A 
and LMP2B (see 1.3.1 and figure 5; Sample et al., 1989). 
K15 contains signaling motifs in its C-terminus: potential binding sites for SH2 and SH3 
domain-containing proteins and for TRAFs 
Two different forms of the K15 ORF, K15-P (predominant, found in the majority of KSHV 
genomes tested) and K15-M (minor) have been identified (Poole et al., 1999), which are 
almost identical concerning splicing pattern (figure 5) and protein structure, but show as little 
as 33% aa identity (Glenn et al., 1999, Poole et al., 1999, Choi et al., 2000a). 
The putative signaling motifs in the cytoplasmic C-terminus of these two K15 variants are 
highly conserved (see below), suggesting the conservation of associated functional properties. 
The cytoplasmic domain of K15 contains proline-rich domains that could potentially serve as 
SH3-B domains (K15-P: PP387PLPP, K15-M: P396PLPS, P480PPFQP, and T452PPPT) and a 
motif that is reminiscent of a TRAF binding site (consensus PxQxT/S) present in LMP1 
(K15-P: ATQ475PTDD, K15-M: PFQ484PADE). Furthermore, two potential highly conserved 
SH2-B sites are present in the cytoplasmic domains of K15-P and K15-M (K15-P: 
VFGY431ASIL and DDLY481EEVL, K15-M: TVTY444ASIL and DEVY490EEVL). However, 
since the YASI motif is not proceeded by negatively charged aa in either K15 type, it may not 
serve as an SH2-B motif but rather as an internalization motif (Bonifacino & Dell´Angelica 
1999). Since most K15 studies published so far have been performed with the P-type of K15, 
only signaling motifs of K15-P are depicted in figure 3. 
 
K15-M: P396PLPS Y444ASIL INQ464SGIS    PPPFQ484PADE Y490EEVL 
K15-P: P387PLPP Y431ASIL PDQ451SGMS    QAATQ475PTDD Y481EEVL 
LMP1:               PQQ206ATDD 
LMP2A:          Y112EEA 
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A CD8-K15 chimera is tyrosine phosphorylated and can downregulate BCR signaling 
Studies with BJAB cells stably transfected with a CD8-K15 chimera, in analogy to CD8-K1 
(see 1.3.5), revealed that the K15 cytoplasmic domain was not able to induce intracellular 
calcium mobilization and intracellular tyrosine phosphorylation upon α-CD8 antibody 
stimulation when compared to BJAB cells expressing the CD8-K1 chimera (Choi et al., 
2000a). In this system, the cytoplasmic tail of K15 was found to be constitutively 
phosphorylated at Y481 of the YEEV motif (Choi et al., 2000a). 
CD8-K15 seems to be capable of downregulating BCR signaling in B-cells, since 
stimulation of B-cells with an anti-IgM (BCR) antibody, which normally leads to BCR 
crosslinking and subsequent B-cell activation, resulted in a reduction of cellular tyrosine 
phosphorylation and levels of free calcium concentration in CD8-K15 expressing B-cells. 
This effect of CD8-K15 was abolished by mutating the prolines in the putative SH3-B motif 
(PPPLPP) to glycines in addition to point mutating Y481 to phenylalanine, indicating that both 
motifs could be crucial for blocking BCR signaling (Choi et al., 2000a). However, it has not 
been demonstrated yet that full length K15 can block BCR signaling as described for LMP2A 
and K1, and the mechanism by which K15 may be exerting this dominant negative effect on 
BCR signaling has not been investigated so far. 
K15 interacts with TRAFs and Hax-1 
The cytoplasmic domain of K15-P and K15-M can interact in vitro and in vivo with TRAFs 
-1, -2 and -3, reminiscent of EBV LMP1 which induces multiple signaling cascades via its 
interaction with TRAFs (Glenn et al., 1999, Brinkmann et al., 2003, see 1.3.1.1). In contrast 
to TRAF-1 and TRAF-3, TRAF-2 was no longer able to bind to a K15 deletion mutant 
lacking aa 473-489, which include the Y481EEV motif and the TRAF-like binding site 
ATQ475PT (Brinkmann et al., 2003). Furthermore, the C-terminus of K15 interacts with Hax-
1, which partly seems to involve the Y431ASI motif of K15 (Sharp et al., 2002). Hax-1 was 
shown to inhibit Bax-induced apoptosis (Sharp et al., 2002), but the relevance of its 
interaction with K15 is not clear. 
K15 expression in vivo 
In uninduced primary effusion lymphoma (PEL) cell lines, a 23 kDa protein was detected by 
by Western blotting with a monoclonal antibody (mab) raised to the C-terminal domain of 
K15 (Sharp et al., 2002). Upon TPA induction, expression of this 23 kDa protein decreased 
over time, suggesting latent kinetics for this protein. Immunofluorescence analysis of 
uninduced PEL cells with the K15 mab showed a cytoplasmic staining pattern in the majority 
of cells (Sharp et al., 2002). These observations contradict results obtained by RT-PCR by 
Glenn et al. (1999) and Choi et al. (2000a), who detected very low expression of K15 
   46
transcripts in uninduced PEL cells and a strong increase of K15 transcript expression upon 
induction with TPA, which would suggest K15 to be a lytic transcript. 
Since serum of some KS patients reacted with the cytoplasmic domain of K15-M and K15-P 
by Western blotting, K15 expression in KS seems likely (Glenn et al., 1999), but so far, K15 
expression has not been shown directly in KS lesions. K15 expression has been observed in 
MCD plasmablasts by immunofluorescence (Sharp et al., 2002). Reports about the 
intracellular localisation of transiently transfected K15 observed by immunofluorescence 
describe the formation of large patches on external and cytoplasmic membranes in 293 cells 
(Glenn et al., 1999), cytoplasmic, plasma membrane and perinuclear localisation in cos-1 and 
293 cells (Choi et al., 2000a, Sharp et al., 2002), and localisation to the endoplasmatic 
reticulum in Hela cells (Sharp et al., 2002). 
The high GC-rich terminal repeat region complicates the identification of the K15 promoter 
region, but 5´ RACE and primer extension studies indicate that the transcriptional start site of 
K15 might be located to the terminal repeat region (Lucille Rainbow, personal 
communication). A proximal TATATAA box motif and probable associated lytic cycle 
promoter elements are present just upstream of ORF K15-M exon 1 (BC-1 DNA), but not in 
K15-P (Poole et al., 1999). 
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Figure 6: Summary of the identified cellular interaction partners of viral TMPs of γ-herpesviruses and 
downstream signaling events. For many of the discussed viral terminal membrane proteins, the exact binding 
site via which interaction with the cellular effector molecules takes place is not determined yet. If the exact 
binding site is known, this is indicated in the text or in figures 3 and 4. 
 
 characteristics R1 K1 STP LMP1 TIO TIP LMP2A K15 
Direct interaction 
with 
Syk, but not Src - N-terminus with 
µ chains of BCR 
in the ER 
- Syk 
- Vav, PI3K, Cbl 
(CD8-K1) 
- Ras (StpC) 
- TRAF 1,2,3 
(StpA, StpC) 
- TRAF 1,2 
(StpB) 
- Src (StpA,B) 
- Fyn, Lck (StpA) 
-TRAF 1,2,3,5 via CTAR-1 
-TRADD, RIP via CTAR-2 
-JAK3 via CTAR-3 
- Via SH3-B site 
with Lyn, Hck, 
Lck, Src, Fyn, 
Yes but not Abl, 
PI3K, Grb2 
- Via SH2-B site 
with Lck, Src, 
Fyn but not 
phospholipase γ, 
Abl, Grb2, Vav 
- Lck, TAP, 
p80 
STAT 1,3 
- in vitro 
with Lyn, 
Hck, Lck 
weaker with 
Src, Fyn, Yes 
- Csk (in 
epithelial cells) 
- Nedd4-like 
ubiquitin 
ligases 
- Erk1 
- Lyn (via 
Y112EEA), Syk 
(via ITAM Y74, 
Y85), Fyn 
- TRAF 1, 2, 3  
(LMP1-K15 
chimera) 
- Hax-1 
Phosphorylated by Syk, Src (full 
length R1) 
Syk, Src at Y271, 
Y282, weakly by 
Lyn and ZAP70 
(CD8-K1) 
Src (StpA in vitro 
at Y115) 
not known In vivo by Lck, 
Src, Fyn 
Lck on Y in 
vitro 
Lyn, Syk, Erk1 phosphorylated at 
Y481 
Activated by Not known, 
maybe by 
oligomerisation 
Signals 
constitutively; 
maybe by 
oligomerisation 
Oligomerisation? Self-multimerisation, no 
ligand needed 
not known not known  not known 
Induction of Ca-
mobilization 
CD8-R1 chimera 
upon α-CD8 
stimulation 
K1 in B cells 
upon α-CD8 
stimulation 
- - n.d.  CD8-LMP2A 
N-terminal 
chimera 
No 
(CD8-K15 
chimera) 
Induction of cellular 
tyrosine 
phosphorylation 
CD8-R1 chimera 
in B cells upon 
α-CD8 
stimulation 
K1 in B cells 
upon α-CD8 
stimulation 
- - n.d. Tip-488 
suppresses 
Y~P 
- No 
(CD8-K15 
chimera) 
Induction of the 
activation of 
NFAT (by CD8-
R1 chimera upon 
α-CD8 
stimulation and 
full length R1 
without 
stimulation in B 
cells) 
- NFAT, NF-κB, 
AP-1, Oct2, Lyn, 
Syk, PLC-γ2 
Ras (?) 
- p85 of PI3K, 
Akt 
- inhibits PTEN 
and FKHR 
- secretion of 
inflammatory 
cytokines 
- NF-κB via 
TRAFs (StpC) 
- Erk2 (StpC) 
-NF-κB and p38 via 
CTAR-1,-2 
-JNK via CTAR-2 
- JAK3 and STAT 1,3 
- induces expression of: 
a) IL-6 in epithelial cells 
via TRAFs (NF-κB 
dependent) 
b) Fas, ICAM-1, CD40, 
LFA-3 
c) TRAF1 in B cells via 
CTAR-1 
d) A20, EGFR in epithelial 
cells via CTAR-1 
n.d. -STAT 3 
when Lck 
present (Tip-
484) 
-Activation 
or 
suppression 
of Lck 
activity (see 
text) 
- NF-κB (?), 
NFAT 
- Erk2, JNK1 in 
epithelial cells 
- PI3K/Akt in B 
cells and 
epithelial cells 
- β-catenin 
signaling in 
epithelial cells 
 
n.d. 
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 characteristics R1 K1 STP LMP1 TIO TIP LMP2A K15 
Self oligomerisation Little, likely via 
disulfide bonding 
of extracellular 
domain 
likely via 
disulfide bonding 
of extracellular 
domain 
Likely via 
collagen repeats 
(StpA, StpC) 
Yes, multimerizes via its 
membrane domains 
Homodimers n.d. Aggregation 
(?), clustering 
via C-terminus 
(?) 
n.d. 
Transformation of 
rodent fibroblasts 
When cloned into 
HVS genome 
Yes, but with low 
efficiency 
StpA and StpC, 
but not StpB 
 n.d. no - n.d. 
In vivo cell growth 
transformation 
When cloned into 
HVS genome 
When cloned into 
HVS genome 
StpA and StpC, 
but not StpB 
 n.d. Induces T 
cell 
lymphomas 
in transgenic 
mice 
- n.d. 
Transformation of 
T-lymphocytes 
from common 
marmosets 
yes yes StpA and StpC, 
but not StpB 
 n.d. no Transforming 
in keratinocyte 
cell line HaCaT 
n.d. 
Localization in lipid 
rafts 
n.d. yes (unpublished 
results) 
n.d. yes n.d. yes yes n.d. 
Effect on viral 
replication and 
interference with 
host immune 
control 
n.d. - inhibits lytic 
cycle in BCBL-1 
- dom.neg. K1 
mutants inhibit 
lytic cycle in 
BCBL-1 
- downregulates 
BCR surface 
expression 
-downregulation 
of KSHV genes 
- inhibition of B 
cell activation 
n.d.  n.d. TCR and 
CD40 down- 
regulation 
via p80 and 
Lck in 
human T 
cells? 
 
- Inhibits lytic 
cycle induction 
by inhibiting 
BCR signalling 
in vitro 
 
- Induces B cell 
survival in 
transgenic mice 
 
Downregulation 
of BCR 
signalling? 
 
Table 1: Functional features of γ-herpesvirus terminal membrane proteins. Besides structural commonalities (see figures 3 and 4), the viral terminal membrane proteins 
(TMPs) LMP1 and LMP2A of EBV, R1 of RRV, K1 and K15 of KSHV, Stp and Tip of HVS and Tio of HVA share functional features. The cellular signaling cascades initiated 
by these TMPs are summarised in figure 6. 
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1.4 Objectives 
Because of the resemblance of K15 to EBV latent membrane proteins LMP1 (with respect 
to TRAF binding) and LMP2A (with respect to the presence of SH2-B and SH3-B sites as 
well as structural similarities), we asked whether K15 is also able to elicit cellular signaling 
cascades. Since LMP1, StpC and K1 were shown to induce the activity of transcription 
factors, and K15 proteins could bind TRAFs which were proven to be essential for NF-κB 
activation by LMP1 and StpC, we investigated whether K15 could activate the NF-κB 
transcription factor. 
Another transcription factor, AP-1, is a target of several terminal membrane proteins of γ-
herpesviruses. LMP1 for example induces AP-1 via activation of the MAPKs p38 and JNK1, 
and StpC activates the MAPK Erk2, possibly through its interaction with and activation of 
cellular Ras. We therefore examined whether K15 has regulatory effects on one of the three 
MAPK pathways that lead to activation of AP-1 family members of transcription factors. 
Furthermore, we wanted to identify the site of tyrosine phosphorylation and the kinases 
phosphorylating K15 proteins - members of the Src family of non-receptor protein tyrosine 
kinases were potential candidates due to their role in signaling of viral TMPs LMP2A, K1, 
R1, StpA, Tip and Tio. 
In order to define the intracellular distribution of K15 proteins, immunofluorescence studies 
and cellular fractionation studies of transiently transfected cells were carried out. In addition, 
we investigated the in vivo expression of K15 proteins in several KSHV cell culture systems. 
Studies with the EBV LMP2A and the KSHV K1 protein indicated that they may play a role 
in the maintenance of viral latency, and we were therefore interested whether K15 proteins 
could also have a regulatory effect on the viral life cycle of KSHV. 
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2. Material and Methods 
2.1 Reagents and Chemicals 
Chemicals were purchased from the following companies: Amersham, AppliChem, Biomol, 
BioRad, Boehringer Mannheim, Difco, Eurogentech, Fluka, Gibco, ICN, Invitrogene, Life 
Technologies, Merck, Molecular probes, New England Biolabs, Pierce, Promega, Riedel-
deHaën, Roche, Roth, Santa Cruz, Seromed, Serva, Sigma and Stratagene. 
Consumables came from Amersham, Beckman, Biozym, Costar, Eppendorf, Falcon, Gilson, 
Greiner, Kodak, Macherey-Nagel, Pharmacia, Robbins, Qiagen, Sarstedt, Schleicher&Schuell 
and Whatman. 
Radionucleotides were purchased from Hartmann Analytics and restriction enzymes came 
from Amersham, New England Biolabs and Life Technologies. Oligonucleotides were 
purchased from MWG Biotech. 
2.1.1 Antibodies 
α-K15: 
Generated by M. Glenn (Glenn et al., 1999), rabbit polyclonal antibody, used in a dilution of 
1:1000. GST-K15355-489 fusion protein was prepared as described in 2.6.7. The K15 portion of 
the protein was cleaved by incubating in the presence of PreScission protease while still 
bound to GST beads according to the manufacturer´s instructions (Amersham Pharmacia). 
The cleaved C-terminal cytoplasmic domain of K15 (aa 355-489) was eluted with PBS and 
used to immunize two rabbits according to standard protocols. 
 
α-K15 C12C4: 
Mouse monoclonal, see 2.3.8. Tissue culture supernatant used in a 1:4 dilution. 
 
α-JNK1 C-17: 
Santa Cruz, rabbit polyclonal affinity-purified, used in a 1:1000 dilution. 
Raised against a peptide at the C-terminus of JNK1 of human origin. 
Molecular weight of JNK-1: 46 kDa 
 
α-Erk2 D-2: 
Santa Cruz, mouse monoclonal IgG2b, used in a 1:2000 dilution. 
Raised against a peptide at the C-terminus of human Erk2-encoded MAP kinase. 
Molecular weight of Erk2: 42 kDa 
 
α-p38 MAPK H-147: 
Santa Cruz, rabbit polyclonal, used in a 1:200 dilution. 
Raised against a recombinant protein corresponding to aa 213-360 at the C-terminus of human 
p38. 
Molecular weight of p38: 38 kDa 
 
α-Caveolin-1 (N-20): 
Santa Cruz, rabbit polyclonal affinity-purified, used in a 1:200 dilution. 
Raised against a peptide at the N-terminus of human caveolin-1. MW: 21-24 kDa 
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α-c-myc 9E10: 
Biomol, mouse monoclonal, protein A purified IgG1, used in a 1:1000 dilution. 
Immunogen: human pp62 c-myc (408-432) peptide. Targets the c-myc epitope 
EQKLISEEDL. 
 
α-phosphotyrosine P-Thyr-100: 
Cell Signaling, mouse monoclonal, used in a 1:2000 dilution. 
Binds phospho-tyrosine in a manner largely independent of the surrounding aa sequence. 
 
α-Flag M2: 
Sigma, mouse monoclonal, purified IgG1, used in a 1:2000 dilution. 
Recognizes the Flag epitope sequence DYKDDDDK. 
 
α-HA antibody 12CA5: 
Boehringer Mannheim, mouse monoclonal, IgG2bκ, used in a 1:4000 dilution for Western 
Blotting. Recognizes the HA peptide sequence YPYDVPDYA derived from the human 
influenza hemagglutinin protein. 
 
α-Calnexin: 
Hammond et al., 1994, rabbit polyclonal, used in a 1:1000 dilution. 
Calnexin is a 64 kDa type I membrane protein with chaperone-like function in the ER. 
 
α-K8.1 A/B: 
Zhu et al., 1999, mouse monoclonal, IgG2a, tissue culture supernatant used in a 1:2 dilution. 
Reacts with KSHV virion envelope-associated glycoproteins. 
2.2 Vectors and Primers 
If not otherwise indicated, all vectors listed code for resistance to Ampicillin. 
2.2.1 Eucaryotic expression vectors 
pFJEA: 
Eucaryotic expression vector containing a SRα-O promoter. Provided by J. Jung (Takebe et 
al., 1988). 
 
pcDNA3: 
T7 and SP6 promoter for in vitro transcription, CMV promoter for expression in mammalian 
cells. Bovine growth hormone polyadenylation signal. Ampr and Neomycinr. Invitrogen. 
 
pcDNA3.1(+): 
Derived from pcDNA3, with differences in the MCS and lack of the SP6 promoter. Ampr and 
Neomycinr. Invitrogen. 
 
pcDNA3.1 Myc-His (-) A: 
Derived from pcDNA3.1. With a C-terminal peptide containing the c-myc epitope and a 
polyhistidine metal-binding tag. Invitrogen. 
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pEF C-X: 
pEF BOS (Mizushima & Nagata, 1990) with 5´Cla/Sal/Bam/Xba polylinker, EF-1 α 
Promoter. Invitrogen. 
 
pEGFP-N1: 
N-terminal enhanced fluorescent protein (EGFP) vector suitable for generation of GFP fusion 
proteins for expression and localisation studies or expression of GFP in mammalian cells. 
Gene of interest will be inserted into the MCS and expressed as a fusion to the N-terminus of 
EGFP. CMV promoter, Kanr, Neor. Clontech. 
 
K15 wildtype constructs
(ex 1-8, aa 1-489)
K15 clone 35
K15 ex1-8 Y481F
K15 ex1-8 ∆473-489
F481
ORF K15 1 65432 87
K15 mutant constructs
Flag tag
artificial Kozak sequenceK
Y481K
K15 ex1-8 Kozak Y481F
F481K
K15 clone 24
and MBK15
Y481
Y481K
K15 Kozak
 
Figure 7: Expression constructs of K15 wildtype and C-terminal K15 mutants used in this study. See text 
(2.2.1) for further details. 
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Y481
K15 ex1/6-8
K15 ex1 as/6-8
Y481
K15 ex1 as/4-8
Y481
ORF K15 1 65432 87
LMP1-K15355-489 5´ Flag tag, LMP1 6 TM domains (aa 1-185) fused to 
K15 cytoplasmic domain (aa 355-489)
K15 natural splice variants
K15 N-terminal
deletion constructs
Y481
Y481
Y481
Y481
Y481
K15 ex8 (aa 355-489)
K15 ex7.2 (aa 327-489)
K15 ex7.1 (aa 314-489)
K15 ex6 (aa 296-489)
K15 ex4 (aa 188-489)
LMP1/K15 chimera LMP1-K15355-472
LMP1-K15355-438
LMP1-K15355-415 5´ Flag tag, LMP1 aa 1-185 fused to K15 aa 355-415
5´ Flag tag, LMP1 aa 1-185 fused to K15 aa 355-472
5´ Flag tag, LMP1 aa 1-185 fused to K15 aa 355-438
 
Figure 8: K15 N-terminal deletion constructs, LMP1-K15 chimera constructs and natural splice variants 
used in this study. See text (2.2.1) for further details. TM = transmembrane, as = alternative splice. For a 
detailed map of the deletion constructs of the LMP1-K15 chimera, see also figure 19. 
K15 expression constructs (see figures 7 and 8): 
pK15 clone 35: 
Contains a full length cDNA (exons 1-8) of K15 from the BCBL-1 PEL cell line (see 2.3.2) 
cloned into the EcoRI/XbaI sites of pFJEA. Contains an artificial Kozak sequence, begins at 
the putative start codon of K15 in exon 1, and contains a Flag epitope tag at its C-terminal 
end. Provided by J.-K. Choi (Choi et al., 2000a). 
 
pK15 ex1-8 (aa ∆473-489): 
Lacks the C-terminal 17 aa of K15. Generated by PCR amplification of K15 clone 35 with the 
upstream primer LAMPB5´ and reverse primer ex8ad1. PCR product was cloned into pGEM-
T and subsequently cloned into the NotI site of pFJEA (M. Glenn). 
 
pK15 ex1-8 Y481F: 
Carries the Y481→F481 point mutation in the Y481EEV motif of K15. Generated by PCR 
amplification of K15 clone 35 with the upstream primer LAMPB5´for and the reverse primer 
LAMPaY:Frev. PCR product was cloned into pGEM-T and subsequently cloned into the NotI 
site of pFJEA (M. Glenn). 
 
pK15 clone 24: 
Full length K15 cDNA clone (K15 aa 1-489) from the BCP-1 KSHV isolate. Generated by 
RT-PCR amplification of the K15 region using primer LRH6for (binding 192 bp upstream of 
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the putative start codon of K15) and primer ex8arev (binding to the start region of ORF75 245 
nucleotides downstream of the K15 stop codon). The resulting PCR product was cloned into 
pGEM-T (L. Rainbow, Glenn et al., 1999). 
 
pMBK15: 
pK15 clone 24 was digested with EcoRI and cloned into pFJEA. 
 
pMBK15 Kozak: 
Full length K15 with an artificial Kozak sequence at the ATG in exon 1 but without any tag. 
Generated by PCR on pMBK15 using primers K15EcoRIKozakfor and reverse primer 
FlagLAMPa3´. Cloned EcoRI in pFJEA. 
 
pMBK15 Kozak Y481F: 
Generated as pMBK15 Kozak but with reverse primer LAMPaY:Frev introducing the aa 
substitution Y481→F481. 
 
pMBK15 Kozak on pcDNA3.1: 
pMBK15 Kozak was digested EcoRI and the insert cloned EcoRI into pcDNA3.1. 
 
pK15 splice variants K15 ex1/6-8, K15 ex1 as/6-8 and K15 ex1 as/4-8: 
The cDNAs were generated by RT-PCR amplification of the K15 region (BCP-1 KSHV 
isolate, see 2.3.2) using primers LR65for (binding 192 bp upstream of the ATG in exon 1) 
and ex8arev, followed by a nested PCR with forward primer FJLampfor (binding 45 
nucleotides upstream of the K15 start codon), and reverse primer FJLamprev (binding at the 
K15 stop codon). PCR products were cloned into pGEM-T, and subsequently into the EcoRI 
and KpnI sites of pFJEA (L. Rainbow). 
 
K15 N-terminal deletion constructs: 
pK15 ex4-8: 
Initiates at the ATG in exon 4 and codes for aa 188-489 of K15. The PCR product amplified 
with primers MBexon4for and FlagLAMPa3´ from pK15-24 was cloned in pGEM-T and 
subsequently into the PspAI/SpeI sites of pFJEA.  
 
pK15 ex6-8 on pFJEA or pcDNA3.1: 
Begins at the ATG in exon 6 and codes for aa 296-489 of K15. The PCR product was 
amplified with primers MBexon6for and FlagLAMPa3´ from pK15-24 and cloned 
KpnI/EcoRI in pcDNA3.1 and subsequently KpnI/NotI in pFJEA. 
 
pK15 ex7.1-8 on pFJEA: 
Begins at the first ATG in exon 7 and codes for aa 314-489 of K15. The PCR product was 
amplified with primers MBexon7.1for and FlagLAMPa3´ from pK15-24 and cloned in 
pGEM-T and subsequently KpnI/NotI in pFJEA.  
 
pK15 ex7.2-8 on pFJEA or pcDNA3.1: 
Begins at the second ATG in exon 7 and codes for aa 327-489 of K15. The PCR product 
amplified with primers MBexon7.2for and FlagLAMPa3´ from pK15-24 was cloned 
KpnI/EcoRI in pcDNA3.1 and subsequently KpnI/NotI in pFJEA. 
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pK15 ex8: 
Codes for the putative C-terminal domain of K15 (aa 355-489). PCR was performed with 
primers ex8forVNSYRQ and FlagLAMPa3´ on pMBK15, and the amplified fragment was 
cloned KpnI/EcoRI in pcDNA3.1. 
 
pLMP1-K15355-489: 
Chimera consisting of the six N-terminal transmembrane domains of LMP1 (aa 1-185) and 
the cytoplasmic region of K15 (aa 355-489). Constructed by amplification of the 
transmembrane domain of LMP1 from plasmid pSG5-LMP1 using primers LMPLAMPa5´ 
(introduces the Flag epitope tag) and LMPLAMPa3´ (the first 25 nucleotides are homologous 
to a region in the C-terminus of K15). The resulting amplicon was purified and used as a 
primer together with primer FlagLAMPa3´ in a PCR using genomic BCP-1 DNA (see 2.3.2) 
as template. The resulting product was cloned KpnI/EcoRI into pcDNA3 (M. Glenn). N-
terminally Flag-tagged. 
 
pLMP1-K15355-489 deletion constructs (see also figure 8): 
Generated by PCR on plasmid pLMP1-K15355-489 with forward primer LMPLampa5´ and 
reverse primers ex8aD1rev, ex8aD2rev, ex8aD3rev to generate pLMP1-K15355-472, pLMP1-
K15355-438, pLMP1-K15355-415, respectively. Cloned KpnI/EcoRV in pcDNA3. All are N-
terminally Flag-tagged. M. Glenn. 
 
 
pSV-LMP1: 
Expression vector based on pHEBO (Sugden et al., 1985) in which LMP1 is expressed from a 
subgenomic EBV fragment under transcriptional control of the SV40 promoter/enhancer 
(Kieser et al., 1997). Provided by A. Kieser. 
 
pSG5-LMP1: 
LMP1 wildtype cloned in pSG5 (Huen et al., 1995, Liebowitz et al., 1992). pSG5 (Stratagene) 
contains the SV40 early promoter and a β-globulin intron upstream of the cloning site. 
Provided by A. Eliopoulos. 
 
pTRAF-1, -2, -3: 
cDNA plasmids expressing Flag-tagged human TRAF-1, -2, -3. Provided by M. Rothe. 
 
pcSrc, pcFyn, pEFYes: 
C-terminally myc-tagged protein tyrosine kinases. Src (full length chicken Src, aa 1-533) and 
Fyn (full length, human, aa 1-537) are both cloned EcoRI/BamHI into pcDNA3.1 Myc-His (-) 
A. Yes was cloned in pEF C-X. Constructed and provided by S. Lang. 
 
pEFLck, pEFHck: 
C-terminally myc-tagged full length PTKs, both cloned into pEF C-X. Constructed by A. 
Baur, provided by S. Lang. 
 
pSRα-HA-JNK1: 
HA-tagged MAPK JNK1 (Minden et al., 1994, Derijard et al., 1994). Provided by A. Kieser. 
 
pSRα-HA-Erk2: 
HA-tagged MAPK Erk2 (Minden et al., 1994). Provided by A. Kieser. 
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pCMV-HA-p38: 
HA-tagged MAPK p38α (Minden et al., 1994). Provided by A. Kieser. 
 
pRKH5: 
Expression vector containing a CMV promoter. Provided by A. Kieser. 
 
pRK-TRAF-2(87-501): 
Dominant negative mutant of TRAF-2 lacking aa 1-86 (comprising the N-terminal RING 
finger domain) cloned into pRKH5 (Hsu et al., 1996, Natoli et al., 1997, Rothe et al., 1995). 
Provided by A. Kieser. 
 
pTRAF-6(300-524): 
Dominant negative mutant of human TRAF-6. Lacks aa 1-299 including the RING finger 
domain. Cloned into pcDNA3.1 (Schultheiss et al., 2001). Provided by A. Kieser. 
 
pCis2: 
Expression vector provided by A. Kieser. 
 
pRas N-17: 
Dominant negative mutant of Ras with a single point mutation (Asparagine 17) cloned into 
pCis2 (Stacey et al., 1991). The aa substitution is localised to the putative Mg2+ binding site of 
Ha-Ras. Provided by A. Kieser. 
 
pKRSPA: 
Expression vector containing the Rous sarcoma virus promoter and the SV40 polyadenylation 
signal cloned into the distal ends of the MCS of the pBluescript-KS+ vector from Stratagene 
(Dorn et al., 1990). Provided by S. Ludwig. 
 
pErk2 C3 (Y185→F185): 
Dominant negative mutant of Erk2 in the vector background pKRSPA with one single aa 
substitution (Y185→F185) (Robbins et al., 1993, Ludwig et al., 1996). Provided by S. Ludwig. 
 
pRaf C4B: 
Dominant negative mutant of c-Raf-1. Carboxy-terminal deletion mutant which contains the 
Ras binding domain (Bruder et al., 1992) fused to HA and cloned into pKRSPA (Flory et al., 
1996, Ludwig et al., 1998). Provided by S. Ludwig. 
 
pRTA: 
RTA (ORF50) expressing plasmid with a Flag peptide sequence at the N-terminus. Contains 
the cDNA sequence of RTA following the CMV enhancer-promoter sequence cloned 
EcoRI/XbaI into pFlagCMV2 (Song et al., 2002). Provided by Ren Sun. 
 
pCaveolin-1-GFP: 
C-terminally GFP-tagged canine caveolin-1. Vector backbone is pEGFP-N1, Kanr (Pelkmans 
et al., 2001). Provided by A. Helenius. 
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2.2.2 Reporter vectors 
pRTU14: 
AP-1 reporter construct with the luciferase reporter gene under the control of a minimal 
promoter and four TREs (TPA response elements) (Kieser et al., 1996). Provided by A. 
Kieser. 
 
pRTU1: 
pRTU14 lacking the TREs (Kieser et al., 1996). Provided by A. Kieser. 
 
p3EnhκBconA-Luc: 
NF-κB reporter plasmid. Comprises the firefly luciferase gene cloned downstream of a 
minimal promoter into which three κB elements derived from the immunoglobulin kappa 
chain enhancer are inserted (Arenzana-Seisdedos et al., 1993, Eliopoulos et al., 1997). 
Provided by A. Eliopoulos. 
 
pGL2basic: 
Luciferase reporter vector (Promega). Lacks eucaryotic promoter and enhancer sequences. 
Expression of luciferase activity depends on insertion and proper orientation of a functional 
promoter upstream of the luciferase coding region. 
 
p3kbORF50P: 
3 kb promoter region of ORF50 amplified with primers NheIRTAfor and BglIIRTA2 from 
HBL-6 DNA (KSHV positive PEL cell line) and cloned NheI/BglII upstream of the luciferase 
cDNA of pGL2basic (Deng et al., 2000). Generated by A. Viejo-Borbolla. 
2.2.3 Procaryotic expression vectors 
pGEM-T easy: 
System for cloning of PCR products with single 3´ thymidine overhangs at the insertion site 
(Promega). Contains T7 and SP6 RNA polymerase promoters flanking a multiple cloning 
region within the α–peptide coding region of β–galactosidase. 
 
pGEX-6P-1, pGEX-3X: 
GST fusion vectors (Amersham Pharmacia). Contain a tac promoter for chemically inducible 
expression (IPTG) and an internal lacIq gene. pGEX-6P-1 encodes the recognition sequence 
for site-specific cleavage by PreScission protease and pGEX-3X the factor Xa protease 
recognition site between the GST domain and the MCS. 
 
GST-K15 fusion proteins (see figure 19): 
pGST-K15355-489: 
Entire predicted cytoplasmic domain (aa 355-489) of K15 (BCP-1 derived, see 2.3.2) fused to 
GST, cloned into pGEX-6P-1 (Glenn et al., 1999). 
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pGST-K15355-472: 
GST fusion plasmid in which the carboxy terminal 17 aa of K15 were deleted. Generated by 
PCR on pGST-K15355-489 using the 5´ primer GSTex8afor and the 3´ primer ex8aD1rev, 
cloned into pGEX-3X (M. Glenn). 
 
pGST-K15355-438: 
Generated using plasmid pGST-K15355-489 as template together with primer GSTex8afor and 
reverse primer ex8aD2rev, cloned into pGEX-3X (M. Glenn). 
 
pGST-K15355-373: 
Generated using plasmid pGST-K15355-489 as template together with primer GSTex8afor and 
reverse primer ex8aD4rev, cloned into pGEX-3X (M. Glenn). 
 
pGST-c-Jun: 
c-Jun-GST fusion protein (Kieser et al., 1997). Provided by A. Kieser. 
2.2.4 Primers 
Table 2 summarises the primers being used for reverse transcriptase reactions and PCR. 
Table 2: Primers used for RT-PCR and PCR. The primer sequences are shown in 5´ to 3´ direction. Primer 
LMPLAMPa5´ introduces the Flag epitope tag DYKDDDDK (sequence underlined), whilst the first 25 
nucleotides of LMPLAMPa3´ are homologous to a region within the carboxy terminus of K15 (sequence 
underlined). Substituted bases are marked in bold. 
Name 5´-3´ sequence 
LR65for ACGATCTAGATCCGGAATATTTATGAGC 
LRH6for ATCCGGAATATTTATGAGCC 
LAMPB5´for ATCGGATCCAAAATGAAGACACTCATATTCTTCTGG 
MBK15Bfor CTCCCCGGGCATTTACAACAACTCTATTG 
FJLAMPfor ATCGAATTCCATTTACAACAACTCTATTG 
K15EcoRIKozakfor TATGAATTCGCCACCATGAAGACACTCATATTCTTCTGG 
LR65for ACGATCTAGATCCGGAATATTTATGAGC 
MBexon4for CTCCCCGGGGCTTGGTCATGGGTTACCCTGTATCC 
MBexon6for ATCGGTACCATGCTGCATTTAATTG 
MBexon7.1for ATCGGTACCATGCTTCTCCCTAGTG 
MBexon7.2for ATCGGTACCATGATCATCTGCATCAG 
MBexon8forVNSY ATCGGTACCGCCACCATGGTAAATAGTTACCGACAG 
GSTex8afor CAGGGATCCTAAATAGTTACCGACAGAGAAGGGG 
ex8aD4rev ACTCCCGGGTGTGGTGTAAGTTCTGGTCCC 
ex8aD3rev ACTCCCGGGTCGTTCAGTAGTTGGCTCCCG 
ex8aD2rev ACTCCCGGGACCGGACACTAAAATACTGGC 
ex8aD1rev ACGCCCGGGTTAGGCTTGGGCGGTGTCTATACGGAAGGC 
FlagLAMPa3´ TATGAATTCCTAGTTCCTGGGAAATAAAAC 
LAMPaY:Frev TATGAATTCCTAGTTCCTGGGAAATAAAACCTCCTCAAACAGGTC 
FJLAMPrev ATCGGTACCTAGTTCCTGGGAAATAAAAC 
LRR6rev CATGTAGCCATGTCACTAACCTC 
ex8arev CTCCAACCACAGCCCAGTGACG 
LMPLAMPa5´for GACGGTACCATGGACTACAAGGACGATGACGACAAGGAACAC GACCTTGAGAGGGGCCCACCG 
LMPLAMPa3´rev CCTTCTCTGTCGGTAACTATTTACTTCATCACTGTGTCGTTGTCCATGG
NheIRTAfor ACGCTAGCGCTCCTTCAATTGGAAGCA 
BglIIRTA2rev ACAAGATCTTTGTGGCTGCCTGGACAGTATTC 
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2.3 Eucaryotic cell culture methods 
2.3.1 General components for cell culture 
DMEM (Gibco)    + 0.11 g/l Sodiumpyruvate, with Pyridoxine 
MEM (Biochrom)    + Eagle´s BSS, NEAA, L-Glutamine, 2.2 g/l 
      NaHCO3 
RPMI 1640 (Gibco)    + L-Glutamine 
RPMI 1640 (Cytogen)   + Glutamine, Hepes 
Grace´s Insect medium (Gibco)  + L-amino acids 
Penicillin, Streptomycin (Cytogen)  10.000 U/ml, 10 mg/ml 
L-Glutamine (Cytogen)   200 mM 
NEAA (Gibco)    100x 
Pyruvate (Gibco)    100 mM 
β-mercaptoethanol (Gibco)   50 mM 
Trypsin/EDTA (Cytogen)   0,05/0,02% in PBS 
FCS (Gibco)     heat-inactivated for 30 min at 56°C 
Puromycin (Sigma)    5 mg/ml stock 
G418 (Sigma)     67 mg/ml stock 
Neomycin (Amimed)    10.000 µg/ml 
Amphotericin B (PAN Systems)  250 µg/ml 
FCS hybridoma grade (PAA lab.)  heat-inactivated for 30 min at 56°C 
HAT Media supplement (Sigma)  50x 
 
PBS (1x)     137 mM NaCl 
      2.7 mM KCl 
      6.6 mM Na2HPO4 x 2H2O 
      1.5 mM KH2PO4 
2.3.2 Eucaryotic cell lines 
Adherent cell lines: 
HEK 293: 
With Adenovirus Type 5 (Ad 5) DNA transformed human embryonic kidney epithelial cell 
line (ACC 305 from the German Collection of Microorganisms and Cell Cultures). 
 
293-T: 
The 293-T cell line is a highly transfectable derivative of the 293 cell line, into which the 
temperature sensitive gene for SV40 T-antigen was inserted. Expresses the SV40 T antigen. 
(ATCC CRL-11268). 
 
Cos7: 
Kidney fibroblasts, isolated from the African green monkey (Cercopithecus aethiops). SV40 
transformed, expresses the SV40 T antigen (ATCC CRL-1651). Derived from the CV-1 cell 
line (ATCC CCL-70) by transformation with an origin defective mutant of SV40 which codes 
for wildtype T antigen. 
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Ptk2: 
Epithelial cell line (kidney) isolated from Potorous tridactylis (ATCC CCL-56). 
 
DU145: 
Human epithelial cell line isolated from a prostate carcinoma (ATCC HTB-81). 
 
T24: 
Human epithelial cell line isolated from a bladder carcinoma (ATCC HTB-4). 
 
Vero: 
Epithelial cell line (kidney) isolated from the African green monkey (Cercopithecus aethiops) 
(ATCC CCL-81). 
 
Insect cells SF9: 
Cells isolated from Spodoptera frugiperda (ATCC CRL-1711). 
 
Adherent cell lines carrying a recombinant KSHV genome: 
DU145 rKSHV: 
DU145 cells stably transfected with rKSHV.152 (Vieira et al., 2001). In rKSHV (derived 
from BCBL-1, see 2.3.2), a GFP/neo cassette was inserted between the polyadenylation sites 
for ORFs 57 and K9 (see figure 1). The GFP gene is expressed from the elongation factor 1-α 
promoter. The neo gene (RSV promoter) confers resistance to G418. 
 
T24 rKSHV: 
T24 cells stably transfected with rKSHV.152 (Vieira et al., 2001). 
 
Vero rKSHV: 
Vero cells stably transfected with recombinant KSHV (rKSHV.219) with a cassette inserted 
between ORF K9 and 57 (see figure 1) that contains the red fluorescent protein under the 
control of the lytic PAN RNA promoter along with GFP being expressed by the human 
elongation factor 1-α promoter and the PAC gene for resistance to puromycin expressed by 
the RSV promoter. Kindly provided by J. Vieira. 
 
Suspension cells: 
PEL cell lines: 
BCBL-1: 
Body cavity lymphoma cell line, established in vitro from a malignant effusion. KSHV+, 
EBV- (Renne et al., 1996). 
 
BCP-1: 
Established from peripheral-blood mononuclear cells of a HIV seronegative patient with PEL 
who previously had KS. KSHV+, EBV-, HIV- (Boshoff et al., 1998). 
 
CroAP-3: 
Human B-cell lymphoma cells, established from the malignant PEL of a 42-year-old HIV+ 
man at diagnosis without a previous history of KS. KSHV+, EBV-, HIV- (ACC 275; Carbone 
et al., 1998). 
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CroAP-5: 
Human B-cell lymphoma cells, established in 1998 from the pleural effusion of a 35-year-old 
HIV+ man with PEL and a sarcoma. KSHV+, EBV+, HIV- (ACC 215; Carbone et al., 1998). 
 
CroAP-6: 
Derived from the pleural effusion of a 26-year-old man with a 2 year history of HIV infection. 
Cell phenotype: lymphoid, non-B non-T-cell phenotype. Approximate copy number of 
KSHV: 20-80 copies of KSHV DNA per cell. KSHV+, EBV-, HIV- (Carbone et al., 2000). 
 
Jsc-1: 
Established from the ascites fluid of a HIV+ patient. Low level of EBV latent gene expression. 
Lytic and latent KSHV gene expression. Produces more infectious virus than BCP-1 (see 
above) upon induction with TPA (Cannon et al., 2000). 
 
ISI: 
Established in 1996 from a PEL related to AIDS. KSHV+, EBV- (Oksenhendler et al., 1998). 
 
BBG-1: 
Established from an AIDS patient with a cutaneous lymphoma from the patient´s peripheral 
blood mononuclear cells. Spontaneously expresses KSHV lytic antigens and EBV 
transforming latent antigen EBNA2. KSHV+, EBV+, HIV- (Morand et al., 1999). 
 
B-cell lines: 
DG75: 
Derived from the pleural effusion of a child with a primary abdominal lymphoma, which 
resembled Burkitt´s lymphoma. KSHV-, EBV- (Ben Bassat et al., 1977). 
 
Raji: 
B-lymphocytes established from a Burkitt´s lymphoma. KSHV-, EBV+ (ATCC CCL-86). 
 
BJAB: 
Continuous lymphoma cell line, derived from the tumour of an exceptional African case of 
Burkitt´s lymphoma. Contains no detectable amount of EBV (Clements et al., 1975). 
 
Myeloma cell line P3X63Ag8.653: 
Isolated from BALB/c mice. HAT sensitive (ATCC CRL-1580). Used for fusion of spleen 
cells from immunized Balb/c mice to generate hybridoma cell lines. See also 2.3.8. 
2.3.3 Cell culture conditions 
All cell culture media contained Penicillin (50 U /ml), Streptomycin (50 µg/ml) and glutamine 
(300 µg/ml). 
 
Cos7, 293, 293-T, T24, DU145: DMEM with 10% (v/v) FCS 
B-cells, PEL cells:   RPMI 1640 with 10% (v/v) FCS 
BCP-1 and CroAP-3 cells:  RPMI 1640 with 20% (v/v) FCS 
Vero, PtK2:    MEM with 10% (v/v) FCS 
SF9 insect cells:   Grace´s insect medium with 10% (v/v) FCS 
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Hybridoma cells:   RPMI 1640 with: 1% (v/v) NEAA, 0.1% (v/v) β– 
     Mercaptoethanol, 0.5% (v/v) Neomycin, 1% (v/v)  
     Amphotericin, 10% (v/v) FCS, 2% (v/v) HAT 
Vero rKSHV:    MEM with 10% (v/v) FCS, Puromycin 5µg/ml 
DU145rKSHV, T24 rKSHV:  DMEM with 10% (v/v) FCS, G418 250 µg/ml 
 
Cells were kept in humified air with 5% CO2 at 37°C. Insect cells were cultured at 27°C and 
split at 100% confluency. All cell lines were split at 80% confluency. 
2.3.4 Cryoconservation 
For conservation, cells were resuspended in 1 ml of the appropriate cell culture medium with 
20% FCS and 8 % DMSO, transferred in a cryo tube and frozen in a polystyrene box at -
20°C. After 4 h, the cells were transferred to -80°C for 24 h and then stored in liquid nitrogen. 
PEL cell lines were frozen in FCS containing 8% DMSO. For recovery, cells were thawn for 
10 min at 37°C, washed with 10 ml medium and transferred to a tissue culture flask. 
2.3.5 Lytic cycle induction, preparation of rKSHV.219 and infection of epithelial and B-
cells with rKSHV.219 
TPA (Sigma, in DMSO) was added to the cells at 20 ng/ml, and n-butyrate (Sigma, in H2O) at 
1 mM final concentration for induction of the lytic viral life cycle. 
Suspension cells were split to a density of 2.5 x 105 cells/ml at 12-20 h before induction with 
TPA or n-butyrate and were lysed 48 h later. 
Vero rKSHV.219 cells were induced with 1 mM n-butyrate and Baculovirus ORF50 
(prepared as described in 2.3.6) diluted 1:20 in fresh medium at 80% confluency. In order to 
produce rKSHV.219 for infection studies, MEM medium without puromycin was added to the 
cells before induction containing n-butyrate and Baculovirus ORF50. One day after induction, 
medium was replaced with fresh medium without puromycin. The medium containing free 
rKSHV.219 was collected 3 days after induction, centrifuged for 15 min at 3.000 x g, filtered 
through a 0.45 µm filter and stored at 4°C. 
Epithelial cell lines 293-T, 293 or Vero were plated to be 50% confluent at the time of 
infection with rKSHV.219 prepared as described above and B-cell lines BCBL-1, BJAB and 
Raji were infected at a cell density of 2.5 x 105 cells/ml. In order to determine the infectivity 
of rKSHV.219 (infectious units per ml, IU/ml), a serial dilution of rKSHV.219 was applied to 
the epithelial cell lines. rKSHV.219 was added at 1:2 dilution to the B-cell lines. After a 12 h 
incubation, virus containing medium was removed and fresh medium was added to the 
epithelial cells. B-cells were left in rKSHV.219 containing medium for the entire time. IU/ml 
were determined by counting GFP expressing cells. 
2.3.6 Production of Baculovirus ORF50/RTA 
Baculovirus ORF50 was kindly provided by J. Vieira. For production of new Baculovirus 
ORF50, insect cells cultured in suspension at 27°C were infected at a cell density of 1 x 106 
cells/ml with Baculovirus ORF50 directly added to the cells (1:20 dilution). When a 
cytopathic effect was observed (usually two days post infection), the medium was collected, 
cleared from cells by centrifugation at 3.000 x g and stored at 4°C. 
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2.3.7 Transient transfection 
Electroporation of suspension cells was carried out with the Biorad Gene pulser Xcell 
Electroporation system. Cells were split one day prior transfection. At the day of transfection, 
cells were pelleted by centrifugation, washed once with RPMI 1640 medium without FCS 
[RPMI (-)] and resuspended to a cell density of 1.5-2.5 x 107 cells/ml in RPMI (-). DNA was 
added to 200 µl of cell suspension in an eppendorf tube and mixed by carefully pipetting up 
and down once. During a 10 min incubation at RT, 0.2 cm cuvettes (Biorad) were prepulsed 
with RPMI (–) at 100 Volts and 975 µF. Then, the DNA/cell suspension mix was added to a 
prepulsed cuvette and pulsed at 100 Volts and 975 µF in the Biorad Gene pulser. Immediately 
after the pulse, 200 µl of RPMI containing 30% FCS were added to the cuvette and the cells 
were transferred to a 6 well plate already containing 2 ml of RPMI with 10% FCS. The length 
of the pulse should not vary more than 2-3 msec between samples that are to be compared. 
 
293, 293-T and Vero cells were transfected using the Fugene 6 transfection reagent (Roche) 
according to the manufacturer´s instructions. Fugene 6 is a lipid-based transfection reagent, 
and usually a transfection efficiency of ~40% was reached. The DNA:Fugene 6 ratio was kept 
constant at 1µg:3µl throughout all experiments. Usually, cells were plated one day prior 
transfection and were 50% confluent at the day of transfection. Vero rKSHV cells were plated 
at a cell density of 0.8 x 105cells/ml (= 1.6 x 105 cells per well of a six well plate) the day 
prior transfection and transfected with Fugene at 80% confluency. For reporter assays using 
the AP-1 reporter plasmid pRTU14 and for the Erk2 Kinase assay, 293-T cells were 
transfected at 80% confluency and the medium was replaced with fresh medium containing 
1% FCS prior addition of the DNA-Fugene 6 mix.  
 
Cos7 cells were transfected with the Effectene transfection reagent (Qiagen), which is based 
on a non-liposomal lipid. For six well plates, 400 ng DNA were diluted with the DNA 
condensation (EC) buffer to a total volume of 100 µl. 1.6 ml of fresh growth medium were 
added to each well of the six well plate. To the DNA, 3.2 µl Enhancer and 5 µl Effectene 
were added according to the manufacturer´s instructions. After a 10 min incubation at RT, 
600 µl of medium containing 10% FCS were added to the complex, mixed by pipetting up 
and down twice and added dropwise to the cells. 
Total amounts of transfected DNA were adjusted using salmon testis DNA (Sigma) for all 
transfection methods. 
2.3.8 Generation of mouse monoclonal antibodies to the C-terminal K15 domain 
In order to generate antibodies directed against K15 in its native form, Balb/c mice were 
immunized with purified K15-GST fusion protein (GST-K15355-489, see 2.6.7). The protein 
concentration was adjusted to 300 µg/ml and each mouse was immunized with 40 µg of 
antigen three times over a time period of four months and boosted once three days before 
sacrificing the mice (=160 µg protein total per mouse). For the first immunisation, the antigen 
was mixed 1:1 with complete Freunds Adjuvans (Sigma) and injected intraperitoneally. For 
the following immunisations, incomplete Freunds Adjuvans was used (Methods Enzymol., 
1986, 121, Hybridoma techniques and monoclonal antibodies). Spleens were removed and 
spleen cells fused with the P3X63Ag8.653 myeloma cell line to generate antibody secreting 
hybridoma cell lines. Fused cells were seeded into dishes to derive clonal colonies. After 
fusion and single-cell cloning, each hybridoma supernatant was tested for reactivity against 
GST and GST-K15 protein by ELISA as follows: 
96 well plates were coated overnight at RT with 200 ng purified GST-K15355-489 diluted in 0.1 
M NaHCO3 pH 8.5 per well. The following day, plates were washed six times with PBS-T 
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(see 2.6.3) and incubated for 2 h at RT with blocking buffer (see 2.6.3). After washing once 
with PBS-T, plates were incubated with hybridoma culture supernatants diluted 1:1 in 
blocking buffer for 1 h at RT. Plates were then washed six times with PBS-T and incubated 
with anti-mouse AP-conjugated secondary antibody diluted 1:1000 in blocking buffer for 1 h 
at RT. After six washes with PBS-T, AP-substrate (1 mg/ml p-Nitrophenyl phospate in AP 
substrate buffer) was added for 1 h at 37°C and plates were analysed photometrically in an 
ELISA plate reader (Anthos reader 2001) at 405 nm. 
The monoclonal antibodies were further characterized by immunoblotting or in a peptide 
array as described in 2.6.3 or 2.6.6, respectively. 
 
AP-substrate buffer: 0.75% glycine 
   1 mM MgCl2 
   1 mM ZnCl2 
   pH 10.4 with NaOH 
2.4 Procaryotic culture methods 
2.4.1 Culture media and growth conditions 
LB-medium:      2YT-medium: 
1% (w/v) Trypton (Becton Dickinson)  1.6% (w/v) Peptone (Difco) 
0.5% (w/v) Yeast extract (Difco)   1% (w/v) Yeast extract 
1% (w/v) NaCl     0.5% (w/v) NaCl 
pH 7.0 with NaOH     pH 7.0 with NaOH 
 
Agar-plates: 
LB-Medium with 1.5% (w/v) Bacto-Agar (Becton Dickinson) 
 
Overnight cultures were usually grown in LB medium at 37°C and 220 rpm. The medium was 
inoculated with bacteria kept on agar plates at 4°C or from cryoconserved cultures (2.4.3). 
The medium/agar plates, according to the properties of the plasmid being introduced, were 
supplemented with a final concentration of: 
   Ampicillin   100 µg/ml 
   Kanamycin   25 µg/ml 
   Chloramphenicol  20 µg/ml 
   IPTG    0.5 mM 
   X-Gal    100 mM 
2.4.2 Bacterial strains 
E. coli BL21: 
hsdS gal (λc Its857 ind1 Sam7 nin5 lacUV5-T7 gene 1) 
 
E. coli TG-2: 
supE hsd∆5 thi ∆(lac-proAB) ∆(srl-recA)306::Tn10(tetr)F´[traD36 proAB+ lacIq lacZ∆M15] 
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2.4.3 Cryoconservation of bacteria 
800 µl of overnight culture were added to 75 µl DMSO in a cryo tube and stored at -80°C. 
2.4.4 Preparation of competent cells and transformation 
Competent bacteria were prepared using the rubidium chloride method. An overnight culture 
was diluted 1:100 in LB medium and grown at 37°C and 200 rpm to an OD600 between 0.6 
and 0.8. From now on, all steps were performed at 4°C and buffers were ice cold. Cells were 
kept on ice for 15 min, centrifuged at 1.000 x g for 10 min and cell pellets were resuspended 
gently and thoroughly in 20 ml RF1 buffer per 50 ml of starting culture. After a 15 min 
incubation on ice, cells were centrifuged as above, resuspended in 2 ml RF2 per 50 ml of 
starting culture and aliquoted à 200 µl. After 15 min incubation on ice, cells were competent 
and were used for transformation or stored at -80°C. 
For each transformation, 200 µl of competent bacteria were mixed with DNA (e.g. 100 ng 
plasmid DNA) in a 1.5 ml tube, incubated on ice for 1 h and subsequently heat shocked for 45 
sec at 42°C and put on ice for 5 min. After addition of 800 µl LB medium prewarmed to 42°C 
and an incubation period of 45 min at 37°C and 200 rpm, 100 µl of cell suspension was plated 
onto LB agar plates containing the appropiate antibiotic for selection. Plates were incubated 
overnight at 37°C. 
 
RF1:  100 mM RbCl2   RF2:  10 mM MOPS 
  30 mM K acetate     75 mM CaCl2 
  10 mM CaCl2      10 mM RbCl2 
  50 mM MnCl2 
  15 % (v/v) glycerol     15% (v/v) glycerol 
  pH 5.8 with acetic acid    pH 6.5 with KOH 
2.5 Molecular biological methods 
2.5.1 Isolation of plasmid DNA 
Plasmid DNA was isolated with the QIAprep Spin Miniprep Kit from Qiagen or with the 
Nucleobond AX Maxiprep Kit from Machery & Nagel according to the manufacturer´s 
instructions. 
2.5.2 Enzymatic modification of DNA 
Digestion of DNA with specific restriction endonucleases, dephosphorylation with alkaline 
phosphatase and ligations were performed with enzymes and the suitable provided buffers 
from Roche, Boehringer Mannheim, New England Biolabs or Life Sciences according to the 
manufacturer´s instructions or to Sambrook et al. (1989). 
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2.5.3 Amplification of DNA 
Standard PCR reactions were carried out in a final volume of 50 µl with the following 
components: 200 ng of template DNA, two specific primers (5 pmoles each), 200 µM dNTPs, 
3 mM MgCl2, 1x polymerase buffer, 5 U Taq/Pfu polymerase and H2O in a 0.2 ml PCR tube. 
DNA fragments were amplified with the appropriate oligonucleotide primers listed in table 2 
in a Perkin Elmer GeneAmp PCR System 2400 thermocycler. The length of denaturation, 
annealing and elongation were dependent on the characteristics of the DNA template (e.g. 
genomic DNA or plasmid DNA, GC-content of the fragment), the primers (the optimal 
annealing temperature was usually investigated experimentally starting with a value 
calculated according to the formula 4x (G/C) + 2x (A/T) - 5) and the length of the amplified 
PCR product. 
2.5.4 Preparation of RNA and RT-PCR 
Total RNA was prepared with the RNeasy Mini Kit from Qiagen according to the 
manufacturer´s instructions. DNase digestion was carried out during the RNA purification 
step using the RNase-free DNase set from Qiagen. To ensure purity and RNA concentration, 
it was analysed spectrometrically and an aliquot was run on a 1% agarosegel. 
For reverse transcription reactions, the Expand reverse transcriptase from Roche was used. 
Expand reverse transcriptase is a RNA directed DNA polymerase and is a genetically 
engineered version of the moloney murine leucaemia virus reverse transcriptase. This enzyme 
synthesizes a complementary cDNA strand (cDNA) with mRNA or single-strand DNA as 
substrate in the presence of an oligo (dT) or a specific primer. 
First-strand cDNA synthesis: 1-1.5 µg of total RNA and 10 picomoles specific reverse primer 
were pipetted in a 0.2 ml PCR tube and filled up with H2O to give a final volume of 11.5 µl. 
RNA and primer were denatured at 65°C for 10 min in a thermocycler, immediately cooled on 
ice and the following components were added to give a final volume of 20 µl: 1 x Expand 
buffer, 10 mM DTT, 2.5 mM dNTPs, 20 Units RNase Inhibitor and 50 Units Expand reverse 
transcriptase. The tubes were incubated at 42°C for 1 h in a thermocycler and stored at -20°C. 
For the subsequent PCR, 6-10 µl of cDNA were mixed with two specific primers (10 pmoles 
each), 200 µM dNTPs, 1x polymerase buffer, 3 mM MgCl2, 5 U of Taq/Pfu polymerase and 
filled up with H2O to a final volume of 50 µl. Cycling conditions were determined 
experimentally. 
2.5.5 Electrophoresis of DNA and extraction from agarose gels 
DNA loading buffer (5x) was added to plasmid DNA or DNA fragments and the DNA was 
separated electrophoretically with 0.5-1.5 % agarosegels in TAE running buffer. DNA-
fragments were purified with the QIAquick Gel Extraction Kit from Qiagen according to the 
manufacturer´s instructions. 
Molecular weight marker: 1 kb plus DNA ladder (Invitrogen) 
 
DNA-loading buffer (5x):    TAE buffer (1x): 
100 mM Tris-HCl, pH 7.4    40 mM Tris-acetate 
10 mM EDTA, pH 8.0    1 mM EDTA 
45% (v/v) Glycerol 
Orange G 
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2.5.6 DNA sequencing 
All fragments, which were amplified by PCR and subsequently cloned into eucaryotic or 
procaryotic vectors, were fully sequenced with the ABI Prism dRhodamine terminator cycle 
sequencing ready reaction kit (Applied Biosystems). Per sequencing reaction, 500 ng of 
plasmid DNA were added to 4 µl terminator ready reaction mix and 1.6 pmole specific primer 
and filled up with H2O to give a final volume of 10 µl. Thermal cycling was performed with 
the following parameters, with the annealing temperature depending on the specific 
sequencing primer: 96°C for 10 sec, 56°C (variable) for 10 sec, 60°C for 4 min, for 25 cycles. 
Afterwards, excess of dye terminators was removed by ethanol precipitation as follows: 
10 µl of the PCR-product was added to 37 µl precipitation mix (70% EtOH, 0.5 mM MgCl2) 
in a 1.5 ml high yield nucleic acid recovery tube (Robbins), vortexed and incubated for 15 
min at RT. After centrifugation (14.000 x g, 15 min) the supernatant was removed and the 
pellet was dried at 95°C for 1 min. The sample pellet was resuspended in 6 µl of template 
suppression reagent, heated for 2 min at 95°C, cooled on ice, centrifuged and transferred to a 
0.5 ml sequencing sample tube (Applied Biosystems). Sequencing was carried out with the 
ABI Prism 310 Genetic Analyzer. 
2.6 Biochemical and cell biology methods 
2.6.1 Preparation of cell lysates 
Cells were washed once with PBS (adherent cells) or medium without FCS (suspension cells) 
and lysed on ice with lysis buffers (see below) for 10 min. Lysates were cleared from cell 
debris by centrifugation at 14.000 x g for 10 min at 4°C. 
For the analysis of proteins of cell lines or transiently transfected cells, the following lysis 
buffers containing protease inhibitors were used for different applications: 
 
1% NP40 Lysis Buffer: 50 mM Tris-HCl pH 7.4 
    150 mM NaCl 
    0.5 mM EDTA 
    1% NP40 
 
TNE:    10 mM Tris-HCl pH 7.4 
    150 mM NaCl 
    5 mM EDTA 
 
TBS:    20 mM Tris-HCl pH 7.4 
    150 mM NaCl 
    1 mM EDTA 
 
TBS-T:   TBS and 1% Triton X-100 
 
Protease inhibitors:  1 mM phenylmethylsulfonyl fluoride (PMSF) 
    50 µM leupeptin 
    100 U/ml aprotinin 
    200 µM benzamidine 
    1 µM pepstatin A (in DMSO) 
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To ensure that equal amounts of proteins were loaded per lane, the protein concentration of 
crude cell extracts was determined using the Bradford reagent (Biorad) according to the 
manufacturer´s instructions. This test is based on binding of Coomassie brillant blue G-250 to 
proteins, which alters the maximum of absorption of the dye from 465 nm without protein to 
595 nm with protein (Bradford 1976). BSA served to generate the standard curve. 
2.6.2 SDS-polyacrylamide gelelectrophoresis (SDS-PAGE) 
For detection of proteins by Western blot, cleared cell lysates or fractions of the sucrose 
gradient containing K15 proteins were not boiled prior to SDS-PAGE. Cell lysates were 
diluted with 5x protein loading buffer and 20 µl were loaded per lane. According to the size of 
the protein of interest, the separation gel contained 10-12% and the stacking gel 4% 
polyacrylamide. Gels were run at 25 mA each in a Hoefer mighty small electrophoresis 
chamber (Amersham). 
 
Protein loading buffer (5x):   Protein loading buffer (1x): 
300 mM Tris-HCl, pH 6.8   50 mM Tris-HCl, pH 6.8 
50 % (v/v) glycerol    10% (v/v) glycerol 
10% (w/v) SDS    2% (w/v) SDS 
0.1% (w/v) BPB    0.05% (w/v) BPB 
300 mM β-Mercaptoethanol   100 mM DTT 
 
Electrophoresis buffer: 
25 mM Tris-Base 
250 mM glycine 
0.1% (w/v) SDS 
pH 8.3 
 
Molecular weight standard: 10.000 - 200.000 Da, prestained (Biorad) 
 
For detection of proteins after SDS-PAGE, gels were blotted (see 2.6.3) or stained. For 
staining, gels were washed once in H2O, stained for 1 h in Coomassie blue staining solution 
(Biorad) and destained with H2O for 1 h. For storage, gels were put on Whatman paper and 
dried for 1 h at 80°C. 
In order to estimate the protein concentration of purified proteins expressed in bacteria, 
different amounts of BSA protein were run in parallel with SDS-PAGE and the colour 
intensities of the purified protein and the known amount of BSA protein were compared. 
2.6.3 Immunoblotting 
After separation by SDS-PAGE, the protein gel, Whatman filter paper, porous pads and a 
nitrocellulose membrane (Hybond ECL, Amersham) were soaked in blotting buffer. The gel 
and membrane were sandwiched between Whatman 3MM paper, two porous pads and two 
plastic supports and immersed in a blotting tank containing blotting buffer. The membrane 
was placed toward the anode. 
The protein transfer to nitrocellulose membranes took place in ice cold blotting buffer at 350 
mA for 1 h in a Mini Trans Blot Cell (Biorad). To check for the efficiency of the blotting 
process, membranes were stained with Ponceau S for 1 min and destained with PBS for 10 
min. Saturation of the protein binding surface of the membranes (blocking) was carried out at 
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RT for 1 h in blocking buffer or overnight at 4°C. Subsequently, proteins of interest were 
visualized with specific primary antibodies and a secondary antibody recognizing the primary 
antibody and being covalently coupled to the enzyme horseradish peroxidase (HRP). When 
HRP converts a substrate containing cumaric acid, luminol and H2O2, a fluorescence signal is 
emitted which can be detected by autoradiography. 
The primary antibodies with the according dilutions used for immunostaining of immunoblots 
are listed in 2.1.1. Blots were probed for 1 h at RT with the primary antibody diluted in 
blocking buffer (see2.1.1), followed by three washing steps (10 min each) with PBS-T. 
Subsequently, membranes were incubated with the HRP-coupled secondary antibodies 
(DAKO) in blocking buffer for 45 min at RT followed by three washes with PBS-T. For 
detection, a standard enhanced chemiluminescence (ECL) reaction kit (Perkin Elmer) was 
used. The signal was visualised by exposing the membranes for different time intervals (10 
sec – 15 min) to Hyperfilm ECL (Amersham). 
In order to reprobe Western blots, nitrocellulose membranes were stripped for 30 min at 50°C 
in stripping buffer. Afterwards, the membranes were washed several times in PBS-T and 
blocked for 1 h at RT or at 4°C overnight in blocking buffer. 
 
Blotting buffer: 25 mM Tris base 
   250 mM glycine (pH 8.3) 
   20% (v/v) Methanol 
 
Blocking buffer: PBS-T 
   5% (w/v) nonfat dried milk 
 
PBS-T:  PBS 
   0.1% (v/v) Tween 20 
 
Ponceau S staining solution: 
   3% (w/v) TCA 
   0.2% (w/v) Ponceau S 
 
Stripping buffer: 62.5 mM Tris-HCl, pH 6.8 
   2% SDS 
   100 mM β-mercaptoethanol 
2.6.4 Luciferase Reporter Assay 
A commonly used method to examine effects of a certain protein on transcription factors or 
promoters is to clone the regions of interest (e.g. promoter regions, transcription factor 
binding sites) upstream of a reporter gene (e.g. firefly luciferase), whose expression and 
activity will be regulated by the upstream region. Increased transcription of the luciferase 
cDNA correlates with an increased luciferase activity in the cell lysate (Nordeen, 1988). 
In order to check expression of the transfected proteins, a Western blot was performed with 
the cell lysates. 
To assay NF-κB activity, 293-T cells were transiently co-transfected with 50 ng of the NF-κB 
luciferase reporter plasmid p3EnhκBconA-Luc containing three tandem repeats of the NF-κB 
sites from the IgGκ promoter and the indicated amounts of K15 expression constructs or 
LMP1, as mentioned in the figure legends, per well of a 6 well plate. At 29 h post-
transfection, cells were washed once with PBS and incubated for 10 min on ice with 300 µl 1x 
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Reporter Lysis Buffer (Promega) per well of a 6 well plate and transferred in a 1.5 ml tube. 
Lysates were cleared by centrifugation for 10 min at 14.000 x g at 4°C and the supernatant 
was transferred to a new tube. Lysates were assayed immediately for luciferase activity in a 
luminometer (Berthold Lumat LB9501) or stored at -20°C. For measurement of luciferase 
activity, 20 µl of cleared lysate was added to 100 µl luciferase assay buffer and light emission 
was measured for a time period of 10 seconds. NF-κB activity was calculated as fold 
induction compared to mock (=empty expression vector) transfected controls. 
For analysis of AP-1 activity, 50 ng of the reporter plasmid pRTU14 or the negative control 
reporter pRTU1 were co-transfected with different amounts of K15 or LMP1 expression 
constructs as indicated in the figure legends. Dominant negative mutants of TRAF-2, TRAF-
6, Ras, Raf, Erk2 or the respective empty expression vectors were co-transfected as indicated 
in the figures. After transfection, cells were maintained in medium containing 1% FCS to 
downregulate serum-activated signaling pathways. Cells were lysed 24 h post-transfection in 
reporter lysis buffer and the luciferase activity assayed as mentioned above. 
For ORF50 reporter assays, 293-T cells were co-transfected with 50 ng of the p3kbORF50P 
reporter plasmid and different amounts of K15 expression constructs. Cells were lysed 40 h 
after transfection. 
Suspension cells (BCBL-1) were transfected by electroporation as described in 2.3.7 with 5 
µg of luciferase reporter plasmid and 10 µg of expression constructs. 24 h post-transfection, 
cells were washed twice with PBS and lysed in 50 µl of luciferase assay buffer. 
 
Luciferase Assay Buffer: 40 mM Tricine pH 7.8 
    10 mM MgSO4 
    0.5 mM EDTA 
    0.5 mM ATP 
    10 mM DTT 
    0.5 mM Coenzyme A 
    0.5 mM D-Luciferin 
2.6.5 Immunofluorescence and fluorescence microscopy of adherent cells 
Ptk2 cells were plated for transient transfection onto 20x20 mm glass coverslips in a six well 
plate. 48 h after transfection, cells were washed once with PBS and fixed for 20 min at RT 
with 3% paraformaldehyde (PFA) in PBS. Cells were washed three times with PBS and 
residual PFA was inactivated with 50 mM NH4Cl in PBS for 10 min. Subsequently, cells 
were permeabilised with 0.1-0.2% Triton X-100 in PBS for 5-10 min. After three washing 
steps with PBS, unspecific protein binding sites were blocked with blocking solution (0.2% 
gelatine in PBS) for 30 min at RT. The primary antibody was diluted in blocking solution and 
incubated with the cells for 1 h at RT (100 µl per cover slip). Afterwards, cells were washed 
three times with blocking solution and incubated with the secondary antibody (see below) 
diluted in blocking solution for 30 min at RT, subsequently washed three times with blocking 
solution and once with PBS. Finally, the DNA was stained with Hoechst 33258 in PBS (1 
µg/ml, 5 min, RT) and cells were washed three times with PBS. PBS was removed by a short 
washing step in distilled water and the cover slips were mounted in 30 µl Mowiol containing 
25 mg/ml DABCO. 
Vero cells carrying the recombinant KSHV.219 genome, which express GFP constitutively 
and RFP if induced (see 2.3.5), were plated onto 20x20 mm glass cover slips in six well 
plates. 48 h after induction, cells were washed twice with PBS, fixed with 3% PFA for 20 min 
at RT, washed three times with PBS, coated with 30 µl Mowiol/DABCO for 1 h or overnight 
and analysed by fluorescence microscopy. 
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Blocking solution: 0.2% (w/v) gelatine in PBS 
3% (w/v) Paraformaldehyde in PBS with 0.1 mM CaCl2 and 0.1 mM MgCl2, pH 7.4 
0.1-0.2% (v/v) Triton X-100 in PBS 
Mowiol 4-88 (Calbiochem), DABCO (Sigma) 25 mg/ml, Hoechst 33258 (1 mg/ml stock) 
Secondary antibodies: donkey α-rabbit IgG Cy3 (1:200), donkey α-mouse IgG Cy3 (1:200) 
(both Dianova Immunotech GmbH), swine anti-rabbit FITC (1:40) (DAKO). 
2.6.6 Peptide array 
In order to characterize the epitope recognised by the monoclonal K15 antibodies (see 2.3.8) 
the full length K15 protein was synthesized as peptides of 15 aa on Whatman filter paper with 
the SPOT-technique by Ronald Frank at the GBF in Braunschweig (R. Frank, 2002). Each 
step was carried out with 10 ml of solution on a rocking platform at RT, and all washing steps 
lasted 10 min. 
For the antibody binding test, the dried filter was moistened with EtOH, washed 3 times with 
TBS and blocked overnight with Genosys blocking buffer at 4°C. The following day, the filter 
was washed once with TBS-T and incubated with the secondary antibody conjugated with the 
enzyme alkaline phosphatase (AP) in order to test the background binding caused by the 
secondary antibody. The AP conjugate was diluted 1:500 in Genosys blocking buffer and 
incubated with the filter for 90 min. Afterwards, the filter was washed twice with TBS-T, PBS 
and CBS each. Then, the staining solution was added to the filter and incubated for a 
maximum of 30 min under slow agitation. After washing with PBS, the background staining 
was documented by scanning the filter (HP Scanjet 5370C). 
If the secondary antibody used caused significant background staining, the filter was stripped 
as follows (all steps carried out with 15 ml of solution): The filter was washed twice with 
H2O, once with DMF, then with DMF in a sonication bath at RT until the background staining 
vanished, three times with buffer A (with 5 min on a rocking platform and 5 min in the 
sonication bath at 40°C), three times with buffer B and three times with EtOH. 
After stripping, the blocking step was repeated as described above followed by a washing step 
with TBS-T and incubation with the primary specific K15 monoclonal antibody diluted 1:2 in 
Genosys blocking buffer for 3.5 h. Afterwards, the filter was washed three times with TBS-T 
and incubated with the secondary antibody and stained as described above. For long term 
storage, the filter was stripped, dried, sealed in plastic foil and kept in -20°C. 
 
Peptide TBS:  50 mM Tris-HCl pH 7.0 
   137 mM NaCl 
   2.7 mM KCl 
 
Peptide TBS-T: peptide TBS pH 7.0 for washing, pH 8.0 for blocking 
   0.05% Tween 20 
 
Peptide PBS:  137 mM NaCl   CBS:           137 mM NaCl 
   2.7 mM KCl              2.7 mM KCl 
   8 mM Na2HPO4x2H2O            50 mM Citric acid-1-hydrate 
   1.5 mM KH2PO4    
   pH 7.0 with HCl             pH 7.0 with NaOH 
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Buffer A:     Buffer B: 
 8 M Urea     10% (v/v) acetic acid 
 1% (w/v) SDS    50% (v/v) EtOH 
 pH 7.0 with acetic acid   40% H2O 
 0.5% (v/v) β-mercaptoethanol 
 
Genosys blocking buffer:   Staining solution for AP conjugates: 
 20% (v/v) Genosys buffer (Sigma)  For 10 ml CBS: 
 5% (w/v) Saccharose    5 mM MgCl2 
 in TBS-T pH 8.0    2.4 mg BCIP 
 pH 7.0      3 mg Methylthiazoletetrazolin 
2.6.7 Purification of GST-fusion proteins 
An overnight culture of E. coli strain BL21 transformed with expression plasmids of the GST-
fusion proteins GST-c-Jun, GST-K15355-489 or GST-K15355-472 was diluted 1:20 in 1 litre of 
LB-Amp medium, grown at 37° C to a density of OD600 = 0.4, induced with 0.5 mM IPTG 
and grown for another 4 hours at 30° C in an orbital shaker at 220 rpm. Cultures were 
harvested by centrifugation (1.000 x g, 30 min, 4°C) and each pellet was resuspended in 20 
ml of GST lysis buffer. After a 10 min incubation on ice, the cell suspension was sonicated on 
ice (3 x 10 sec with one minute pauses inbetween, 50% duty cycle, Branson sonifier 250), 
centrifuged for 10 min at 17.000 x g and the supernatant was divided into two 15 ml tubes 
(Falcon). 700 µl of glutathione-sepharose beads (Amersham) were washed three times with 
PBS and were added to each 10 ml of supernatant. Binding of the GST-fusion proteins to the 
beads was carried out for 30 min at 4°C on a roller. Then, samples were centrifuged for 1 min 
(500 x g), the supernatant was removed and each bead pellet was washed four times with 10 
ml of GST-lysis buffer and twice with 10 ml of TBS (see 2.6.1). To elute the fusion proteins, 
each bead pellet was resuspended in 300 µl of GST-elution buffer, transferred to a 1.5 ml tube 
and rotated for 30 min at RT. The beads were pelleted (10.000 x g , 30 sec) and the 
supernatant transferred to a new tube. Elution was repeated twice, supernatants pooled, 
aliquoted and stored at -80°C. 
The eluted GST fusion proteins were analysed by SDS-PAGE using BSA as standard to 
estimate the protein concentration. 
 
GST lysis buffer: PBS 
   1% (v/v) Triton X-100 
   10 mM DTT 
   1 mM PMSF 
 
GST-elution buffer: 50 mM Tris-HCl pH 8.0 
   1% Triton X-100 
   10 mM glutathione 
2.6.8 Pulldown assay with GST fusion proteins 
For GST-pulldown experiments, BL21 E. coli cultures transformed with the GST-K15 
expression plasmids or GST alone were grown at 37°C in 2YT medium plus ampicillin, 
induced at OD600 of 0.3-0.4 with 1 mM IPTG and grown for 6 h at 30°C. Cells were harvested 
by centrifugation (1.000 x g, 30 min, 4°C) and the pellet was resuspended in 1000 µl PBS 
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(containing protease inhibitors) per 10 ml of culture and an OD600 of 2.5. After sonication on 
ice (as in 2.6.7, but 3x 1 min), Triton X-100 was added to 1% final concentration, cells kept 
on ice for 10 min and then centrifuged for 15 min at 14.000 x g at 4°C. The supernatant was 
adsorbed onto 20 µl of glutathione sepharose beads prepared as described in 2.6.7 for 1 h at 
4°C, after which beads were washed twice in PBS, followed by washing once in 1% NP40 
lysis buffer. 
HEK 293-T cells were transfected (as described in 2.3.7) with 1 µg of cDNA expression 
construct per well of a 6 well plate of myc-tagged Src kinases Src, Lck, Yes, Fyn or Hck. 48 h 
after transfection, cells were washed once on ice with PBS and lysed in 1% NP40 lysis buffer 
containing protease inhibitors for 10 min on ice. Cell lysates were centrifuged at 14.000 x g 
for 10 min at 4° and precleared by incubating with 50 µl of glutathione beads for 1 h at 4°C. 
Cleared lysates were then incubated for 1 h or overnight at 4°C with either GST control 
protein or GST-K15 fusion protein immobilised to glutathione beads. The beads were washed 
three times in 1% NP40 lysis buffer and proteins adsorbed to beads were boiled in 50 µl of 1x 
SDS electrophoresis sample buffer (see 2.6.2) and analysed by SDS-PAGE and Western 
blotting. 
2.6.9 Cellular fractionation 
B-cells and transiently transfected cos7 cells (three 75 cm2 flasks) were washed once with 
RPMI without FCS or with PBS, respectively, counted, and cell pellets were resuspended in 
the appropiate volume of ice cold HB-T buffer to adjust the cell concentration to 3 x 107 
cells/ml. For transiently transfected cos7 cells, transfected cells were filled up with 
untransfected cos7 cells to give 3 x 107 cells/ml. Cells were incubated on ice for 20 min and 
then pipetted in a “cell cracker” provided by Robert Lindner and Ernst Ungewickell, Institute 
of Cell Biology, MHH. In the cell cracker, the cells are passaged through a tube of 8.02 mm 
in diameter with a total volume of 0.5 ml, in which metallic spheres of different diameters can 
be inserted. For cos7 and B-cells, a sphere with a diameter of 8.01 mm was used. After 
passaging the cell suspension 10 times on ice through the cell cracker with one 1 ml syringe 
on each side of the sphere, the degree of homogenisation was checked by comparing intact 
cells to the homogenate with Trypan blue staining (cells were incubated 1:1 with a 0.4% 
trypan blue solution for 2 min) under the light microscope. Nuclei should only be stained blue 
if the cells are cracked, and usually over 50% of the cells were successfully cracked. After 
homogenisation, the suspension was incubated in ice for 1 h with 100 µg/ml DNaseI. 
Afterwards, the homogenate was centrifuged for 10 min at 1.000 x g at 4°C to pellet nuclei 
and non broken cells. The supernatant was transferred to a new tube and centrifuged again for 
10 min at 1.000 x g. To avoid cross-contamination of the pellet and supernatant fraction after 
ultracentrifugation, the supernatant was layered on top of a 10% sucrose cushion (10% w/v 
sucrose in HB-T) of 200 µl in a polycarbonate centrifuge tube (11x34 mm, Beckman) and 
subjected to centrifugation at 100.000 x g for 1.5 h in a Beckman table top ultracentrifuge TL-
100 in a TLA 100.2 rotor. The supernatant after ultracentrifugation was transferred to a new 
tube and the pellet resuspended in HB-T buffer in 1/8 of the volume undergoing 
ultracentrifugation. All fractions were shock frozen in liquid nitrogen and stored at -80°C. 
The supernatant after ultracentrifugation was subject to an acetone precipitation. The 
supernatant was mixed thoroughly with 5 volumes of acetone (stored at -20°C), incubated at -
20°C for 30 min, centrifuged at 14.000 x g for 15 min at 4°C and the pellet resuspended in 
HB-T buffer. 
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HB-T:  10 mM triethanolamine DNase I: 10 mg/ml DNaseI (Calbiochem) 
  10 mM acetic acid    5 mM Na-acetate pH 4-5 
  1 mM EDTA     1 mM CaCl2 
  250 mM sucrose   
  pH 7.4     
  protease inhibitors 
2.6.10 Lipid raft preparation by sucrose density centrifugation 
One day prior to transfection, cos7 cells were plated out in 75 cm2 tissue culture flasks 
(Costar) and were transfected the following day at ~50% confluency with Effectene (3.1 µg 
DNA per 75 cm2 flask) according to the manufacturer´s instructions (Qiagen). 48 h post-
transfection, cells were washed once with PBS, trypsinised, resuspended in PBS, centrifuged 
(10 min 1.000 x g), washed with 10 ml PBS, counted and pelleted (10 min 1.000 x g). The 
cell pellets were resuspended in the appropriate volumes of ice cold TNE buffer (see 2.6.1) 
containing 1% Triton X-100 to adjust the cell concentration to 107 cells/ml for all samples. 
Cells were lysed for 30 min on ice, homogenised with a 200 µl pipette (10 strokes) and 
centrifuged for 10 min at 900 x g at 4°C. 1 ml of the supernatant was mixed with 1 ml of 85% 
sucrose in TNE and pipetted on the bottom of an ultracentrifuge tube (14x95 mm, 
Beckmann). 6 ml of a 35% sucrose solution in TNE were layered on top followed by 3.5 ml 
of a 5% sucrose solution in TNE. The samples were subjected to ultracentrifugation at 
200.000 x g (40.000 rpm) in a SW40 rotor for 22 h at 4°C and subsequently, 1 ml fractions 
were collected starting at the top of the gradient. The pellet was resuspended in 200 µl of TNE 
buffer containing 1% Triton X-100. Equal amounts of each fraction 1-12 (20 µl) were 
analysed by SDS-PAGE and Western blotting (of the pellet fraction, only 4 µl were loaded). 
Fractions 4-5 of the gradient contain lipid rafts and the proteins associated with them. 
Fractions 9-12 contain soluble and solubilised proteins of the non-raft membrane. 
2.6.11 Immunoprecipitation and Immunocomplex Kinase Assay 
As indicated in the figure legends, 293-T cells were co-transfected with 1 µg of HA-tagged 
MAP kinase and 1 µg of K15 cDNA expression constructs as described in 2.3.7. Where 
indicated, 700 ng of dominant negative mutants or their respective empty expression vectors 
were co-transfected. After transfection, cells were maintained in medium containing 1% FCS 
to downregulate serum-activated signaling pathways. 24 h after transfection, cells were 
washed once with PBS and lysed in 400 µl of TBS-T buffer (see 2.6.1) containing protease 
and phosphatase inhibitors per well of a 6 well plate. 
The monoclonal α-HA antibody 12CA5 was immobilized to Protein G sepharose beads 
(Amersham) as follows: 80 µl of resuspended beads were washed twice with 1 ml PBS and 
twice with 1ml TBS-T (15.000 x g, 30 sec). 200 µg of α-HA antibody were dissolved in 500 
µl PBS containing 4% sucrose and 0.02% Na-azide, incubated on ice for 15 min and added to 
the beads. After a 2 h incubation on a roller at 4°C, beads were pelleted (15.000 x g, 30 sec), 
washed three times in TBS-T and finally resuspended in 1.2 ml PBS containing 4% sucrose 
and 0.02% Na-azide and stored at 4°C. 
Cleared cell lysates were incubated overnight on a roller at 4°C with 12 µl of HA-beads to 
immunoprecipitate HA-tagged MAP-kinases. Afterwards, samples were centrifuged (30 sec, 
15.000 x g) and supernatants transferred to a new tube to be analysed for expression of K15 
constructs by Western blot. Beads with bound MAP kinase were washed twice with TBS-T, 
twice with kinase reaction buffer, adjusted to 25 µl and kept on ice. 
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In vitro kinase reactions to assay the activity of immunoprecipitated HA-MAPK were 
performed as follows: Kinase reactions were started with the addition of the 
immunoprecipitated MAP-kinase bound to HA-beads to 10 µl of a kinase reaction mix 
containing 10 µCi of [γ-32P] ATP (3000 Ci/mmol, 10 mCi/ml, Hartmann Analytics) per 
reaction sample and 200 ng of either purified bovine myelin basic protein (MBP; Upstate 
Biotechnology), ATF2 fusion protein (34 kDa; Cell Signaling) or purified GST-c-Jun (2.6.7) 
as a substrate in kinase reaction buffer. The samples were incubated for 30 min at 25°C and 
kinase reactions were stopped by putting the samples on ice and adding 4 µl of 4 x stop 
buffer. Samples were then heated for 5 min at 100°C, cooled on ice for 2 min, separated by 
SDS-PAGE (15 µl per lane), blotted onto Hybond-C nitrocellulose membranes (Amersham) 
and analysed by autoradiography. Immunoblots were performed with the same membranes 
used for autoradiography to check for equal expression levels of the immunoprecipitated 
MAP kinases. 
For the Src kinase assay, 293-T cells were transfected with either 1 µg of expression plasmids 
for myc-tagged Src kinases Src, Hck, Lck, Yes or Fyn or empty expression vector. After 
transfection, cells were kept in complete medium with 10% FCS and cells were lysed 24 h 
post-transfection in TBS-T as mentioned above. Immunoprecipitation of the myc-tagged Src 
kinase was carried out overnight with 12 µl of anti-c-myc (clone 9E10) coated protein A 
agarose beads (Clontech) per sample. The in vitro kinase reaction was done as described 
above, but with 200 ng of purified GST-K15355-489 or GST-K15355-472 fusion protein (see 
2.6.7) as substrate. Immunoblots were performed with the same membranes used for 
autoradiography to check for equal amounts of purified GST-K15 fusion protein. 
 
Kinase reaction buffer: 20 mM Tris-HCl pH 7.4 
    20 mM NaCl 
    1 mM DTT 
    10 mM MgCl2 
    2 µM ATP 
    0.5 mM β-glycerophosphate 
    0.5 mM sodium-orthovanadate 
 
4 x stop buffer:    Phosphatase inhibitors: 
 200 mM Tris-HCl pH 6.8   0.5 mM sodium-orthovanadate 
 4 mM EDTA     0.5 mM β-glycerophosphate 
 100 mM DTT     0.5 mM sodium-molybdate 
 40% glycerol     0.5 mM sodium-fluoride 
 8% SDS     0.5 mM sodium-pyrophosphate 
 0.1% bromphenolblue 
 
Protease and phosphatase inhibitors were added to TBS-T. The specific MEK1/2 inhibitors 
PD98059 and UO126 (both Calbiochem) were used at a concentration of 50 µM from a 50 
mM stock solution in dimethyl sulfoxide (DMSO). UO126 was prepared fresh for every 
experiment. Inhibitors were added to the medium 14 h after transfection and cells were 
incubated for a further 8 hours before being extracted as described above. 
2.6.12 Coupled in vitro transcription/translation 
In vitro translated proteins were prepared non-radioactively with the TNT-System following 
the manufacturer´s instructions (Promega: TNT coupled reticulocyte lysate system). 5 µl per 
reaction were analysed by SDS-PAGE and immunoblotting. 
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3 Results 
3.1 Characterisation of the K15 proteins of KSHV 
3.1.1 Expression and cellular localisation of K15 proteins 
When we started our work on K15, the most common KSHV cell culture system were cell 
lines etablished from patients with primary effusion lymphoma (PEL) that carry and maintain 
KSHV genomes. These PEL cell lines are either co-infected with KSHV and EBV, or with 
KSHV alone. Three independent groups identified differentially spliced transcripts derived 
from ORF K15 of KSHV by RT-PCR on RNA extracted from PEL cell lines BCBL-1, BCP-1 
and Hbl-6 (for details see 2.3.2; Glenn et al., 1999, Poole et al., 1999, Choi et al., 2000a). The 
most prominent transcript that was identified in these cell lines is multiply spliced, consists of 
eight exons and encompasses ~1500 bp. Of these PEL cell lines, Hbl-6 codes for the K15-M 
(minor) variant that shares only 33% amino acid identity with the K15-P (predominant) 
variant that is found in the majority of KSHV genomes. Despite their low similarity at the 
amino acid level, the eight exon transcripts of K15-M and K15-P are almost identical in their 
splicing pattern (see figure 5 in 1.3.6; Glenn et al., 1999, Poole et al., 1999). Furthermore, the 
splicing pattern of the K15-P and K15-M variants shows striking similarity in number and 
length of exons to the EBV LMP2A transcript (figure 5 in 1.3.6), which localises to the far 
right end of the EBV genome as K15-M and K15-P in KSHV (figure 2 in 1.3 and 1.3.1.2). 
As a first approach to characterise the protein derived from ORF K15, we analysed the 
protein sequences of the EBV membrane proteins LMP1 and LMP2A in parallel to the two 
K15 variants K15-P and K15-M with the membrane protein topology prediction programme 
TMHMM at http://www.cbs.dtu.dk, which is one of the most reliable topology prediction 
programme available today (Melén et al., 2003). As shown in figure 9 and as expected from 
the literature, 12 transmembrane domains and an N-terminal cytoplasmic domain were 
predicted for LMP2A (aa 1-497, pI 4.8, NCBI # CAD53382), and 6 transmembrane domains 
joined to a cytoplasmic C-terminus were predicted for LMP1 (aa 1-386, pI 4.0, NCBI 
#CAD53472) (see 1.3.1 and figure 3). The K15-M protein (aa 1-498, pI 8.0, NCBI accession 
#AAD45296) was predicted to consist of 12 transmembrane domains followed by a 
cytoplasmic C-terminal domain (figures 9 and 15). The K15-P protein (aa 1-489, pI 8.6, 
NCBI accession #AAD45297) was similarly predicted to contain 12 hydrophobic regions 
(figure 9). Of these, the third did not quite reach significance in the prediction algorithm for a 
transmembrane domain. However, based on the otherwise similar arrangement as in K15-M, 
it is likely that it also contains 12 transmembrane domains, joined to a cytoplasmic C-terminal 
domain encoded by exon 8 (figures 9 and 15). 
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Figure 9: Predicted transmembrane topology of viral terminal membrane proteins EBV LMP1 and 
LMP2A, RRV R15 and the two KSHV K15 variants K15-P and K15-M. The membrane topology was 
predicted with the TMHMM programme at http://www.cbs.dtu.dk. The x-axis shows the number of amino acids, 
the y-axis the relative probability of a potential transmembrane domain. Red lines = transmembrane domain, 
blue lines = inside, pink lines = outside. See text for further details. 
When we analysed the region at the far right end of the RRV strain 17577 genome 
(accession number #NC_003401, Searles et al., 1999) between the terminal repeats and 
ORF75, we found that this region has the potential to encode a transcript with an exon/intron 
pattern similar to ORF K15 and EBV LMP2A. This potential ORF R15 would hypothetically 
encode a transcript of 1674 bp that could give rise to a protein of 557 aa (pI 8.389). Analysis 
of the R15 protein sequence with the TMHMM programme revealed that the R15 protein 
would consist of 11 transmembrane domains and a cytoplasmic C-terminal domain (figure 9). 
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Hence, the two K15 variants K15-P and K15-M and the hypothetical R15 protein are very 
similar to the EBV LMP2A protein concerning their membrane topology. Furthermore, the 
EBV TMPs LMP1 and LMP2A, RRV R15 and KSHV K15 contain hydrophilic N- (LMP2A) 
or C-termini (K15, R15, LMP1) that are between 119 and 198 aa in length (aa 1-119 for 
LMP2A, aa 188-386 for LMP1, aa 388-557 for R15, aa 348-489 for K15-P, aa 353-498 for 
K15-M) (see figures 9 and 15). 
 
In addition to the full length eight exon transcript, three K15-P splice variants identified by 
RT-PCR in BCP-1 cells by Glenn et al. (1999) were examined in this study. Splice variant 
K15-P ex1/6-8 uses exons 1, 6, 7 and 8, and would therefore lack exons 2-5 compared to the 
K15 exon 1-8 transcript (figure 5 in 1.3.6). This splice variant could potentially give rise to a 
protein with 3-4 transmembrane domains joined to a cytoplasmic C-terminus. 
The splice variants K15-P ex1 as/6-8 and K15-P ex1 as/4-8 use an alternative ATG codon 
and splice donor in exon 1 together with exons 6, 7, 8 or exons 4, 5, 6, 7, 8, respectively 
(figure 5 in 1.3.6; as = alternative splice). The use of this alternative splice donor in exon 1 
would imply the use of a different reading frame in exon 1, resulting in an alternative six aa at 
the N-terminus of the resulting proteins compared to the full length eight exon transcript or 
splice variant K15-P ex1/6-8. The subsequent sequence of these two K15 splice variants 
would be in the same frame as K15-P ex1-8 or K15-P ex1/6-8. Splice variant K15-P ex1 as/6-
8 would be predicted to encode a protein with two transmembrane domains, whereas splice 
variant K15-P ex1 as/4-8 could potentially be composed of three transmembrane domains 
followed by a cytoplasmic C-terminus (data not shown). Since the K15-P variant is detected 
in the majority of KSHV genomes (see 1.3.6), the experiments of this study were performed 
with this K15 variant. 
The first step in order to characterise proteins encoded by the KSHV K15 ORF was to 
transiently express the eight exon K15 transcript (K15 ex1-8, aa 1-489) and the three splice 
variants (K15 ex1/6-8, K15 ex1 as/4-8, K15 ex1 as/6-8) in different cell lines and to analyse 
protein expression with a polyclonal antibody generated against the putatively cytoplasmic 
domain of K15 (Material and Methods, 2.1.1). We then investigated the subcellular 
localisation of ORF K15 derived proteins by biochemical subcellular fractionation assays and 
by immunofluorescence studies. 
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Proteins of 45, 34 and 23 kDa are expressed from the K15 ex1-8 expression construct 
The longest of the K15-encoded proteins, containing all 8 exons, is predicted to give rise to 
a membrane protein of 489 amino acids with a molecular weight of 54 kDa. However, when 
we transiently transfected cos7 cells with the K15 ex1-8 expression construct, a major protein 
of ~45 kDa was detected by immunoblotting with a polyclonal antiserum raised against the 
cytoplasmic domain of K15 (figure 10 A lane 1). In addition, two minor protein bands were 
detected with molecular weights of ~34 and ~23 kDa, which may be the result of alternative 
splicing, proteolytic processing or internal initiation of translation (figure 10 A, lanes 1 and 
2). Upon heat treatment (5 min, 100° C) of the cos7 lysates, the 45 kDa K15 protein was not 
detected anymore (figure 10 A, compare lanes 1 and 2). This may be caused by aggregation of 
the multiple transmembrane domains upon heat treatment, which would prevent the protein to 
enter the SDS gel. This notion was supported by the presence of the ~34 and ~23 kDa 
proteins after heat treatment, which would both be predicted to have fewer transmembrane 
domains (figure 10 A, lanes 1 and 2). The results shown in figure 10 A were also obtained 
with 293-T and Vero cells transiently transfected with the K15 ex1-8 expression construct 
(data not shown). 
In vitro transcription/translation of the K15 exon 1-8 construct gave rise to a protein of ~45 
kDa (figure 10 B, lane 1), that migrated as fast as the 45 kDa protein transiently expressed in 
cos7 cells (figure 10 B, compare lanes 1 and 3). A 34 kDa protein was weakly expressed in 
vitro, whereas the 23 kDa protein was not detectable in vitro (figure 10 B, lane 1). This may 
be due to the absence of cellular factors in the reticulocyte lysate used for the in vitro assay, 
that are required for the posttranslational processing of the 45 kDa protein. 
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Figure 10: A protein of 45 kDa was expressed in vivo and in vitro from a K15 cDNA expression construct 
containing all eight exons. The K15 ORF is multiply and alternatively spliced. The major transcript identified 
by RT-PCR in PEL cell lines is fully spliced and contains all 8 exons (K15 ex1-8; aa 1-489). It encodes a 
membrane protein with up to 12 transmembrane domains and a putatively cytoplasmic C-terminal domain (aa 
348-489). Splice variants K15 ex1/6-8, K15 ex1 as/6-8 and K15 ex1 as/4-8, also identified in PEL cell lines by 
RT-PCR, differ in number of transmembrane domains but all contain the C-terminal domain encoded by exon 8. 
Western blots A-D were probed with a polyclonal K15 rabbit antibody raised to the K15 C-terminal domain. 
(A) Transient expression of K15 ex1-8 and splice variant K15 ex1/6-8 in cos7 cells. The K15 ex1-8 cDNA 
expression construct, predicted to encode a protein of 54 kDa, gives rise to a major protein with an apparent 
mass of 45 kDa and two minor proteins of 23 and 34 kDa in SDS-PAGE (lane 1). The 45 kDa protein is sensitive 
to heat treatment (lane 2). The K15 splice variant K15 ex1/6-8 gives rise to a protein of the predicted mass of 34 
kDa and a minor protein of 25 kDa, which both can be detected with or without heat treatment of the lysate 
(lanes 3 and 4). (B) The K15 ex1-8 expression construct was in vitro transcribed/translated and analysed by 
Western blotting. In vitro transcribed/translated K15 ex1-8 protein (lane 1) was run in parallel to a cos7 lysate 
expressing K15 ex1-8 (lane 3). (C) K15 ex1-8 and N-terminal deletion constructs starting at internal ATG 
codons (K15 ex4-8, K15 ex6-8, K15 ex7.1-8, K15 ex7.2-8) were transiently expressed in cos7 cells and analysed 
by Western blotting. (D) Several protein bands were detected by Western blotting in cos7 lysates transiently 
expressing K15 natural splice variants K15 ex1 as/4-8, K15 ex1 as/6-8 and K15 ex1/6-8. See text for details. 
To address the question whether the smaller K15 proteins of 23 and 34 kDa expressed from 
the K15 ex1-8 construct were derived from internal initiation, and since the K15 ORF 
contains several internal in frame ATG codons, we constructed K15 N-terminal deletion 
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mutants beginning at the internal ATG in exon 4 [K15 ex4-8, aa 188-489 (predicted mass of 
33 kDa)], the ATG in exon 6 [K15 ex6-8, aa 296-489 (predicted mass of 22 kDa)] or at the 
ATGs in exon 7 [K15 ex 7.1-8, aa 314-489 (predicted mass of 20 kDa) and K15 ex7.2-8, aa 
327-489 (predicted mass of 18.5 kDa)]. The resulting recombinant expression constructs K15 
ex6-8, K15 ex7.1-8 and K15 ex7.2-8 were predicted to encode proteins with one 
transmembrane domain, whereas the protein derived from K15 ex4-8 could potentially be 
composed of three transmembrane domains. 
As shown in figure 10 C (lane 2), the K15 exon 6-8 construct gave rise to a protein of ~23 
kDa, suggesting that the 23 kDa expressed from K15 ex1-8 may be derived from internal 
initiation at the ATG in exon 6 (figure 10 C, compare lanes 2 and 4). Expression of construct 
K15 exon 7.1-8 gave rise to a doublet of ~20 and ~18 kDa, and K15 ex7.2-8 expressed a 
protein of ~18 kDa (figure 10 C lanes 5 and 6). The K15 ex4-8 construct gave rise to a protein 
of the predicted mass of ~34 kDa, corresponding in size to the 34 kDa protein expressed from 
the K15 ex1-8 construct (figure 10 C, compare lanes 3 and 4). This indicates that the 34 kDa, 
as well as the 23 kDa protein, may be derived from the full length K15 cDNA by internal 
initiation at ATGs in exon 4 and exon 6, respectively. 
When the smaller K15 splice variants were transiently expressed in cos7 cells, proteins of 
approximately ~34 kDa and ~25 kDa (K15 ex1/6-8; figure 10 A lanes 3 and 4 and figure 10 D 
lane 3), ~34 kDa and ~21 kDa (K15 ex1 as/4-8; figure 10 D lane 1), and ~26 and ~21 kDa 
(K15 ex1 as/6-8; figure 10 D lane 2) were detected by immunoblotting with polyclonal K15 
antiserum. The ~34 kDa protein seen with K15 ex1/6-8 corresponds to the size expected for 
this cDNA, as do the ~34 kDa and ~26 kDa proteins seen with K15 ex1 as/4-8 and K15 ex1 
as/6-8, respectively. However, multiple protein bands were derived from all three splice 
variants (figure 10 D, lanes 1-3), and the additional 21 kDa protein seen with K15 ex1 as/4-8 
and K15 ex1 as/6-8 was more abundantly expressed than the 34 and 26 kDa proteins. These 
smaller proteins may, as well as the 34 and 23 kDa proteins expressed from the K15 ex1-8 
expression construct, be derived from additional splicing events or internal initiation. 
K15 proteins are membrane associated 
In order to analyse whether the proteins derived from the full length K15 expression 
construct are membrane proteins as was predicted by the TMHMM programme (figure 9), 
subcellular fractionation experiments were performed as described in Material and Methods 
(2.6.9). The K15 ex1-8 construct was transiently expressed in cos7 cells and 48 h after 
transfection, cells were resuspended in hypotonic buffer and mechanically lysed. After a 
1.000 x g centrifugation step to deplete lysates from cell debris and nuclei, the cleared lysates 
were subjected to an ultracentrifugation step at 100.000 x g to pellet cellular membranes and 
proteins associated with them. The supernatant after high speed ultracentrifugation 
corresponds to the cytosolic fraction containing soluble proteins. 
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As depicted in figure 11 A (upper panel, lane 4), the 45 kDa K15 protein could be pelleted 
with cellular membranes after high speed centrifugation (100.000 x g). Upon longer exposure, 
the 34 and 23 kDa protein species were also detectable in the membrane fraction (not shown). 
As a positive control for the subcellular fractionation method, the different fractions of cos7 
lysates (supernatant after 1.000 x g, supernatant and pellet after ultracentrifugation) were 
probed with an antibody to endogenous calnexin. Calnexin is a type I transmembrane protein 
with a predicted mass of 64 kDa and an apparent mass of 88 kDa, which was reported to have 
chaperone-like functions in the ER (Hammond et al., 1994 and references therein). As 
expected, Calnexin was detected in the membrane fraction after ultracentrifugation (figure 11 
A, lower panel lanes 3 and 4) and not in the cytosolic fraction (figure 11 A, lower panel lanes 
1 and 2). 
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Figure 11: K15 derived proteins transiently expressed in cos7 cells could be pelleted with cellular 
membranes in a subcellular fractionation assay. Cos7 cells were lysed as described in Material and Methods 
(2.6.9) and nuclei and non-broken cells were pelleted by centrifugation at 1.000 x g. The resulting supernatant 
was subjected to ultracentrifugation at 100.000 x g. The pellet after high speed ultracentrifugation contains 
cellular membranes and membrane proteins, while the supernatant contains the cytosolic fraction and soluble 
proteins. Subcellular fractionation assay fractions were analysed by SDS-PAGE, and Western Blots were probed 
with an antibody to K15 (upper panels in A and B). Endogenous Calnexin, a type I membrane protein in the ER, 
served as a positive control and was detected, as expected, in the pellet (membrane) fraction with a Calnexin 
antibody (lower panels in A and B). K15 ex1-8 (aa 1-489) could be pelleted with cellular membranes (A, lane 4), 
as well as the 23 kDa protein derived from the recombinant expression construct K15 ex6-8 that starts at the in 
frame ATG in exon 6 (B, lane 4). 
Lysates of cos7 cells transiently transfected with the recombinant K15 expression construct 
K15 ex6-8 were also subjected to subcellular fractionation. K15 ex6-8, beginning at the 
internal ATG in exon 6 and giving rise to a 23 kDa protein with one putative transmembrane 
domain and a cytoplasmic C-terminus, was also found to be membrane-associated (figure 11 
B upper panel lane 4) as Calnexin (figure 11 B lower panel lanes 3 and 4). 
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K15 proteins are localised in lipid rafts 
Many cellular and viral membrane proteins have been reported to be associated with 
membrane microdomains termed “lipid rafts”. Examples include the viral membrane proteins 
LMP1 and LMP2A of EBV and the cellular B- and T-cell antigen receptors. Lipid rafts have 
been proposed to function as platforms for receptor signaling and trafficking (reviewed in 
Brown & London 2000). Lipid rafts are membrane microdomains rich in cholesterol and 
sphingolipids that are resistant to solubilisation with non-ionic detergents such as Triton X-
100 at 4°C. Hence, lipid rafts and proteins associated with them float up to a position of lower 
density (5-35%) in a sucrose gradient in the presence of 1% Triton X-100, whereas soluble 
proteins and solubilised membrane proteins remain at the bottom of the gradient at the higher 
sucrose concentration (35-42.5%) (see figure 12 A, left panel). 
The K15 isoforms, i.e. full length K15 ex1-8 and splice variants K15 ex1/6-8, K15 ex1 as/4-
8 and K15 ex1 as/6-8, were transiently expressed in cos7 cells and cell lysates were subjected 
to a sucrose density fractionation as described in Material and Methods (2.6.10) and figure 
legend 12. In addition, a chimeric protein composed of the six transmembrane domains of the 
EBV LMP1 protein and the K15 cytoplasmic C-terminus (LMP1-K15355-489) was analysed for 
lipid raft localisation. After the overnight ultracentrifugation step, 1 ml fractions were 
collected from the top of the gradient (see figure 12 A, left panel) and equal volumes of 
fractions 1-12 were analysed by Western blotting with the polyclonal K15 antibody. As a 
positive control for successful lipid raft preparation, Western blots were routinely stripped and 
reprobed with an antibody to endogenous Caveolin-1. The 21-24 kDa membrane protein 
Caveolin-1 is a component of Caveolae which represent a specialized subset of lipid rafts 
(Simons & Toomre 2000, Galbiati et al., 2001), and therefore Caveolin-1 served as a marker 
protein for lipid rafts (shown for K15 ex1-8 in figure 12 A, not shown for K15 splice variants 
and LMP1-K15355-489 in figure 13). 
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Figure 12: The 45 kDa K15 protein derived from the K15 ex1-8 expression construct localised to lipid 
rafts. Cos7 cells transiently transfected with the (A) K15 ex1-8 construct or (B) K15 ex6-8 construct (see 
Material and Methods 2.2.1, figure 8) were lysed 48 h after transfection in TNE buffer and cell extracts were 
analysed on a flotation sucrose gradient as described in Material and Methods (2.6.10). After ultracentrifugation, 
1 ml fractions were collected starting at the top of the gradient and analysed on Western blots with a rabbit 
polyclonal antibody to the C-terminal domain of K15. 
(A) Left panel: After ultracentrifugation, lipid rafts and lipid raft-associated proteins localise at the interface of 5 
and 35% sucrose (fractions number 3-5). Solubilised membrane proteins of the non-raft plasma membrane and 
soluble proteins localise to the higher density sucrose fractions (35-42.5% sucrose) corresponding to fractions 
10-12. The pellet fraction (P) contains proteins associated with the cytoskeleton. (A) Right upper panel: The 45 
kDa K15 protein is found in fractions 4 and 5 of the sucrose gradient which correspond to the lipid raft 
containing fractions. The 45 kDa K15 protein is also found in fractions 10-12 and in the pellet fraction (P). Right 
lower panel: Western blot membranes shown in the upper panel were stripped and reprobed with an antibody to 
endogenous Caveolin-1, which served as a marker protein for lipid rafts and mainly localised, as expected, to 
lipid raft containing fractions 4 and 5. (B) The 23 kDa protein expressed from the recombinant K15 ex6-8 
construct was shown to be membrane associated (see figure 11 B), but did not localise to lipid raft fractions. The 
23 kDa protein localised to the fractions corresponding to soluble and solubilised proteins (fractions 11-12) and 
the pellet fraction after sucrose density centrifugation. 
As shown in figure 12 A (right upper panel), the 45 kDa protein derived from the 8 exon 
K15 cDNA expression construct (K15 ex1-8; aa 1-489) could be detected in fractions 4 and 5 
of the sucrose gradient which represent the interface of 5 and 35% sucrose. These fractions 
correspond to the position of lipid rafts, as indicated by the presence of caveolin-1 (figure 12 
A, right lower panel). The 8 exon 45 kDa K15 protein also localised to non-raft membranes 
(fractions 10, 11 and 12, sucrose concentration of 35-42.5%) of the sucrose gradient, where 
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solubilised membrane proteins and soluble proteins would be expected (figure 12 A, right 
upper panel). This result is reminiscent of LMP1 and LMP2A, which both localise to lipid 
rafts and also to non-raft cell membranes in EBV-transformed B-cells (LCLs) (Higuchi et al., 
2001). The 45 kDa K15 protein was also detected in the pellet fraction containing 
cytoskeleton-associated proteins (figure 12 A, right upper panel), which is also observed for 
the LMP1 protein, but not for LMP2A (Higuchi et al., 2001). 
K15 proteins of ~34 kDa (splice variant K15 ex1/6-8, figure 13 A) and ~21 kDa (splice 
variants K15 ex1 as/4-8, figure 13 B and K15 ex1 as/6-8, figure 13 C) floated to the lipid raft 
fractions of the sucrose gradient as the 45 kDa K15 protein (figure 12 A). In contrast, the ~34 
kDa protein derived from splice variant K15 ex1 as/4-8 (figure 13 B) and the ~26 kDa protein 
derived from splice variant K15 ex1 as/6-8 (figure 13 C) did not float up to the lipid raft 
fractions in the sucrose gradient. This could be due to the different use of exon 1 of these two 
splice variants, since the ~34 kDa protein derived from splice variant K15 ex1/6-8, which 
encodes the complete exon 1 as the K15 ex1-8 construct, did localise to lipid rafts. This is 
reminiscent of the LMP1 protein: an LMP1 deletion mutant lacking the N-terminus and the 
first transmembrane domain does not localise to lipid rafts (see discussion). 
Only a portion of the K15 proteins was incorporated into lipid rafts (figures 12 and 13). On 
the basis of densitometry scanning of the blots shown in figures 12 and 13, approximately 
21% of the 45 kDa immunoreactive K15 protein (K15 ex1-8) (excluding the material in the 
pellet fraction) was present in lipid rafts. For the smaller ~34 kDa K15 ex1/6-8 splice variant, 
a comparable amount (26%) was found in lipid rafts, in contrast to only 5% in the case of K15 
ex1 as/4-8 and a similar small proportion in the case of K15 ex1 as/6-8. It thus appears that 
the K15 ex1 as/4-8 and K15 ex1 as/6-8 derived ~21 kDa proteins were incorporated less 
efficiently than the 45 kDa (K15 ex1-8) or ~34 kDa (K15 ex1/6-8) isoforms. 
The LMP1-K15355-489 chimeric protein, which had an apparent mass of 37 kDa as predicted, 
localised to lipid rafts and non-raft cell membranes (figure 13 D). This would be expected, 
since the transmembrane domains of LMP1 have clearly been shown to be crucial for lipid 
raft localisation. 
The 34 and 23 kDa proteins that were expressed from the full length K15 cDNA expression 
construct K15 ex1-8 (see figure 10 A) were not present in the lipid raft fractions (not shown). 
In accordance with this observation, the 23 kDa protein expressed from the recombinant K15 
ex6-8 construct was not localised to lipid rafts (figure 12 B). This would point to an important 
role of the N-terminal transmembrane domains of K15 for its localisation to lipid rafts. 
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Figure 13: Analysis of lipid raft localisation for K15 splice variants and an LMP1-K15 chimeric protein by 
sucrose density centrifugation. Cos7 cells were transiently transfected with expression constructs for the 
natural splice variants K15 ex1/6-8 (A), K15 ex1 as/4-8 (B), K15 ex1 as/6-8 (C) or the LMP1-K15355-489 chimera 
(D). Cell lysates were subjected to a sucrose density centrifugation as described in figure legend 12 and Material 
and Methods (2.6.10). Fractions of the sucrose gradient were analysed by SDS PAGE, and Western blots were 
probed with the polyclonal K15 antibody. (A) The ~34 kDa protein derived from splice variant K15 ex1/6-8 
localised to the lipid raft fraction and fractions of high density sucrose. The asterisk (*) indicates a possible 
dimeric form of the ~34 kDa protein. (B) The ~21 kDa protein derived from splice variant K15 ex1 as/4-8 was 
found in lipid rafts and fractions of high density sucrose, while the ~34 kDa protein did not float up to the lipid 
raft fractions. (C) The ~21 kDa protein derived from K15 ex1 as/6-8 localised to lipid rafts and to fractions of 
high density sucrose, while the ~26 kDa protein was not associated with lipid rafts. (D) The LMP1-K15355-489 
chimera was found in lipid rafts and fractions of high density sucrose. 
Caveolin-1 interacts with a variety of lipid-modified signaling molecules including G-
proteins, H-Ras and protein tyrosine kinases of the Src family via its scaffolding domain 
(reviewed in Galbiati et al., 2001). Using a peptide approach, Couet et al. (1997) identified a 
motif (consensus Φ-x-Φ-x-x-x-x-Φ or Φ-x-x-x-x-Φ-x-x-Φ, with Φ being W, F or Y) via 
which proteins interacted with a Caveolin-1 scaffolding domain peptide. The K15-P variant 
contains four such potential caveolin-binding sites (depicted in table 3). One is present in 
exon 1 (F6FWNLWLW), another in exon 3 (W148IFFPISF) and two in exon 6 
(F227LWCLYVW, W279CLYVWQSF). Notably, the K15-M variant also contains four 
caveolin-binding sites, one in exon 1 (Y3KKYLWGTW) and three in exon 6 
(F282LLYCFFCW, F285YCFFCWQSF and F302LFLFLAW). Three of these sites are present at 
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similar positions in both variants (underlined), which could point to an important functional 
role of these regions. 
Exon 1 of the two splice variants K15 ex1 as/4-8 and K15 as/6-8 encodes only six aa 
(M1ALGPT6) in contrast to 72 aa (M1KTLIF6FWNLWLW……PSSWHLGII72) encoded by 
exon 1 from K15 ex1-8 or splice variant K15 ex1/6-8. Hence, these two splice variants would 
not contain the potential caveolin-binding site present in exon 1 in K15 ex1-8 and K15 ex1/6-
8, which might explain their absence in lipid rafts. The K15 ex6-8 construct, which does not 
localise to lipid rafts, would also lack this site and additionally the site in exon 6. The less 
efficient incorporation of the 21 kDa protein derived from splice variants K15 ex1 as/4-8 and 
K15 ex1 as/6-8 in lipid rafts could also be explained by the lack of exon 1 in these K15 
isoforms. To explain the residual incorporation of these proteins into lipid rafts one could 
hypothesise that this 21 kDa protein is palmitoylated or myristoylated, which would allow 
lipid raft localisation. 
Subcellular localisation of K15 membrane proteins by microscopy 
The biochemical analysis of the subcellular localisation of the K15 variants indicated that 
individual K15 proteins may localise to different cellular compartments. Therefore, we 
investigated the localisation of full length K15 ex1-8, K15 splice variants K15 ex1/6-8 and 
K15 ex1 as/4-8 and K15 ex6-8 by immunofluorescence microscopy (figures 14, 16). For a 
comparative analysis between K15 ex1-8 and viral TMPs K1 and LMP1, we analysed the 
protein expression pattern of these proteins, as well as of the LMP1-K15355-489 chimeric 
protein composed of the six transmembrane domains of LMP1 (aa 1-185) fused to the 
cytoplasmic domain of K15 (aa 355-489) (figures 15, 17). 
When the epithelial cell line Ptk2 was transiently transfected with the K15 ex1-8 expression 
construct giving rise to a major 45 kDa and two minor proteins of 34 and 23 kDa (figure 10 
C), and K15 expression was analysed with K15 antiserum, K15 showed a distinct punctate 
expression pattern that was equally distributed over the entire cell (figure 14 A, B). K15 
partially accumulated in the plasma membrane, and could as well localise to intracellular 
membranes or endosomes. K15 was concentrated in a perinuclear region, reminiscent of 
Golgi or late endosome localisation. However, since we did not perform cycloheximide 
experiments to synchronise protein expression, the strong perinuclear staining may arise from 
overexpression of the K15 protein, and may not reflect its physiological localisation. 
We have shown that K15 localised to lipid rafts and contains putative caveolin binding sites 
that are partially conserved between the two K15 variants K15-P and K15-M (table 3). 
Therefore, we investigated whether K15 and Caveolin-1 showed a similar subcellular 
expression pattern. As depicted in figure 14 C and D, a fusion protein composed of GFP fused 
to the C-terminus of Caveolin-1 (Caveolin-1-GFP) transiently expressed in Ptk2 cells showed 
a punctate expression pattern and partly formed larger spots. These larger spots were 
particularly conspicuous in some regions of the plasma membrane (indicated by arrows in 
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figure 14 C), but were also distributed in the cytoplasm. In live cell microscopy of cells 
expressing Caveolin-1-GFP, Pelkmans et al. (2001) described small scattered spots on the 
plasma membrane, and they suggest that these spots may represent individual caveolae. They 
also described larger, more brightly stained intracellular organelles scattered through the 
cytoplasm, which is consistent with our data. 
In order to analyse whether K15 and Caveolin-1 co-localised, Ptk2 cells were co-transfected 
with the Caveolin-1-GFP fusion protein and the K15 ex1-8 expression construct. As depicted 
in figure 17 G and H, both proteins were found at the plasma membrane where they partially 
formed larger spots. However, when the two images were merged, there was no obvious co-
localisation between the two proteins (figure 17 I). 
For further analysis of the subcellular distribution of K15, we double-labelled Ptk2 cells 
transiently expressing K15 ex1-8 with an antibody recognizing endogenously expressed 
Calnexin and a K15 antibody. Calnexin is a type I transmembrane protein and localises to the 
ER (Hammond et al., 1994). As expected for an ER marker, a perinuclear and reticulated 
distribution pattern was observed with the Calnexin antibody (figure 17 E). K15 ex1-8 
showed an equal overall distribution pattern (figure 17 D), and when the two images were 
merged it became obvious that the majority of K15 did not co-localise with Calnexin/the ER 
with the exception of the perinuclear region (figure 17 F). 
In contrast, the K15 splice variant K15 ex1/6-8 showed a cellular distribution pattern 
characteristic of the ER (figure 16 E and F). The expression pattern of this protein was not 
punctate as that observed for K15 ex1-8, but clearly reticulated as seen with the ER marker 
Calnexin (figure 17 E). 
   90
A K15 ex1-8
Caveolin-GFPC
B
D
α-K15
GFP
 
Figure 14: Subcellular localisation of K15 ex1-8 and Caveolin-1-GFP by immunofluorescence microscopy. 
Ptk2 cells were transiently transfected with 1 µg of the respective expression constructs as indicated in the 
figures with the Fugene transfection method. 48 h post transfection, cells were fixed with PFA and analysed for 
protein expression by fluorescence microscopy as described in detail in Material and Methods (2.6.5). Nuclei 
were stained with the Hoechst dye as described in 2.6.5. (A) The K15 ex1-8 construct coding for the major 45 
kDa and minor 34 and 23 kDa K15 proteins was transiently expressed in Ptk2 cells and K15 proteins were 
localised with K15 antiserum and a secondary Cy3 conjugated antibody. (B) Overlay of image A with Hoechst 
stain. (C) Transient expression of a chimeric protein composed of GFP fused to the C-terminus of Caveolin-1 in 
Ptk2 cells. (D) Overlay of image C with Hoechst stain. 
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Figure 15: Ptk2 cells transiently expressing the EBV LMP1 protein or the LMP1-K15355-489 chimera. Ptk2 
cells were transiently transfected with 1 µg of the respective expression constructs as indicated in the figures 
with the Fugene transfection method. 48 h post transfection, cells were fixed with PFA and analysed for protein 
expression by fluorescence microscopy as described in detail in Material and Methods (2.6.5). Nuclei were 
stained with the Hoechst dye as described in 2.6.5. (A) The EBV LMP1 protein was detected with an LMP1-
antibody and a secondary Cy3 conjugated antibody. (B) Overlay of image A with Hoechst stain. (C) The 
chimeric protein composed of the six transmembrane domains of LMP1 fused to the C-terminal domain of K15 
was transiently expressed in Ptk2 cells and detected with K15 antiserum and a secondary Cy3 conjugated 
antibody. (D) Overlay of image C with Hoechst stain. 
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Figure 16: Ptk2 cells transiently expressing the K15 splice variants K15 ex1 as/4-8, K15 ex1/6-8 or the 
recombinant K15 ex6-8 construct. Ptk2 cells were transfected and fixed as described in figure legend 15. (A) 
The localisation of the K15 splice variant K15 ex1 as/4-8 was analysed with K15 antiserum and a secondary Cy3 
conjugated antibody. (B) Overlay of image A with Hoechst stain. (C) Expression of the 23 kDa protein derived 
from the recombinant K15 ex6-8 construct was detecetd with K15 antiserum and a secondary Cy3 conjugated 
antibody. (D) Overlay of image C with Hoechst stain. (E) Expression of splice variant K15 ex1/6-8 was analysed 
with K15 antiserum and secondary Cy3 conjugated antibody (F) Overlay of image E with Hoechst stain.
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Figure 17: Co-localisation studies of transiently transfected Ptk2 cells. Ptk2 cells were transiently transfected 
with 1 µg of the respective expression constructs as indicated in the figures with the Fugene transfection method. 
48 h post transfection, cells were fixed with PFA and analysed for protein expression by fluorescence 
microscopy as described in detail in Material and Methods (2.6.5). Nuclei were stained with the Hoechst dye as 
described in 2.6.5. Images A-C: Ptk2 cells were co-transfected with expression constructs for the Flag-tagged K1 
type I transmembrane protein and K15 ex1-8 (without any tag) and cells were double-labelled with a Flag 
antibody and K15 antiserum. As secondary antibodies, anti-mouse Cy3 for Flag-K1 (A) and anti-rabbit FITC for 
K15 (B) were used. (C) Overlay of images A and B and Hoechst stain. Images D-F: Ptk2 cells transiently 
expressing the K15 ex1-8 expression construct were double-labelled with the K15 monoclonal antibody (see 3.2) 
and an anti-rabbit antibody for endogenous Calnexin. As secondary antibodies, anti-mouse Cy3 for K15 (D) and 
anti-rabbit FITC for Calnexin (E) were used. (F) Overlay of images D and E and Hoechst stain. Images G-I: K15 
ex1-8 and Caveolin-GFP (see also figure 14) were coexpressed in Ptk2 cells and labelled with a K15 monoclonal 
antibody (see 2.3.8) and anti-mouse Cy3 conjugated secondary antibody (G). (I) Overlay of images G and H and 
Hoechst stain. 
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The EBV LMP1 protein has been reported to localise to the plasma membrane, intracellular 
membranes and lipid rafts (see 1.3.1.1). When we immunolabelled Ptk2 cells transiently 
transfected with LMP1 with an LMP1 antibody, LMP1 was equally distributed over the entire 
cell in a distinct punctate pattern and localised to a perinuclear region (figure 15 A and B). 
Interestingly, the LMP1-K15355-489 chimeric protein showed a subcellular distribution pattern 
very different from that of LMP1 (figure 15 C and D). LMP1-K15355-489 did not show a 
punctate pattern as K15 ex1-8 or LMP1, but rather a reticulated distribution reminiscent of the 
ER. The LMP1-K15 chimera also localised to the perinuclear region and to the plasma 
membrane (figure 15 C). At the plasma membrane, the chimera was partially present in larger 
spots as seen with the Caveolin-1-GFP fusion protein (figure 15 C, indicated by an arrow, 
compare with figure 14 C). 
 
Since K1 and K15 transcripts are both present in latently KSHV infected B-cells and 
upregulated upon TPA treatment which induces lytic viral gene expression (see 1.3.5 and 
1.3.6), we wondered whether these two proteins may co-localise. This idea was also supported 
by our observation that K1 localised to lipid rafts (data not shown). As depicted in figure 17 
A, the KSHV K1 type I transmembrane protein was mainly localised to the perinuclear 
region, with a less distinct punctate but more diffuse staining pattern when compared to K15 
or LMP1. K1 staining was partially reminiscient of ER localisation, and K1 was not found to 
form larger spots at the plasma membrane as does K15 ex1-8 (figure 17 A and B). This result 
would be consistent with observations by Lee et al. (2000), who described that K1 directly 
interacts with the µ chains of the BCR, thereby leading to the retention of B-cell antigen 
receptor subunits in the ER (see 1.3.5). 
In Ptk2 cells transiently expressing the K1 and K15 ex1-8 protein and labelled with Flag-
antibody recognising Flag-tagged K1 and K15 antibody, these two proteins were found to co-
localise (figure 17 C). However, co-localisation was rather observed in the cytoplasm and in a 
perinuclear region, and not at the plasma membrane. 
 
The K15 splice variant K15 ex1 as/4-8 did clearly not localise to the plasma membrane but 
rather to a perinuclear region, where it formed clusters (figure 16 A and B). The staining 
pattern of this splice variant appeared more diffuse than that of K15 ex1-8 (figure 14 A and B) 
and was also very different than that of splice variant K15 ex1/6-8 (figure 16 E and F). 
Expression construct K15 ex6-8, which was biochemically shown to localise to cellular 
membranes (figure 11 B) but not to lipid rafts (figure 12 B), mainly localised to the 
perinuclear region, and clearly not to the plasma membrane (figure 16 C and D). The staining 
pattern of K15 ex 6-8 was composed of small spots in the perinuclear region and stronger 
staining close to the nucleus reminiscent of Golgi localisation. Its staining pattern seemed 
diffuse-punctate but clearly not reticulated as that of K15 ex1/6-8 (figure 16 E and F) and was 
more reminiscent of the staining pattern obtained with splice variant K15 ex1 as/4-8 (figure 
16 A and B). 
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In summary, the full length K15 isoform and K15 splice variants were shown to localise to 
different subcellular compartments as judged by biochemical subcellular fractionation assays 
(figures 12 and 13) and immunofluorescence microscopy (figures 14-17). Only the K15 ex1-8 
protein formed larger spots in the plasma membrane that could represent caveolae/lipid rafts, 
but further co-localisation experiments are needed to underline this observation. The splice 
variant K15 ex1/6-8, lacking exons 2-5 and thereby being composed of fewer transmembrane 
domains than K15 ex1-8, shows a very different subcellular localisation by 
immunofluorescence microscopy. This does not contradict the flotation experiments that 
showed that this protein localised to lipid rafts, since lipid rafts are also present in intracellular 
membranes. Interestingly, the splice variant K15 ex1 as/4-8, that uses exon 1 differently, 
showed a subcellular distribution clearly different from K15 ex1-8 and K15 ex1/6-8, which 
indicates that the protein sequence encoded by exon 1 may be important for the subcellular 
localisation. 
Since the K15 ex1-8 construct was clearly shown to localise to lipid rafts that are important 
sites for receptor signaling, we next investigated whether the K15 protein might exert 
signaling activity. 
3.1.2 Signaling activities of K15 membrane proteins 
Many cellular proteins such as adaptor proteins and protein kinases (e.g. protein tyrosine 
kinases of the Src family or PI3 kinase) contain non-catalytic domains termed SH2 or SH3 
domains, via which they can bind to proteins having SH2-binding (SH2-B) or SH3-binding 
(SH3-B) motifs. The consensus motif for SH2-B domains is YXXL/I/V, that, when tyrosine 
phosphorylated, allows binding of SH2 domain containing proteins. SH2-B motifs of the 
consensus YXXA/P/T have also been reported. Different SH2 domains have differing 
preferences for hydrophobic or hydrophilic residues immediately carboxyl prime to the 
tyrosine residue (Songyang et al., 1993, 1994). The C-terminal putatively cytoplasmic domain 
of K15, common to all splice variants identified so far, contains motifs that could function as 
SH2-B and SH3-B motifs and contains tyrosine, serine and threonine residues that are 
potential phosphorylation sites for cellular kinases (shown in figure 18 and table 3). 
Analysis of the twelve tyrosines of K15 ex1-8 and their surrounding motifs reveals that 
Y481, located to the C-terminal putatively cytoplasmic domain of K15, is situated in a context 
that would be suitable for optimal binding to identified proteins involved in signal 
transduction (table 3). The Y481EEV motif in the K15 cytoplasmic domain is preceded by 
negatively charged aa (see figure 18) and resembles an SH2-B site similar to the preferred 
SH2-B site for Src family non-receptor protein tyrosine kinases (PTKs) YEEI. An analysis 
with the programme Motif Scan at http://scansite.mit.edu revealed that the Y481EEV motif of 
K15 would be a suitable docking site for SH2 domain containing proteins such as the Src 
family members of PTKs Src, Fyn, Fgr and Lck, the adaptor protein Nck and the receptor 
tyrosine kinase fibroblast growth factor receptor (FGFR) (table 3). 
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Tyrosine motifs Y52TQA, Y90ACL, Y163AFA, Y190PVS, Y213LGF and Y282VWQ are located 
to regions with low surface accessibility according to the membrane topology prediction 
(figure 9). Of these motifs, Y163AFA could represent an SH2-B site and the Y90ACL motif 
bears some resemblance to an immunoreceptor tyrosine-based inhibitory motif (ITIM). It has 
been demonstrated that the phosphatase SHP-1 binds to the ITIM within the cytoplasmic 
domain of the Fc receptor. This interaction is important in the negative regulation of the BCR 
(Benschop & Cambier, 1999, Cambier et al., 1994, Weiss & Littman, 1994). The consensus 
ITIM binding motif for SHP-1 is T/S-X-X-X-X-X-L, which is very similar to the K15 Y90 
motif SVTY90ACL and to the LMP2A Y85 motif SLY85LGL. Notably, this motif is also 
present in the K15-M variant (SVY46YQL). 
Tyrosine motifs Y345LYK and Y347KEK are located to the very membrane proximal part of 
the cytoplasmic domain. Similar motifs are present at equivalent positions in the K15-M 
variant (Y351LYR and Y353RES), but no interaction partners were predicted for these motifs 
(figure 18, table 3). Y358RQR and Y366TRD are located to the putatively cytoplasmic region of 
K15, but are not reminiscent of SH2-B domains. However, a motif similar to Y366TRD is 
present in the K15-M variant (Y371TPH). The Y431ASI motif in the cytoplasmic domain of 
K15 could serve as an SH2-B motif, and the PTK C-terminal Src kinase (Csk), which is a 
negative regulator of Src family kinases, may be an interaction partner for K15 via this motif 
(table 3). The Y431ASI motif is also reminiscent of an internalization motif found in plasma 
membrane proteins with the consensus Y-X-X-hydrophobic, with leucine being the preferred 
residue at the hydrophobic position, although isoleucine, phenylalanine, methionine and, to a 
lesser extent, valine are tolerated (Bonifacino & Dell´Angelica 1999). 
According to phosphorylation site prediction programmes at http://scansite.mit.edu and 
http://cbs.dtu.dk, the tyrosine residue of the Y481EEV motif can potentially be phosphorylated 
by the receptor tyrosine kinases FGFR and platelet-derived growth factor receptor (PDGFR), 
and PTK Src family members Src and Lck. In addition, several serine and threonine residues 
of the K15 cytoplasmic domain would be situated in a context suitable for phosphorylation by 
serine/threonine kinases such as MAPKs p38 and Erk1 (S385), glycogen synthase kinase 3 
(GSK3; S433, S442, S446), the calcium/calmodulin-dependent protein kinase II (CaMII; S446, 
T367), the cAMP dependent protein kinase A (PKA; S446, T367), the calcium-dependent protein 
kinase C (PKC; T404) and the protein kinase Akt (T367) (see table 3 and figure 18). 
A comparison between the two K15 variants, K15-P and K15-M that share only 33% aa 
identity, points to a functional role of several signaling motifs (table 3 and figure 18): 
Tyrosine motifs YEEV and YASI are strictly conserved between the K15-P (Y481EEV, 
Y431ASI) and K15-M variant (Y490EEV, Y444ASI) (figure 18 and table 3). Tyrosine motifs 
Y345LYK/Y347KEK/Y366TRD in K15-P and Y351LYR/Y353RES/Y371TPH in K15-M are also 
partly conserved between the two variants. The proline-rich motif in the K15 C-terminal 
domain (P387PLPP) may recruit SH3 domain containing proteins such as the adaptor protein 
Crk and the PTK Src (table 3). Notably, this motif is strictly conserved between K15-P 
(P387PLP) and K15-M (P396PLP) (figure 18 and table 3). 
 Table 3: Potential signaling motifs of KSHV terminal membrane proteins K15-P (aa 1-489) and K15-M (aa 1-498). See text and figure 18 for further details. 
K15-P (489 aa)       K15-M (498 aa)     
K15 tyrosine K15 tyrosine motif Potential 
function and 
binding partners 
Potential 
kinase 
K15 tyrosine K15 tyrosine motif Potential 
function and 
binding partners 
Potential 
kinase 
Y52 YTQA ? - Y3 YKKY ? - 
Y90 YACL SH2-B; SHP - Y6 YLWG ? - 
Y163 YAFA SH-2B ? - Y46 YYQL ? - 
Y190 YPVS ? - Y47 YQLF ? - 
Y213 YLGF ? - Y57 YVQS ? - 
Y282 YVWQ ? - Y146 YNNW ? - 
     Y285 YCFF ? - 
     Y322 YTDG ? - 
Y345 YLYK ? - Y351 YLYR ? - 
Y347 YKEK ? - Y353 YRES ? - 
Y358 YRQR ? -     
Y366 YTRD ? - Y371 YTPH ? - 
Y431 YASI SH2-B or internalization 
signal; Csk kinase 
- Y444 YASI as for K15-P - 
Y481 YEEV SH2-B; Src, Lck, Fyn, FGFR, 
Nck, Fgr 
Lck, Src, PDGFR, 
FGFR 
Y490 YEEV SH2-B; Lck, Src, 
Fyn, Fgr 
Src, 
EGFR, Lck 
K15 serine K15 serine motif     K15 serine K15 serine motif   
S385 HLGNNVISPPPLPPF  - Erk1, p38 S360 YRESRLVSFNNVTT - Akt 
S433 GYASILVS  - GSK3     
S442 AEESREPS  - GSK3     
S446 AEESREPSPQPDQSG  - GSK3, CaMII, 
PKA 
    
K15 threonine K15 threonine motif     K15 threonine K15 threonine motif   
T367 QRRRRIYTRDQNLHH  - Akt, CaMII, PKA T452 ASILGDNTPPPTRA - GSK3 
T404 SHVTDRG  - PKC T372 TTRLPIYTPHDTPH - GSK3 
K15 proline K15 proline rich     K15 proline K15 proline rich   
P387 PPLPP SH3-B; Crk, Src - P396 PPLP SH3-B; p85, Crk, 
Grb2, Src 
- 
     P399 PPLPSRN SH3-B; p85 - 
K15 caveolin-
binding site 
      K15 caveolin- 
binding site 
    
F6 FFWNLWLW  ? - Y3 YKKYLWGTW ? - 
W148 WIFFPISF  ? - F282 FLLYCFFCW ? - 
F277 FLWCLYVW  ? - Y285 YCFFCWQSF ? - 
W279 WCLYVWQSF  ? - F302 FLFLFLAW ? - 
TRAF-binding 
site 
      TRAF-binding 
site 
    
P449 PDQSGMS  TRAFs ? - I462 INQSGIS TRAFs ? - 
A473 ATQPT  TRAFs ? - P482 PFQPAD TRAFs ? - 97
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Figure 18: Potential interaction motifs of the KSHV terminal membrane proteins K15-P and K15-M. The 
cytoplasmic domain of K15 contains motifs reminiscent of SH2-B (YASI, YEEV) and SH3-B (PPLP) sites that 
are conserved between the K15-P and K15-M variant. In addition, certain tyrosine, serine and threonine residues 
are situated in a context suitable for phosphorylation by cellular kinases as e.g. Src family PTKs and MAPKs 
(see text). Possible cellular interaction partners for the two K15 variants are listed in detail in table 3. Similar or 
conserved motifs of the two K15 variants are underlined. 
SH2 and SH3 domain containing proteins have been shown to be crucial downstream 
effectors of LMP2A signaling activities. The PTKs Lyn and Syk are crucial interaction 
partners of the LMP2A protein and mediate its downstream signaling. The Y481EEV motif of 
K15 is reminiscent of the SH2-B motif Y112EEA of LMP2A, which is the docking site for the 
PTK Src family member Lyn (see figure 3 in 1.3.1.1 and 1.3.1.2). Therefore, we investigated 
whether K15 is able to bind to members of the Src family of PTKs. 
The K15 C-terminal domain binds to members of the Src family of PTKs 
To investigate the binding of K15 to members of the Src family of PTKs, a GST-pulldown 
approach was used. A fusion protein composed of GST fused to the C-terminal, putatively 
cytoplasmic domain of K15 (GST-K15355-489) was expressed in E. coli and used to bind the 
myc-tagged PTKs Src, Hck, Fyn, Lck and Yes from transiently transfected 293-T cells (see 
figure 19 and 2.6.8). GST alone served as negative control. As shown in a Western blot 
probed with anti-c-myc antibody, all PTKs examined could be precipitated with the GST-
K15355-489 protein (figure 19, lane 3) but not with GST alone (figure 19, lane 2). In order to 
identify the binding site of the PTKs within the K15 cytoplasmic domain, serial deletion 
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mutants of GST-K15355-489, depicted in the upper panel of figure 19, were used in a GST 
pulldown experiment. 
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Figure 19: The non-receptor protein tyrosine kinases (PTKs) Src, Fyn, Yes, Lck and Hck bind to the C-
terminal domain of K15. The C-terminus of K15 (aa 355-489) was fused to the GST protein and a GST-
pulldown experiment was performed with myc-tagged PTKs transiently expressed in 293-T cells. In order to 
map the PTK binding region in the C-terminal domain of K15, serial C-terminal deletion constructs were used in 
the GST-pulldown assay. GST-K15355-472 lacks the putative SH2-B motif Y481EEV, and GST-K15355-373 
additionally lacks the putative SH2-B motif Y431ASI and the putative SH3-B motif P387PLPP (see also table 3 
and figure 18). Bound PTKs were detected by Western blotting and an antibody to c-myc. 
As shown in figure 19, all analysed PTKs still bound to all deletion mutants lacking, 
respectively, the distal SH2-binding motif Y481EEV (GST-K15355-472), the region of aa 439-
489 (GST-K15355-438), and the P387PLP motif together with the Y431ASI motif (GST-K15355-
373). Motifs Y481EEV, Y431ASI and P387PLPP are conserved between the K15-P and K15-M 
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variants, and could be candidates for SH2- and SH3-binding motifs (figure 18 and table 3). 
The GST-pulldown results suggest that the most proximal region of the cytoplasmic domain 
of K15 (aa 355-373) contributes to the binding of Src kinases, but do not exclude a role for 
the P387PLP or Y431ASI motif in this interaction. The region of aa 355-373 encompasses two 
tyrosine motifs, Y358RQR and Y366TRD, which do not represent typical SH2-B motifs. The 
K15-M variant has a similar motif at the equivalent position in its cytoplasmic C-terminus, 
Y371TPH (figure 18), which indicates that this motif might play a role in K15 signaling. 
However, point mutations in this region would be needed to assure whether the Y366TRD 
motif is indeed a docking site for PTKs of the Src family. 
K15 is phoyphorylated by Src family PTKs at Y481 
It has previously been shown that a chimeric protein composed of the extracellular and 
transmembrane domain of the CD8 receptor fused to the cytoplasmic domain of K15 is 
constitutively phosphorylated on the tyrosine within the distal putative SH2-binding motif 
Y481EEV independent of antibody stimulation (Choi et al., 2000a). Since LMP2A is 
phosphorylated at its ITAM motif by members of the PTK family (see 1.3.1.2), we 
investigated whether K15 was a substrate for these kinases. The cytoplasmic C-terminal 
domain of K15 fused to GST (GST-K15355-489) and the deletion mutant GST-K15355-472 
lacking the potential SH2-binding and phosphorylation motif Y481EEV were expressed in E. 
coli and purified as described in Material and Methods (2.6.7). The purified fusion proteins 
were analysed by SDS-PAGE and equal amounts of protein were used as a substrate in an in 
vitro kinase assay with immunoprecipitated myc-tagged PTKs Src, Fyn, Lck, Hck and Yes 
from transiently transfected 293-T cells (see 2.6.11). 
Figure 20 shows that all kinases examined phosphorylated the C-terminal domain of K15 
(GST-K15355-489, 42 kDa, figure 20 A, left top panel), whereas the GST-K15355-472 fusion 
protein lacking the Y481EEV motif was not phosphorylated (40 kDa, figure 20 A, right top 
panel), nor was unfused GST protein (27 kDa, figure 20 A, left and right top panels). 
Expression of the immunoprecipitated myc-tagged PTKs was examined with an anti-c-myc 
antibody (figure 20 A, left middle panel and figure 20 A, right lower panel). The polyclonal 
K15 antibody, which also recognizes the GST protein, was used to detect the GST-K15355-489 
fusion protein and GST (figure 20 A, left lower panel). 
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Figure 20: The tyrosine residue of the distal SH2-binding motif (Y481EEV) of the K15 C-terminal domain 
is phosphorylated by members of the Src kinase family of protein tyrosine kinases. Purified GST-K15355-489 
and GST-K15355-472 protein was used as a substrate in an in vitro kinase assay with immunoprecipitated myc-
tagged Src kinases and [γ-32P] ATP. (A) The Src kinase family members Src, Fyn, Yes, Lck and Hck 
phosphorylate the C-terminal domain of K15 in an in vitro immunocomplex kinase assay (left top panel). If the 
last 17 aa encompassing the SH2-binding motif (Y481EEV) of the C-terminus were deleted (GST-K15355-472), no 
phosphorylation was observed (right top panel). The expression level of the myc-tagged immunoprecipitated Src 
kinases was detected with an anti-c-myc antibody (left middle panel and right lower panel). The amount of GST-
K15355-489 fusion protein and nonfused GST protein used in the in vitro kinase reactions was analyzed by Western 
Blotting and probed with K15 antiserum (left lower panel). (B) The kinase reactions shown in (A) were analysed 
by Western blotting with an anti-phosphotyrosine antibody. Expression of the GST-K15 fusion proteins GST-
K15355-489 and GST-K15355-472 was detected with K15 antiserum. 
Since the sequence deleted in mutant GST-K15355-472 contains two threonine residues (T474, 
T478), which theoretically could be targets for phosphorylation by other cellular kinases, the 
immunoblots of the kinase assay reactions were probed with an anti-phosphotyrosine 
antibody (figure 20 B). The result shows that GST-K15355-489 (figure 20 B, left top panel), but 
not GST-K15355-472 (figure 20 B, right top panel), was phosphorylated on tyrosine, indicating 
that Y481 in the Y481EEV SH2-binding motif of K15 was phosphorylated by the Src kinases 
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examined. However, assuming that other protein kinases bound to the immunoprecipitated 
Src kinases, the question whether K15 is solely phosporylated at Y481 in the region 
encompassing aa 473-489 could only be addressed with a GST-K15355-489 fusion protein 
carrying the point mutation Y481→F481. 
Activation of the NF-κB pathway by the 45 kDa K15 protein involves Y481 
NF-κB is a dimeric transcription factor that activates transcription from a large number of 
target genes that play key roles in cell growth and death, as well as in immune and 
inflammatory responses. NF-κB activity is frequently increased in human tumours; it is 
essential for growth and survival of tumour cells. Cells tightly regulate NF-κB activity by 
expression of a family of inhibitory proteins, IκBs, that bind to NF-κB sequestering it in the 
cytoplasm (reviewed in Pomerantz & Baltimore 2002, Gosh & Karin 2002). One prominent 
example of bypassing this control mechanism is the EBV LMP1 protein, which is a potent 
inducer of the NF-κB pathway. LMP1 activates IκB kinases (IKK) that subsequently 
phosphorylate IκB on serines. Phosphorylated IκB is then recognized by WD40 domains of 
ubiquitin ligase receptors, ubiquitinated by E3 ubiquitin protein ligases at lysine residues and 
targeted for degradation by the 26 S proteasome, which relieves inhibition of NF-κB-
dependent transcription (see 1.3.1.1 and figure 35 in 4.1). 
The ability of TRAF-1, -2 and -3 to interact with K15 (Glenn et al., 1999, Brinkmann et al., 
2003) resembles their binding to the CTAR-1 region of LMP1, where they provide a link to 
the downstream events that result in activation of the NF-κB pathway (see 1.3.1.1, 1.3.6, 
figure 3 in 1.3.1.1 and figure 35 in 4.1). Therefore, we investigated whether the different K15 
isoforms could activate NF-κB by co-transfecting corresponding expression vectors (figures 7 
and 8 in 2.2.1) together with a luciferase reporter plasmid containing three NF-κB sites into 
293-T cells (2.2.2). 
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Figure 21: The 45 kDa K15 protein activates the transcription factor NF-κB in a luciferase based reporter 
assay. (A) 293-T cells were transiently co-transfected with 50 ng of the luciferase reporter plasmid 
p3EnhκBconA-Luc containing three NF-κB binding sites upstream of the luciferase gene and different amounts 
of K15 expression constructs (200, 500 ng DNA). 24 h after transfection, cells were lysed and analysed for 
luciferase activity. Shown is the relative fold of activation compared to empty vector (mock) transfected (200, 
500 ng DNA) cells based on triplicate samples. Equal expression levels of K15 proteins were analysed by 
Western blot with a K15 antiserum (not shown). (B) BCBL-1 cells were transfected with 5 µg of the NF-κB 
luciferase reporter p3EnhκBconA-Luc and 10 µg of expression constructs for either K15 ex1-8, LMP1 or mock 
DNA by electroporation as described in Material and Methods (2.3.7), lysed 24 h after transfection and analysed 
for luciferase activity as described in 2.6.4. Shown is the relative fold of NF-κB activation compared to mock 
transfected BCBL-1 cells. 
As shown in figure 21 A, K15 ex1-8, expressing the longest K15 isoform (aa 1-489), 
showed a 5-6 fold activation of the NF-κB transcription factor, whereas the smaller K15 
isoforms (K15 ex1/6-8, K15 ex1 as/6-8 and K15 ex1 as/4-8) did not significantly increase 
basal NF-κB activity. As a positive control, pSV-LMP1 coding for the LMP1 protein was 
transfected, which induced an approximately 100 fold activation of this reporter (not shown). 
In comparison, only a moderate three fold NF-κB activation was observed with the LMP1-
K15355-489 chimeric protein (figure 21 A). Protein expression of the different constructs in 293-
T cells was comparable on Western blots (not shown). 
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These results indicate a contribution of the transmembrane regions of K15 to NF-κB 
activation, which can also partly be provided by the LMP1 transmembrane regions. A deletion 
construct lacking aa 473-489, including the Y481EEV motif, and the K15 Y481→F481 point 
mutant did not activate NF-κB (figure 21 A), indicating that phosphorylation of Y481, most 
likely by members of the PTK family, is required for initiating NF-κB signaling. 
The ability of K15 ex1-8 to induce the NF-κB transcription factor was also analysed in the 
naturally KSHV-infected PEL cell line BCBL-1. As depicted in figure 21 B, transiently 
expressed K15 ex1-8 induced NF-κB up to five fold in BCBL-1 cells, whereas LMP1 showed 
a much stronger activation of the NF-κB reporter. 
The activity of the AP-1 transcription factor is induced by K15 
The mitogenic transcription factor AP-1 is a dimer of Jun-Jun or Jun-Fos family proto-
oncoproteins and it has been shown that LMP1 is an inducer of AP-1 activity in 293 cells 
(Kieser et al., 1997). To test whether K15 can activate the AP-1 transcription factor, HEK 
293-T cells were transiently co-transfected with 50 ng of the reporter plasmid pRTU14, which 
consists of a luciferase reporter gene under the control of a minimal promoter and four AP-1 
binding sites [TPA responsive elements (TREs), consensus 5´-TGA(G/C)TCAG-3´], and 
increasing amounts of different K15 expression constructs or plasmid pSV-LMP1 as a 
positive control (figures 7 and 8 in 2.2.1). 
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Figure 22: The transcription factor AP-1 is activated by K15. (A) 293-T cells were transiently co-transfected 
with the AP-1 luciferase reporter plasmid pRTU14 containing four AP-1 binding sites upstream of the luciferase 
gene, and different amounts of K15 expression constructs (100, 200, 500 1000 ng). After transfection, cells were 
grown in medium containing 1% FCS, lysed after 24 h and analysed for luciferase activity. Shown is the relative 
fold of activation compared to mock transfected (100, 200, 500, 1000 ng) cells based on triplicate samples. Equal 
expression levels of K15 proteins were analysed by Western blot with K15 antiserum (not shown). (B) BCBL-1 
cells were transfected with 5 µg of the AP-1 luciferase reporter pRTU14 and with 10 µg of either K15 ex1-8 or 
mock DNA by electroporation as described in Material and Methods (2.3.7), lysed 24 h after transfection and 
analysed for luciferase activity as described in 2.6.4. Shown is the relative fold of AP-1 activation compared to 
mock transfected BCBL-1 cells. 
The results depicted in figure 22 A show that full length K15 ex1-8 (aa 1-489) was a more 
potent inducer of AP-1 activity than LMP1, with K15 activating AP-1 up to 7-8 fold and 
LMP1 activating AP-1 up to 3-4 fold in a dose-dependent manner compared to cells 
transfected with control plasmids. Transiently expressed full length K15 ex1-8 is also able to 
induce the AP-1 transcription factor in the naturally KSHV infected PEL cell line BCBL-1 up 
to four fold (figure 22 B). 
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AP-1 activation of the K15 deletion mutant lacking the Y481EEV motif (K15 ex1-8 ∆473-
489) and the point mutant K15 ex1-8 Y481F was significantly reduced (figure 22 A). This 
result indicates that phosphorylation of tyrosine Y481 of the Y481EEV motif was important for 
K15-induced AP-1 activation. Interestingly, the LMP1-K15355-489 chimera did not induce AP-
1 activity. The three K15 splice variants (K15 ex1/6-8, K15 ex1 as/6-8 and K15 ex1 as/4-8) 
showed no clear-cut activation although they contain the entire K15 cytoplasmic domain 
(figure 22 A). This might suggest that the regions encoded by exons 2-5 are also important for 
induction of AP-1 activity. 
K15 induces the kinase activity of the MAP kinases Erk2 and JNK1, but not of p38 
After we established that K15 was able to induce the AP-1 transcription factor, the next step 
was to elucidate the signaling pathways that are mediating the signaling effects of the K15 
protein. Three major MAP kinase pathways have been described to date that regulate AP-1 
activity in the cell: the Ras-Raf-MEK1/2-Erk1/2 pathway, the MKK4/7(SEK1)-JNK1 cascade 
and the MKK3/6-p38 pathway (Chang & Karin 2001, Pearson et al., 2001). LMP1 induces the 
activity of the transcription factor AP-1 specifically via the c-Jun N-terminal kinase 1 (JNK1) 
pathway (Kieser et al., 1997, Eliopoulos & Young 1998, Eliopoulos et al., 1999). 
Furthermore, LMP1 induces the activity of the MAP kinase p38 (Schultheiss et al., 2001). In 
order to investigate the ability of the longest K15 isoform to induce any of these pathways, 
the activation of the MAP kinases Erk2, JNK1 or p38 was examined in in vitro 
immunocomplex kinase assays (see Material and Methods 2.6.11). LMP1 was included in the 
JNK1 and p38 kinase assay as a positive control. 
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Figure 23: Immunocomplex kinase assays with MAP kinases Erk2, JNK1 and p38. 293-T cells were 
transiently co-transfected with 1 µg of the HA-tagged MAP kinases Erk2, JNK1 or p38, and 1 µg of the K15 or 
LMP1 expression constructs. After transfection, cells were grown in medium containing 1% FCS and lysed after 
24 h in TBS-T buffer containing phosphatase inhibitors. The cell lysates were then subjected to an 
immunoprecipitation with HA-antibody 12C5 coupled to protein G beads overnight. Myelin basic protein 
(MBP), purified GST-c-Jun fusion protein (see 2.6.7) or GST-ATF2 served as substrates in the in vitro kinase 
reactions with Erk2 (A), JNK1 (B) or p38 (C), respectively. The immunoprecipitated kinase was incubated with 
its substrate and [γ-32P] ATP for 30 min at 25°C in kinase reaction buffer and subsequently analysed by 
autoradiography (upper panel A, B, C). Western blots of the kinase reactions were probed with specific Erk2, 
JNK1 or p38 antibodies to assure equal expression levels of the MAP kinases (middle panel A, B, lower panel 
C). Cell lysates were analyzed for equal expression of K15 constructs by Western blot probed with a K15 
antibody (lower panel A, B). 
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As depicted in figure 23 A, the 45 kDa K15 protein (K15 ex 1-8; aa 1-489) was able to 
induce the kinase activity of co-transfected hemagglutinin (HA)-tagged Erk2 kinase in 
transiently transfected 293-T cells as measured by phosphorylation of the myelin basic protein 
(MBP). In contrast to the strong activation of Erk2 kinase by K15 ex1-8, we only observed a 
weak activation of JNK1 in co-transfected 293-T cells (figure 23 B) as monitored by 
phosphorylation of the JNK1 substrate GST-c-jun. The activity of the p38 MAPK was not 
induced by K15, since phosphorylation of the GST-ATF2 protein by p38 was not increased 
when K15 ex1-8 was co-expressed compared to mock infected cells (figure 23 C, compare 
lanes 2 and 3). As expected, the positive control LMP1 induced the kinase activity of co-
transfected HA-JNK1 and HA-p38 in 293-T cells (figure 23 B and C; Kieser et al., 1997, 
Schultheiss et al., 2001). Equal amounts of HA-tagged MAPKs Erk2, JNK1 and p38 being 
immunoprecipitated and used for the kinase assay reactions were confirmed by Western blot 
with antibodies to Erk2, JNK1 or p38 protein (figure 23 A-B, middle panels, C lower panel). 
The activation of the Erk2 and JNK1 kinase activities in 293-T cells induced by the K15 
protein depended on its intact cytoplasmic domain (figure 23 A, B), since no Erk2 or JNK1 
activities were observed upon co-transfection with either the deletion construct K15 ex1-8 
∆473-489 or the point mutant K15 ex1-8 Y481F. Cell lysates were also analysed for equal 
expression levels of K15 proteins by Western Blotting with K15 antiserum (figure 23 A, B 
lower panels, not shown for figure 23 C). 
These findings demonstrate that the 45 kDa K15 protein specifically induced the MAP 
kinases Erk2 and JNK1, but not p38 (summarised in figure 36 in 4.1). Furthermore, 
phosphorylation of Y481, presumably by members of the PTK family, seemed to be crucial for 
K15 signaling activity in these two MAPK pathways. 
Dominant negative mutants of TRAF-2, Ras, Raf, Erk2 and MEK1/2-specific inhibitors 
PD98059 and UO126 reduce K15-induced activities of Erk2 and AP-1 
We have shown that K15 bound TRAF-2 via aa 472-489 of its C-terminal domain 
(Brinkmann et al., 2003), and this region was shown to be crucial for induction of NF-κB and 
AP-1 activity by K15 (figures 21 A and 22 A). Therefore, it was elucidated whether a 
dominant negative TRAF-2 mutant could block K15-induced Erk2 and AP-1 activation. In 
order to further examine the downstream signaling routes linking K15 to Erk2, it was also 
tested if co-expression of dominant negative mutants of Ras (Ras N17), Raf or Erk2 could 
inhibit K15-induced Erk2 and AP-1 activation in immunocomplex kinase assays (figure 24 A) 
and luciferase-based AP-1 reporter experiments (figure 25). In addition, the effects of two 
chemical MEK1/2 specific inhibitors, PD98059 (Alessi et al., 1995, Dudley et al., 1995) and 
UO126 (Favata et al., 1998), were tested on K15 induction of Erk2 and AP-1 (figure 24 B). 
MEK1/2 is the upstream kinase which phosphorylates and thereby activates Erk1/2 (see figure 
36 in 4.1). 
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Figure 24: Dominant negative mutants of TRAF-2, Erk2, Raf and Ras and the MEK1/2 inhibitors UO126 
and PD98059 reduce the Erk2 and AP1 activation induced by K15. (A) 700 ng of dominant negative mutants 
of TRAF-2, Ras, Raf or Erk2 or their respective empty expression vectors pRKH5, pCis2 or pKRSPA were co-
transfected with 1 µg of HA-Erk2 and 1 µg of K15 ex1-8 (aa 1-489) or empty K15 expression vector (mock) 
where indicated. Erk2 kinase activity was monitored by phosphorylation of MBP (upper panel). The Western 
blot probed with anti-Erk2 antibody shows equal expression levels of the Erk2 kinase for all samples. (B) 293-T 
cells were co-transfected with 1 µg of HA-Erk2 and 1 µg of K15 ex1-8 (aa 1-489) expression construct or empty 
K15 expression vector. 14 h after transfection, DMSO alone or the MEK1/2 inhibitors PD98059 or UO126 were 
added to the medium at 50 µM from a 50 mM stock solution in DMSO. Cells were incubated for a further 8 
hours before protein extraction. In vitro kinase assays were performed as described in Material and Methods 
(2.6.11). The Western blots were probed with anti-Erk2 antibody to show equal expression levels of the Erk2 
kinase for all samples. 
Transient co-expression of dominant negative TRAF-2 with HA-Erk2 and full length K15 
reduced K15-induced Erk2 activity as shown by decreased phosphorylation of the Erk2 
substrate MBP compared to co-expression with the empty TRAF-2 vector pRKH5 in 293-T 
cells (figure 24 A, compare lanes 3 and 4). An even more marked inhibition by dominant 
negative TRAF-2 was seen in the AP-1 luciferase based reporter assay (figure 25). In order to 
show the specificity for TRAF-2 and since TRAF-6 is involved in LMP1-induced activation 
of the p38 MAP kinase pathway (Schultheiss et al., 2001), the effect of a dominant negative 
TRAF-6 mutant on K15-induced AP-1 activation was also examined. The result in figure 25 
shows that dominant negative TRAF-6 had no effect on AP-1 induction by K15 compared to 
co-transfected pcDNA3.1 vector. Dominant negative Ras (Ras N17) inhibited K15-induced 
Erk2 and AP-1 activation as shown in the immunocomplex kinase assay (figure 24 A, 
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compare lanes 5 and 6) and the reporter assay (figure 25) compared to the empty expression 
vector pCis2. The dominant negative Raf mutant reduced MBP phosphorylation by Erk2 in 
the immunocomplex kinase assay (figure 24 A, compare lanes 7 and 8), but showed only a 
moderate inhibition in the AP-1 reporter assay compared to the empty expression vector 
KRSPA (not shown). In the AP-1 reporter assay, the dominant negative Erk2 mutant (Erk C3, 
Y185→F185) was able to inhibit AP-1 activation by K15 compared to KRSPA (figure 25). 
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Figure 25: Dominant-negative TRAF-2, Ras and Erk2 mutants inhibit K15-induced AP-1 activity in an 
AP-1 luciferase-based reporter assay. 293-T cells were transiently co-transfected with 50 ng of the AP-1 
reporter plasmid (pRTU14), 500 ng of the K15 ex1-8 (aa 1-489) expression construct and 350, 700 or 1000 ng of 
dominant negative mutants of Ras, TRAF-2, TRAF-6, Erk2 or their respective empty expression vectors pCis2, 
pRKH5, pcDNA3.1, pKRSPA. Shown are relative light units (RLU) with the luciferase values of the 
corresponding empty expression vectors of the different dominant negative mutants set at 1. 
In addition to dominant negative mutants of the components of the Ras-Raf-MEK-Erk 
pathway, the two chemical inhibitors of MEK1/2, PD98059 and UO126, inhibited K15-
induced Erk2 activity in an immunocomplex kinase assay (figure 24 B). Likewise, in the AP-
1 reporter assay, both PD98059 and UO126 at 50 µM inhibited K15 induced AP-1 activity by 
approximately 50-60% (not shown). These results suggest that K15 activates the AP-1 
transcription factor via the Ras-Erk pathway involving the components Ras, Raf, MEK, Erk2, 
and that TRAF-2 may be involved in linking this pathway to K15 phosphorylated on Y481 
(summarised in figure 36 in 4.1). 
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3.2 Physiological (in vivo) expression of K15 
KSHV shows a broad in vitro tropism: it has been shown to infect human B, endothelial, 
epithelial and fibroblast cells (see 1.1 and 1.2). In addition, KSHV infects a variety of animal 
cells, such as owl monkey kidney cells, baby hamster kidney fibroblast cells, Chinese hamster 
ovary cells, and primary embryonic mouse fibroblast cells (Akula et al., 2002, 2003, Bechtel 
et al., 2003, Dourmishev et al., 2003, Naranatt et al., 2003). In vivo, KSHV DNA and 
transcripts have been detected in human B-cells, macrophages, keratinocytes, endothelial 
cells, and epithelial cells (reviewed in Schulz 2001). Only a very small subset of KSHV genes 
is expressed during the latent viral life cycle, namely LANA-1 and LANA-2, kaposin, vFLIP 
and vcyclin (see figure 1 in 1.2). A variety of cell lines have been established from patients 
with primary effusion lymphoma (PEL) that are latently infected with EBV and KSHV or 
with KSHV alone (see 2.3.2 for references and details). In these cell lines, the lytic viral life 
cycle can be artificially induced by the addition of phorbol esters such as TPA or n-butyrate. 
Viral genes transcribed early after induction are referred to as immediate early/early lytic 
genes, followed by lytic genes and late genes (see figure 1 in 1.2). The viral glycoprotein 
K8.1 is such a late gene, and K8.1 protein can be detected 48-72 h after induction. During 
latent infection, PEL cells can also spontaneously undergo lytic replication (1-5% of the cell 
population, depending on the cell line). 
Our group and others identified K15 transcripts in the latently infected PEL cell lines BCP-1 
and BCBL-1, that are upregulated upon TPA treatment (Glenn et al., 1999, Choi et al., 
2000a). This expression pattern indicates that K15 may be expressed during latency and 
during the lytic viral life cycle. However, the transcripts identified by RT-PCR in latently 
infected, non-induced cells, may be derived from the small subset of cells undergoing 
spontaneous lytic replication. We sought to identify the in vivo expression of K15 protein and 
analysed several PEL cell lines using the polyclonal antibody raised against the K15 C-
terminus, and additionally generated a monoclonal antibody. 
Epitope mapping of the monoclonal K15 antibody 
The monoclonal K15 antibody, raised against the putatively cytoplasmic domain of K15 (aa 
355-489), was generated as described in Material and Methods (2.3.8). The epitope in the K15 
aa sequence recognized by this antibody was analysed with a peptide array (figure 26 A, see 
Material and Methods 2.6.6). The complete aa sequence of K15 (aa 1-489) was synthesized as 
peptides of 15 aa on a filter by Ronald Frank (GBF Braunschweig). Each peptide was shifted 
by three aa, resulting in a total of 159 K15 peptide spots on the filter. First, the filter was 
incubated with the secondary alkaline phosphatase conjugated antibody to measure the 
background reactivity (figure 26 A, upper panel). Subsequently, the filter was incubated with 
the K15 monoclonal antibody C12C4 as described in 2.6.6. As depicted in figure 26 A (lower 
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panel), this antibody strongly bound to three spots of the peptide array (spots 118, 119 and 
120), and the aa sequence of K15 corresponding to these spots is depicted in the figure (23 A 
lower panel). Common to all spots was the aa sequence Y358RQRRRRIY (underlined in figure 
26). 
This monoclonal antibody was further characterised by immunofluorescence on K15 ex1-8 
transfected cos7 cells (data not shown) and by Western blotting (figure 26 B), and was found 
to be suitable for both applications. The monoclonal K15 antibody still recognized the 
shortest C-terminal GST-K15 (GST-K15355-373, figure 26 B, left panel, see also figure 19) and 
LMP1-K15 deletion mutant (LMP1-K15355-415, figure 26 B, right panel) by Western Blot 
analysis, which confirms the data obtained with the peptide array. 
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Figure 26: The K15 monoclonal antibody recognizes the epitope Y358RQRRRRIY of the K15 C-terminal 
domain. The K15 monoclonal antibody C12C4 was generated as described in Material and Methods (2.3.8) and 
analysed by a peptide array (A) and by Western Blot (B). The epitope recognized by the antibody is localised to 
the beginning of the putative cytoplasmic domain of K15: the antibody detects the shortest C-terminal deletion 
constructs LMP1-K15355-415 and GST-K15355-373 in SDS-PAGE (B) and binds strongly to peptide spots 118, 119 
and 120 of the peptidearray (A), which all contain the aa sequence Y358RQRRRRIY. 
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A protein of 23 kDa was detected in PEL cell lines with a polyclonal K15 antibody 
Various latently infected PEL cell lines (described in detail in Material and Methods, 2.3.2) 
were analysed by Western Blot for in vivo expression of K15 protein with K15 antibodies. 
Cells were either left untreated, or the viral lytic cycle was induced with TPA and cells were 
lysed 72 h after induction. In order to check whether the lytic cycle was successfully induced, 
the lysates were analysed for the expression of the late lytic K8.1 glycoprotein, which would 
only be expected to be expressed after TPA treatment. The B-cell line DG75, negative for 
both EBV and KSHV, served as a negative control. As shown in figure 27 (upper panel), a 
~23 kDa protein was detected in PEL cell lines CroAP-5, CroAP-6, Jsc-1 and BCBL-1, that 
was absent in DG75 cells. In addition, a protein of ~40 kDa was detected in PEL cell lines 
CroAP-5, CroAP-6 and Jsc-1. However, this ~40 kDa protein was not reproducibly seen in 
PEL lysates, whereas the 23 kDa protein was always detected. Both proteins were present in 
unstimulated and TPA stimulated cells, suggesting that both protein forms may be expressed 
during the latent and lytic viral life cycle. Expression of the 23 kDa protein seemed to be 
slightly upregulated upon lytic cycle induction with TPA (figure 27 upper panel). 
 
The same PEL cell lysates were analysed for protein expression of the late lytic 
glycoprotein K8.1 with a K8.1 monoclonal antibody (figure 27, lower panel). Multiple bands 
were detected by Western Blot with this antibody due to the heavy glycosylation of this 
protein. Weak K8.1 expression was found in non-induced Jsc-1, CroAP-6 and BCBL-1 cell 
lines, suggesting that a subset of the cell population undergoes spontaneous lytic replication 
(figure 27, lower panel). In non-induced CroAP-5 cells, K8.1 was not detected, indicating that 
this cell line is strictly latent. However, K8.1 expression was significantly upregulated in all 
four PEL cell lines treated with TPA, indicating that the lytic cycle was induced (figure 27, 
lower panel). 
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Figure 27: A protein of 23 kDa was detected in PEL cell lines with a polyclonal antibody to the K15 C-
terminus. KSHV-infected PEL cell lines Jsc-1, CroAP-5, CroAP-6 and BCBL-1 were either treated with TPA 
for lytic cycle induction (+) or left untreated (-). 72 h after induction, cells were lysed in 1% NP40 lysis buffer 
(Material and Methods 2.6.1) and subjected to SDS-PAGE. Western Blots were probed with the polyclonal K15 
antibody (upper panel) or a monoclonal K8.1 antibody (lower panel). The EBV and KSHV negative cell line 
DG75 served as a negative control. 
Since the 23 kDa protein was most strongly expressed in Jsc-1 cells, we continued our 
analysis with this PEL cell line. Figure 28 B (upper panel) shows that the 23 kDa protein 
frequently detected in latently infected Jsc-1 cells corresponds in size to the 23 kDa K15 
protein derived from the recombinant K15 expression construct that begins at the internal 
ATG codon in exon 6 (K15 ex6-8). The protein derived from the K15 ex6-8 construct is 
predicted to encode a protein with one putative transmembrane protein and was shown to be 
membrane associated (figure 11 B) but does not localise to lipid rafts (figure 12 B). Hence, 
Jsc-1 cell lysates were subjected to a subcellular fractionation assay as described in Material 
and Methods (2.6.9) in analogy to cos7 lysates transiently transfected with the K15 ex6-8 
construct. Surprisingly, the 23 kDa protein from Jsc-1 lysates was not found to be membrane-
associated as the marker protein calnexin, but localised to the soluble fraction (figure 28 A). 
The same result was obtained for the PEL cell line CroAP-5 (data not shown). Further, the 
monoclonal K15 antibody did not recognise the Jsc-1 23 kDa protein, whereas it detected the 
23 kDa protein expressed from the K15 ex6-8 construct (data not shown). 
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Since the 23 kDa protein expressed in Jsc-1 cells seemed to be a soluble protein, we 
analysed whether this protein was encoded by the cytoplasmic domain of K15. Two possible 
scenarios could explain the origin of the soluble 23 kDa protein: (i) the Jsc-1 23 kDa protein 
may be derived from an additional splice event not identified so far, that splices directly in 
exon 8, or (ii) it could result from cleavage in the cytoplasmic domain of a precursor K15 
protein. This would be reminiscent of the EBV LMP1 protein, which is cleaved in its 
cytoplasmic domain resulting in a 25 kDa protein (see 1.3.1.1). 
 
Assuming that a K15 precursor protein would be cleaved at the junction between the last 
predicted transmembrane domain and the cytoplasmic domain, the resulting protein would be 
predicted to have a molecular weight of 15 kDa and to be a soluble protein. Since the 
predicted mass of a protein does not necessarily resemble its apparent mass in SDS-PAGE, 
we constructed an expression vector coding for the cytoplasmic domain of K15 (K15 ex8, aa 
354-489). When the K15 ex8 construct was in vitro transcribed/translated and run in parallel 
to a Jsc-1 cell lysate and in vitro transcribed/translated K15 proteins expressed from 
constructs K15 ex6-8 or K15 ex7.2-8 (figure 28 B, lower panel), it clearly migrated at ~15 
kDa and thereby faster than the Jsc-1 23 kDa protein. This would suggest that the 23 kDa 
protein detected with the K15 polyclonal antibody in Jsc-1 cell lysates was not derived by 
cleavage in the C-terminal domain of K15. 
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Figure 28: The 23 kDa protein expressed in PEL cell lines was not membrane associated. (A) The 23 kDa 
protein detected in lysates of latently KSHV-infected Jsc-1 cells did not pellet with cellular membranes (upper 
panel) as did the calnexin type I transmembrane protein (lower panel). (B) The 23 kDa protein in Jsc-1 cells 
corresponded in size to a K15 protein beginning at the in frame ATG in exon 6 (K15 ex6-8) transiently 
expressed in cos7 cells (upper panel). In vitro transcription/translation of K15 constructs K15 ex7.2-8 (beginning 
at the second in frame ATG in exon 7) and K15 ex8 (beginning at the epitope recognized by the K15 monoclonal 
antibody, see figure 26 A) showed that the derived proteins migrate faster than the 23 kDa protein of Jsc-1 cells. 
Sharp et al. (2002) reported the detection of a ~23 kDa protein in latently infected Jsc-1 
cells with a monoclonal K15 antibody. The authors showed that the expression of this Jsc-1 
23 kDa protein decreased over time upon TPA induction. This contradicts our results, since 
we observed a slight upregulation of the 23 kDa protein expression after TPA treatment 
(figure 27, upper panel). When we examined Jsc-1 cells by immunofluorescence for 
expression of K15 protein, we obtained negative results with both our polyclonal and 
monoclonal K15 antibody (data not shown). Sharp et al. (2002) reported a cytoplasmic 
immunostaining pattern in the majority of Jsc-1 cells with their K15 monoclonal antibody, 
which would support the idea that the 23 kDa protein is not membrane-associated. The 
observation that the majority of Jsc-1 cells stained positive for K15 (Sharp et al., 2002) would 
also suggest that the 23 kDa protein was a truly latent protein, since if it was a lytic protein, it 
would be expected to be expressed in only a small subset of cells undergoing lytic replication. 
The observation by Sharp et al. (2002) that K15 is expressed during latency and decreasing 
upon TPA treatment contradicts data obtained by RT-PCR and viral gene expression arrays 
that showed low expression of K15 transcripts in latently infected BCP-1 cells and 
upregulation of expression upon lytic cycle induction (Glenn et al., 1999, Choi et al., 2000a, 
Paulose-Murphy et al. 2001, Nakamura et al. 2003). 
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Several K15 transcripts were detected in Jsc-1 cells by RT-PCR 
In order to trace the origin of the 23 kDa protein expressed in PEL cell lines, which may 
originate from splice events that were not identified so far, we performed an RT-PCR on 
RNA extracted from uninduced Jsc-1 cells with a specific reverse primer annealing 233 bp 
downstream of the K15 stop codon in exon 8 (exon8arev, see table 2 in 2.2.4 and Material and 
Methods 2.5.4). The subsequent PCR was performed with primers beginning 25 bp upstream 
of the ATG in exon 1 (MBK15Bfor, table 2 in 2.2.4) and a reverse primer annealing 51 bp 
downstream of the stop codon in exon 8 (LRR6rev, table 2 in 2.2.4). The B-cell line Raji, 
EBV positive but negative for KSHV, served as a negative control. As shown in figure 29, 
three bands of ~2.2 kb, ~1.6 kb and ~1.4 kb and one weak band of ~1.0 kb could be detected 
after gel electrophoresis. Jsc-1 transcripts were excised from the gel and cloned into the 
pGEM-T vector and several clones were sequenced. 
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Figure 29: K15 transcripts identified by RT-PCR on Jsc-1 RNA. The reverse transcriptase reaction was 
performed with a gene specific primer annealing 233 bp downstream of the stop codon of ORF K15 (see text). 
The subsequent PCR with a K15 forward primer annealing 25 bp upstream of exon 1 and a K15 reverse primer 
binding 51 bp downstream of the K15 stop codon identified several transcripts with different splicing patterns 
(see text for details). kb = kilobases, M = 1kb ladder, bp = basepairs. 
The ~2.2 kb Jsc-1 transcript corresponded to the genomic, non-spliced K15 ORF, while the 
1.4 kb transcript corresponded to the fully spliced eight exon form (figure 29). An alignment 
with the BCBL-1 K15 sequence (NCBI accession #AAD45297) showed that the BCBL-1 and 
Jsc-1 ex1-8 sequences were 99% identical, with only three aa substitutions: one in exon 1 
(N9→D), one in exon 3 (V131→M) and one in exon 5 (F237→L). 
   118
When we cloned the ~1.6 kb band in the expression vector pGEM-T and sequenced several 
clones, we obtained three different transcripts that are depicted in figure 29. One contained all 
eight exons but was not completely spliced. The second contained eight exons, was 
completely spliced, began at an alternative start codon in exon 1 and used a different splice 
donor in exon 1. The third transcript also contained all eight exons, but was not completely 
spliced and showed a deletion of 132 bp (44 aa) in exon 5, which did not alter the reading 
frame. 
The 1.4 kb transcript corresponded to the K15 ex1-8 construct first identified in BCP-1 cells 
and found in this study to induce several signaling pathways. The 1.0 kb transcript began at an 
alternative start codon in exon 1 and used a different splice donor in exon 1, then spliced in 
exon 4 and completely spliced exons 5-8 (figure 29). This 1.0 kb transcript corresponded to 
the splice variant K15 ex1 as/4-8 that was identified in BCP-1 cells by Glenn et al. (1999), 
which was shown in this study to express proteins of 34 and 21 kDa (figure 10 D). However, 
none of the transcripts detected in Jsc-1 cells would be predicted to encode a protein with low 
hydrophobicity. 
 
In summary, we could not clarify the origin of the 23 kDa protein that we detected by 
Western Blot with the polyclonal K15 antibody in Jsc-1 cell lysates. This suggests that this 
protein may be derived from a cellular or viral ORF other than K15, with which our 
polyclonal K15 antibody and the monoclonal K15 antibody from Sharp et al. (2002) do 
crossreact. The most prominent transcripts that were identified in Jsc-1 and BCP-1 cells 
encoded all eight exons and were fully spliced, which would suggest that a protein should be 
expressed from this transcript in KSHV infected B-cells. However, this protein may either be 
expressed at very low levels in vivo or has a short half life. 
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Analysis of K15 protein expression in epithelial cell lines T24, DU145 and Vero stably 
infected with recombinant KSHV 
Since KSHV has also been shown to infect epithelial cells, we analysed three epithelial cell 
lines for K15 protein expression. Epithelial cell lines DU145 and T24 are stably infected with 
recombinant KSHV derived from virions of BCBL-1 cells (rKSHV.152) (figure 30 A; Vieira 
et al., 2001; for details see Material and Methods 2.3.2). 
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Figure 30: Analysis of in vivo K15 expression in epithelial cell lines stably infected with recombinant 
KSHV. (A) Epithelial cell lines T24 and DU145, stably infected with recombinant KSHV.152 (rKSHV.152), 
and Vero cells stably infected with rKSHV.219 were analysed by Western blotting for K15 expression. Both 
recombinant viruses carry a GFP cassette under control of the human EF-1 α promoter. Both cassettes are 
inserted between viral ORFs 57 and K9 of the KSHV genome and confer antibiotic resistance. The cassette of 
rKSHV.219 additionally contains the RFP gene under control of the lytic PAN (polyadenylated nuclear) RNA 
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promoter. (B) KSHV infection of cell lines T24 rKSHV.152 and DU145 rKSHV.152 is reported to be strictly 
latent (see text). Lysates of these two cell lines were analysed by Western blot with the polyclonal K15 antibody. 
Non-KSHV infected cell lines T24 and DU145 served as negative controls. (C) Vero cells stably infected with 
rKSHV.219 were either left untreated or were infected with different amounts of Baculovirus ORF50/RTA as 
indicated in the figure (0, 20 or 50 µl) and treated with n-butyrate (1 mM final concentration) to induce lytic 
viral gene expression. 48 h after induction, cells were lysed and analysed for K15 expression with K15 antiserum 
(upper panel) or expression of the late lytic viral glycoprotein K8.1 with a K8.1 antibody (lower panel). 
Between the polyadenylation sites for ORFs 57 and K9 (figure 1 in 1.2 and figure 30 A) of 
rKSHV.152, a GFP/neo cassette is inserted, with the GFP gene being expressed from the 
human elongation factor 1-α promoter. The neo gene (RSV promoter) confers resistance to 
the antibiotic G418. Hence, cells stably infected with rKSHV.152 would express the GFP 
protein. The two cell lines DU145 rKSHV.152 and T24 rKSHV.152 were reported to be 
strictly latent and the lytic cycle could only be induced by a co-infection with the human 
cytomegalovirus (Vieira et al., 2001). Lysates of uninduced cell lines DU145 rKSHV.152 and 
T24 rKSHV.152 were analysed by Western blotting with the polyclonal K15 antibody, and 
non-infected T24 and DU145 cell lines served as negative control. As shown in figure 30 B, 
no protein bands were detected in lysates from DU145 rKSHV.152 or T24 rKSHV.152 that 
were absent in T24 and DU145. These results would suggest that in strictly latent KSHV 
positive epithelial cells, K15 protein is either not or very weakly expressed. 
 
Since the lytic viral life cycle in cell lines DU145 rKSHV.152 and T24 rKSHV.152 can 
only be induced by infection with HCMV (Vieira et al., 2001), we did not analyse these cell 
lines for K15 expression during the lytic viral life cycle. Another epithelial cell line infected 
with recombinant KSHV, Vero rKSHV.219, became available to us to investigate K15 
protein expression during the lytic viral life cycle. This cell line allows lytic cycle induction 
by phorbol esters and furthermore, the efficiency of lytic cycle induction can be easily 
monitored by expression of the RFP protein upon lytic cycle induction. The Vero rKSHV.219 
cell line is stably infected with recombinant KSHV.219 (rKSHV.219) derived from KSHV 
produced by the PEL cell line Jsc-1. In rKSHV.219, a cassette is inserted between ORFs 57 
and K9 that contains the red fluorescent protein (RFP) along with GFP (under control of the 
human elongation factor 1-α promoter) and the pac gene for resistance to puromycin (figure 
30 A). 
 
Besides TPA and n-butyrate, ectopic addition of an expression construct for the KSHV 
ORF50/RTA protein, which is the major lytic switch protein of KSHV, was shown to be 
sufficient to induce the lytic cyle of KSHV in several cell lines (see 1.2). Since the expression 
of RFP is under control of the viral lytic PAN (polyadenylated nuclear) promoter in 
rKSHV.219, and the PAN gene is a directly responding target for RTA (Wang et al., 2004 and 
references therein), the efficiency of lytic cycle induction could be monitored by the presence 
of GFP expressing cells that are also expressing RFP. 
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We achieved the most efficient induction of the lytic viral life cycle in Vero rKSHV.219 
cells upon addition of 1 mM n-butyrate together with infecting the cells with a Baculovirus 
encoding the lytic switch protein ORF50/RTA (figure 31 A, see Material and Methods 2.3.5 
and 2.3.6). Already 24 h post induction, approximately 30% of cells expressed RFP (figure 31 
A upper panel). 48 h post induction, ~50% of cells were found positive for RFP expression 
(figure 31 A lower panel). 
We analysed lysates of non-induced Vero rKSHV.219 cells and of cells that were treated 
with n-butyrate and additionally infected with the ORF50/RTA Baculovirus by Western 
blotting for K15 protein expression. As depicted in figure 30 C (upper panel), we did not 
detect K15 protein being expressed in neither uninduced nor induced Vero rKSHV.219 cells 
with the polyclonal or monoclonal K15 antibody. When the same lysates were analysed for 
expression of the late lytic viral glycoprotein K8.1 (figure 30 C lower panel), K8.1 was not 
expressed in non-induced Vero rKSHV.219 cells (lane 1), and K8.1 expression was efficiently 
induced by infection with Baculovirus ORF50/RTA alone (lanes 2 and 3) and significantly 
enhanced in the presence of n-butyrate and Baculovirus ORF50/RTA (lanes 4 and 5). 
 
To summarise, K15 protein expression in vivo was not detected in three different epithelial 
cell lines being infected with recombinant KSHV, indicating that K15 is either not expressed 
in KSHV positive epithelial cells, or if expressed its expression is too low to be detected with 
the K15 antibodies. However, in ongoing experiments we detected a ~45 kDa protein in 293 
cells stably infected with the KSHV genome cloned into a bacterial artificial chromosome 
(BAC) vector (data not shown). In this system (provided to us by Zhou et al., 2002), we 
detected K15 protein expression 15 h post induction with n-butyrate and Baculovirus 
ORF50/RTA. The K15 45 kDa protein was most strongly expressed at 2 days post induction, 
and expression decreased three days post induction (data not shown). 
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Figure 31: The lytic viral life cycle can be efficiently induced in Vero cells stably transfected with 
rKSHV.219. (A) Vero rKSHV.219, stably expressing GFP, were infected at 80% confluency with Baculovirus 
ORF50/RTA and treated with 1 mM n-butyrate to induce the viral lytic life cycle. RFP expression, under the 
control of the viral lytic PAN promoter (see text), was observed already at 24 h post induction (upper panel). 48 
h post induction, more than 50% of Vero rKSHV.219 cells expressing GFP were positive for RFP expression, 
indicating lytic viral gene expression (lower panel). (B) rKSHV.219 was harvested 48 h post induction from 
Vero rKSHV.219 cells and added to 293, 293-T or Vero cells. KSHV-infection of these cell lines could be 
monitored and quantified by the appearance of GFP positive cells. One GFP positive cell was considered as one 
infectious unit, and infectious units per ml were determined at 72 h post infection for each cell line. LM = light 
microscopy. 
K15 transcripts were identified in rKSHV.219 infected 293-T epithelial cells by RT-PCR 
Another timepoint for K15 expression may be immediately after KSHV entry in the target 
cell. Therefore, we prepared rKSHV.219 from the cell line Vero rKSHV.219 to perform 
infection studies with rKSHV.219 (see 2.3.5 for details). The day after induction of the lytic 
cyle in Vero rKSHV.219 cells with n-butyrate and Baculovirus ORF50/RTA, the medium 
(containing n-butyrate and Baculovirus ORF50/RTA) was replaced. 24 h later, the medium 
was collected and filtered through a 0.45 µm filter (Material and Methods 2.3.5). The 
production of infectious rKSHV.219 from Vero rKSHV.219 cells was determined by titering 
the medium containing rKSHV.219 on epithelial cell lines 293, 293-T or Vero or B-cell lines 
BCBL-1, BJAB or Raji. The GFP gene carried by rKSHV.219 allowed the detection of 
rKSHV.219 infected cells, and infectious units could be determined by counting GFP 
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expressing cells three days post infection. GFP-expressing cells were first observed 48 h post 
infection in 293, 293-T and Vero cells, and the number of GFP positive cells further increased 
up to 72 h post infection in these cell lines (figure 31 B). The number of GFP-positive cells 
produced per ml of rKSHV.219 containing media was used as the number of infectious units 
(IU) of KSHV per ml. The infectivity of rKSHV.219 (infectious units per ml) was determined 
to be 2.8 x 105 IU/ml for 293 cells, 0.7 x 105 IU/ml for 293-T cells and 1.4 x 107 IU/ml for 
Vero cells at 72 h post infection (figure 31 B). We did not detect any GFP positive cells in the 
B-cell lines BCBL-1, BJAB and Raji infected with rKSHV.219 (data not shown). 
 
In order to analyse rKSHV.219 infected cells for K15 expression, we infected 293-T cells 
with a rKSHV.219 stock diluted 1:2 in medium. 293-T cells were lysed 24, 48 and 72 h post 
infection for RNA preparation or Western blotting. As shown in figure 32 A for the timepoint 
72 h post infection, 293-T cells infected with rKSHV.219 expressed GFP, indicating 
successful infection. The reverse transcriptase reaction was performed with a specific K15 
reverse primer annealing 233 bp downstream of the ORF K15 stop codon (exon 8arev, table 2 
in 2.2.4, see 2.5.4). For the subsequent PCR, a K15 forward primer annealing at the second in 
frame ATG in exon 7 (MBexon7.2for, table 2) and K15 reverse primer binding at the ORF 
K15 stop codon (FlagLAMPa3´, table 2) were employed. As a positive control for the PCR, a 
K15 ex1-8 plasmid (without introns) was used. With these primers, amplification of K15 
cDNA and the K15 ex1-8 plasmid would result in a PCR product of 513 bp, whereas 
amplification of genomic DNA would give rise to a PCR product of 598 bp (intron length 
between exon 7 and 8 is 85 bp). 
As shown in figure 32 B, a band of ~513 bp was detected by PCR on cDNA of 293-T cells 
at 24, 48 and 72 h post infection (lanes 4-6, indicated by an arrow), that was absent when the 
PCR was performed on cDNA of uninfected 293-T cells (lane 3). The 513 bp band was absent 
when the reverse transcription was not performed (-RT, lanes 7-10), showing the specificity 
of the 513 bp transcript. 
When 293-T protein lysates collected at time points 24, 48 and 72 h post infection were 
analysed by Western blotting with K15 antibodies, no protein band was detected that was not 
present in uninfected 293-T cells (figure 32 C). 
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Figure 32: K15 transcripts but no protein expression were detected in 293-T cells at 24, 48 or 72 h post 
infection with rKSHV.219. 293-T cells were lysed at 24, 48 and 72 h post-infection with rKSHV.219 for 
analysis of protein expression and RNA preparation for RT-PCR. (A) Infection of 293-T cells with rKSHV.219 
prepared from Vero rKSHV.219 cells was monitored by GFP expression 72 h post infection. (B) RNA was 
prepared from 293-T cells at timepoints 24, 48 and 72 h post infection with rKSHV.219 and used as a template 
for a reverse transcriptase reaction with a specific reverse primer annealing 233 bp downstream of the ORF K15 
stop codon. Uninfected 293-T cells served as negative control. The subsequent PCR was carried out with a 
reverse primer annealing at the ORF K15 stop codon and a forward primer annealing at the second in frame 
ATG in exon 7. Plasmid DNA of K15 exon1-8 served as a positive control for the PCR reaction. A transcript of 
~513 bp (indicated by an arrow) was detected in 293-T cells at 24, 48 and 72 h post infection, which was absent 
in uninfected 293-T cells and in the control reactions without RT (-RT). (C) 293-T cells were lysed in TBS-T 
buffer at timepoints 24, 48 and 72 h post-infection with rKSHV.219 and analysed for protein expression of K15 
protein by Western blotting with the polyclonal K15 antibody. Uninfected 293-T cells served as a negative 
control. p.i. = post infection, M = marker (DNA 1 kb ladder), RT = reverse transcriptase. 
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3.3 K15: an effect on the viral lytic cycle? 
It has been reported for viral terminal membrane proteins EBV LMP2A and KSHV K1 that 
they may exert an effect on the viral life cycle. LMP2A, which is expressed during latent 
infection in EBV infected B-cells, seems to have a role in the maintenance of viral latency in 
B-cells (see 1.3.1.2). This assumption is based upon the observation that in LCLs infected 
with EBV recombinants lacking LMP2A, BCR crosslinking leads to normal BCR signal 
transduction and activation of the lytic viral life cycle, whereas lytic infection is blocked in 
LCLs infected with wildtype EBV. The effect of K1 on viral replication is controversial (see 
1.3.5). K1 expression by itself cannot initiate viral replication as the major lytic switch protein 
ORF50/RTA (Lagunoff et al., 1997), but two recent reports suggest that K1 may (i) augment 
KSHV reactivation from latency (Lagunoff et al., 2001) or (ii) play a role in maintaining viral 
latency (Lee et al., 2002). Lee et al. (2002) observed that the majority of KSHV genes was 
downregulated after induction of the viral lytic life cycle with TPA in the PEL cell line 
BCBL-1 stably transfected with K1. 
Based on our results that K15 activates the AP-1 and NF-κB transcription factors, we 
analysed whether K15 has an effect on viral gene expression. The KSHV lytic switch protein 
ORF50/RTA, that is sufficient to activate the viral lytic programme of KSHV, shows several 
AP-1 binding sites in its promoter region as predicted by the Mat Inspector programme at 
http://transfac.gbf.de (figure 33, upper panel). We therefore cloned the 3085 bp ORF50 
promoter region (figure 33, upper panel) in the promoter-less luciferase reporter plasmid 
pGL3basic (p3kbORF50P) and transfected it together with different amounts of the K15 ex1-
8 expression construct (100, 250, 500, 1000 ng) in 293-T cells. As shown in figure 33 A, 
when 500 ng of the K15 ex1-8 expression construct were co-transfected with 50 ng of the 
reporter plasmid p3kbORF50P and cells were analysed for luciferase activity 40 h after 
transfection, the luciferase activity was enhanced ~4 fold compared to empty vector (mock) 
transfected cells. This would imply that full length K15 had a positive effect on the ORF50 
promoter region. 
 
One pathway via which K15 could activate the ORF50 promoter would be the Ras-Erk2 
signaling cascade, which K15 has been shown to activate (see chapter 3.1). We therefore co-
transfected 293-T cells with 500 ng of the K15 ex1-8 construct, 50 ng of p3kbORF50P and 
either 350 or 700 ng of dominant negative mutants of Ras, TRAF-2 or Erk2 or their respective 
empty expression vectors pCis2, pRKH5 or pKRSPA, and determined the luciferase activity 
40 h after transfection. Figure 33 B shows the relative inhibition of K15-induced luciferase 
activity by dominant negative mutants Ras, TRAF-2 and Erk2. The luciferase activity of 293-
T cell lysates transfected with the empty expression vectors of the dominant negative mutants 
was set at 1. Dominant negative mutants Ras and Erk2 significantly inhibited the effect of 
K15 on the ORF50 promoter region (Ras 350 ng by 92%, Ras 700 ng by 94%, Erk2 350 and 
700 ng by 80%), whereas dominant negative TRAF-2 showed a less significant effect (350 ng 
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by 30%, 700 ng by 40%). This would suggest that K15 might activate expression of the viral 
ORF50/RTA gene via the MAPK pathway components Ras and Erk2, but further experiments 
are needed to underline this observation. 
0 1 2 3 4 5 6
mock
K15 ex1-8 100 ng
K15 ex1-8 250 ng
K15 ex1-8 500 ng
K15 ex1-8 1000 ng
Relative fold of activation of the ORF50 promoter region
A
B
Erk
2 d
.n.
pK
RS
PA
TR
AF
-2 d
.n.
R
el
at
iv
e 
in
hi
bi
tio
n
of
 O
R
F5
0 
pr
om
ot
er
re
gi
on
ac
tiv
ity
350 ng DNA
700 ng DNA
pR
KH
5
Ra
s d.
n.
pC
is2
0
0,2
0,4
0,6
0,8
1,0
1,2
1,4
ORF50 ORF50ORF49
3085 bp promoter region ORF50
+1
exon 2exon 1
AP-1 binding site
[5´-TGA(G/C)TCAG-3´]
+33-3052
-2970
-2478
-2211
-2096
-1893
-1696
-1513
-1400
-1326
-939
-898
-859
-685
-278
-178
-86
TATA
-24-32
-46
 
Figure 33: K15 activated a luciferase reporter plasmid containing the ORF50 promoter region. Dominant 
negative Ras and Erk2 inhibit K15-induced activation of the ORF50 reporter. A region of 3085 bp of the 
ORF50 promoter region was cloned upstream of a promoter-less luciferase reporter plasmid. The ORF50 
promoter region contains several AP-1 binding sites (consensus 5´-TGA(G/C)TCAG-3´) as predicted by the Mat 
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Inspector programme at http://transfac.gbf.de. (A) 293-T cells were transiently transfected with different 
amounts of the K15 ex1-8 expression construct (100, 250, 500, 1000 ng) together with 50 ng of a reporter 
plasmid containing the 3085 bp ORF50 promoter region cloned upstream of the luciferase gene (p3kbORF50P). 
Cells were lysed 40 h after transfection and analysed for luciferase activity. Shown is the relative fold of 
activation compared to empty vector (mock) transfected (100, 250, 500, 1000 ng DNA) cells based on two 
independent experiments each of them performed in duplicate. (B) 293-T cells were transiently co-transfected 
with 50 ng of the ORF50 luciferase reporter plasmid p3kbORF50P, 500 ng of the K15 ex1-8 expression 
construct and 350 or 700 ng of dominant negative mutants of Ras, TRAF-2, Erk2 or their respective empty 
expression vectors pCis2, pRKH5, pKRSPA. Cells were lysed 40 h after transfection and analysed for luciferase 
activity. The relative fold of activation obtained with K15 ex1-8 co-transfected with the empty expression 
vectors pCis2, pRKH5 or pKRSPA was set at 1 and compared to the relative fold of activation obtained with 
K15 ex1-8 and dominant negative mutants of Ras, TRAF-2 and Erk2. Shown is one representative experiment 
based on duplicate samples. 
Ectopic overexpression of the viral lytic switch protein ORF50/RTA induces viral 
reactivation in a variety of latently KSHV infected cell lines. The ORF50 gene is expressed 
early in lytic reactivation, and its expression can upregulate several promoters of lytic genes 
(Lukac et al., 1999). Since K15 had a positive effect on the ORF50 promoter, we asked 
whether K15 might be able to activate lytic viral gene expression by activating expression of 
RTA. To address this question, we transfected the Vero rKSHV.219 cell line that is stably 
infected with recombinant KSHV.219 (see figure 30 A) with the K15 ex1-8 expression 
construct or empty vector (mock). In addition, Vero rKSHV.219 cells were transfected with 
an expression construct for the Flag-tagged RTA protein. Induction of the lytic viral life cycle 
can be monitored by RFP expression in rKSHV.219 infected cells (see figure 31 A). 
As depicted in figure 34 C, RFP expressing cells could be observed 48 h after transfection 
when RTA was transiently expressed in the cell line Vero rKSHV.219. Hence, ectopic 
expression of the Flag-RTA expression construct lead to the induction of the lytic cycle of 
rKSHV.219, as has been shown in chapter 3.2 with Baculovirus ORF50/RTA (figure 31 A). 
As expected, upon transfection with an empty expression vector (mock), no RFP positive 
cells were observed (figure 34 A). Transient expression of K15 ex1-8 in Vero rKSHV.219 
cells did not result in the expression of RFP, indicating that K15 did not induce the lytic viral 
life cyle in this cell system (figure 34 B). Western blot analysis with a Flag antibody or K15 
antiserum showed that both RTA and K15 ex1-8 were expressed in transiently transfected 
Vero rKSHV.219 cells (not shown). 
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Figure 34: Ectopic expression of K15 ex1-8 in Vero rKSHV.219 cells did not induce viral lytic replication 
as did ectopic expression of the lytic switch protein RTA. As illustrated in figure 30, Vero cells stably and 
latently infected with rKSHV.219 express the GFP protein, whereas RFP protein is only expressed in cells 
undergoing lytic viral replication. Vero rKSHV.219 cells were transiently transfected with 1 µg of either empty 
expression vector (mock) (A), K15 ex1-8 (B) or Flag-tagged RTA (C) and analysed for RFP expression up to 48 
h after transfection. While RTA expression resulted in lytic viral gene expression as judged by the appearance of 
RFP expressing cells (C), no cells positive for RFP expression were observed in K15 ex1-8 expressing cells (B) 
as well as for mock transfected cells (A). (D) Vero rKSHV.219 cells, either treated with 1 mM n-butyrate 
(middle panel) or left untreated (left panel) were co-transfected with expression constructs for K15 ex1-8 and 
RTA, K15 ex1-8 and mock or RTA and mock. 48 h post transfection, cells were lysed and analysed for 
expression of the late lytic protein K8.1 with a specific K8.1 antibody (left and middle panel), K15 and RTA 
expression (right panel). 
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These results show that ectopic expression of K15 ex1-8 in the epithelial cell line Vero 
rKSHV.219 did not result in the induction of the viral lytic life cycle as ectopic expression of 
Flag-RTA under the conditions we used. Hence, K15 was not able to initiate viral lytic 
replication on its own in Vero rKSHV.219 cells. However, this does not rule out that K15 
may augment lytic replication by activating ORF50/RTA expression in cells that already 
undergo lytic gene expression due to RTA expression or treatment with n-butyrate. 
We therefore transfected Vero rKSHV.219 cells with the K15 ex1-8 expression construct 
alone or together with the RTA expression construct in duplicate and either treated cells with 
1 mM n-butyrate to induce the lytic viral life cycle or left cells untreated. Cells were lysed 48 
h after transfection/induction and analysed by Western blot for expression of the late lytic 
KSHV protein K8.1. As depicted in figure 34 D, the K8.1 protein was not expressed in cells 
that were transfected with K15 ex1-8 alone in the absence (left panel, lane 2) or presence 
(middle panel, lane 2) of n-butyrate, which confirmed our results shown in figure 34 B. As 
expected, K8.1 protein was expressed in Vero rKSHV.219 cells transiently transfected with 
Flag-RTA that were not treated with n-butyrate (figure 34 D left panel, lane 3), and K8.1 
expression was further increased in the presence of Flag-RTA and n-butyrate (figure 34 D 
middle panel, lane 3). In Vero rKSHV.219 cells that were co-transfected with Flag-RTA and 
K15 ex1-8, we did not see a significant difference in the level of K8.1 expression compared to 
Vero rKSHV.219 cells transfected with RTA alone (figure 31 D left and middle panels lane 
1). Expression of transiently expressed K15 ex1-8 and Flag-RTA was detected with K15 
antiserum or a Flag antibody (figure 34 D, right panels). 
 
The fact that we did not see an effect of transiently expressed K15 on the lytic viral life 
cycle in the Vero rKSHV.219 cell line does however not rule out that K15 has the ability to 
activate the lytic viral life cycle. The activation of the ORF50 promoter by K15 in 293-T 
luciferase reporter assays may not represent the in vivo situation as such that the ORF50 
promoter is methylated in vivo, and other co-factors might be needed to allow K15 to exert its 
effect on viral gene expression that are not given in the system we employed. 
   130
4 Discussion 
4.1 K15 signaling 
We have shown that the major isoform of K15-derived proteins, containing all 8 exons and 
presumably 489 amino acids, activated the Ras-Raf-MEK1/2-Erk2 MAPK pathway as well as 
the NF-κB pathway and the MAP kinase JNK1 (summarised in figure 36). Activation of these 
pathways depended on Y481 in a carboxyterminal Y481EEV motif that is reminiscent of the 
Y112EEA motif of EBV LMP2A. In B-cells, Y112 of LMP2A is phosphorylated by the Src 
kinases Lyn and Fyn and important for the recruitment of these kinases. We could show that 
several members of the Src kinase family of PTKs, including Src, Fyn, Yes, Hck and Lck, 
bound to the K15 C-terminus and phosphorylated Y481 of K15 in vitro (figures 19 and 20). 
When phosphorylated, the Y481EEV motif would be an optimal SH2-binding site for members 
of the Src kinase family of PTKs (table 3). The ability of K15 to bind to Src kinase family 
members of PTKs and to be phosphorylated by those kinases is reminiscent not only of the 
LMP2A protein, but also of HVS terminal membrane proteins StpA, StpB and Tip, KSHV K1 
and the HVA Tio protein (see table 1; Lee et al., 1997, Choi et al., 2000b, Albrecht et al., 
1999, Biesinger et al., 1995, Lee et al., 1998b). 
Sequences located between aa 355 and 373 at the membrane proximal region of the 
cytoplasmic domain of K15 appear to contribute to the interaction of Src family PTKs with 
K15, since a GST-K15 fusion protein containing this region still bound to all the Src kinases 
tested (figure 19). The two tyrosine motifs in this region, Y358RQR and Y366TRD, are not 
reminiscent of SH2-B motifs, but the fact that the K15-M variant contains a similar tyrosine 
motif at the equivalent position (Y371TPH, see figure 18) points to a functional role of the 
Y366TRD motif of K15-P. Point mutations in this motif would be required to further address 
its role in PTK interaction. Hypothesising that the interaction of K15 with PTKs is crucial for 
downstream signaling, a full length K15 ex1-8 construct carrying point mutations in the 
Y366TRD motif should be analysed for its ability to activate NF-κB and the MAPKs Erk2 and 
JNK1. 
 
A Y481 → F481 mutant abolished the ability of the full length K15 protein to activate the Ras-
Erk2 pathway, as well as JNK1 and NF-κB (figures 21, 22, 23), indicating that 
phosphorylation of Y481, presumably by members of the Src kinase family of PTKs, 
represents a first step in the activation of these pathways. Results by Choi et al. (2000a) 
underline the importance of the the phosphorylation of K15. They found that the K15 C-
terminus, when fused to the CD8 receptor, was constitutively phosphorylated at Y481 in B-
cells (see 1.3.6), although the kinases involved were not identified. When phosphorylated, the 
Y481EEV motif was predicted to be an optimal binding site for SH2 domain containing 
proteins such as the FGFR, Src family PTKs and the adapter protein Nck (see table 3), or it 
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may be a docking site for other not yet identified cellular proteins, which may be crucial for 
mediating K15 downstream signaling events. 
 
The K15 transmembrane domains appeared to be important for the ability of K15-derived 
proteins to initiate different signaling pathways, since only the longest isoform K15 ex1-8, 
containing up to 12 putative transmembrane domains (figures 9 and 18) was capable of 
initiating efficient signaling (figures 21 and 22). LMP1 induces the NF-κB and AP-1 
transcription factors (see 1.3.1.1, figures 21, 22), but the LMP1-K15 chimera, composed of 
the six transmembrane domains of LMP1 fused to the K15 cytoplasmic domain, was not able 
to induce activation of an AP-1 reporter (figure 22), and only showed a moderate activation of 
an NF-κB reporter when compared to the K15 ex1-8 isoform (figure 21). 
The six transmembrane domains of LMP1 mediate efficient clustering of LMP1 in the cell 
membrane, which is a prerequisite for constitutive intracellular signaling of this viral 
oncoprotein (see 1.3.1.1). A chimeric protein composed of six transmembrane domains of 
LMP2A follwed by the LMP1 cytoplasmic domain is not able to activate NF-κB (Kayakas et 
al., 2002), which illustrates that the LMP1 transmembrane domains are not simple membrane 
anchors, but are crucial for efficient signaling of the LMP1 molecule. This suggests that, 
concerning the LMP1-K15 chimera, the six LMP1 transmembrane domains might either not 
allow correct insertion in the membrane that positions the K15 C-terminal domain in a 
manner that allows efficient signaling, or the LMP1 transmembrane domains might lack 
motifs that are crucial for the interaction of K15 with cellular proteins. Therefore, the K15 
transmembrane domains seem to play a crucial role in efficient K15 signal transduction. 
 
Choi et al. (2000a) found that a CD8-K15 chimeric protein could inhibit B-cell receptor 
initiated signaling in the B-cell line BJAB, but was unable to initiate Ca++ mobilization after 
cross-linking with an antibody to CD8. Although we did not examine Ca++ mobilization as a 
consequence of K15-initiated signaling, we think that it is possible that the CD8-K15 
chimeric protein used by Choi et al. (2000a) may have been unable to trigger Ca++ 
mobilization due to the absence of the K15 transmembrane domains. Chimeric proteins 
composed of CD8 fused to the cytoplasmic domains of K1 or R1 are both able to elicit 
intracellular Ca++ mobilisation as well as cellular tyrosine phosphorylation upon treatment 
with an antibody to CD8 (Lee et al., 1998b, Damania et al., 2000a). An explanation could be 
that these chimeras more likely reflect the natural situation, since K1 and R1 both contain one 
transmembrane domain as the CD8 receptor, and not 12 transmembrane domains as K15. 
 
Another study identified Hax-1 as an interaction partner of K15 (Sharp et al., 2002, see 
1.3.6), but the role of this interaction is not clear. Interestingly, Hax-1 was first identified as a 
protein that associates with hemopoietic specific protein 1 (Hs1) (Suzuki et al., 1997), which 
is thought to play a role in signal transduction in B-cells. Upon BCR crosslinking, Hs1 is one 
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of the earliest proteins to be tyrosine phosphorylated by Syk and Lyn (Ruzzene et al., 1996). 
Following phosphorylation, Hs1 translocates to the nucleus and induces apoptosis 
(Yamanashi et al., 1997). However, whether K15 has a role in BCR signal transduction, 
which involves the Ras/MAPK pathway, is not clear, but it would be reminiscent of the EBV 
LMP2A protein, which is known to inhibit BCR signal transduction in EBV infected LCLs 
(see 1.3.1.2), or the Tip protein that may mediate TCR downregulation (Park et al., 2003), as 
well as K1 that downregulates BCR surface expression (Lee et al., 2000). Furthermore, 
cellular effector molecules such as the adapter protein Nck and the serine/threonine kinase 
PKC, which play a role in BCR signal transduction, were identified as putative interaction 
partners of K15 (see table 3), but whether K15 interacts with Nck via its Y481EEV motif or is 
phosphorylated by PKC at T404 as predicted has not been addressed in this study. 
 
Lipid rafts serve as signaling platforms in cellular membranes that can incorporate and 
recruit membrane-associated molecules required for the assembly of signaling cascades 
(reviewed in Simons & Toomre 2000). We therefore examined whether the longest K15 
isoform (which is capable of inducing intracellular signaling) differed from the smaller 
isoforms and the LMP1-K15 chimera (which are not capable of inducing intracellular 
signaling) with respect to their incorporation into lipid rafts. We found that at least the 
isoform K15 ex1/6-8, which contains the complete first exon, appeared to be incorporated into 
lipid rafts to roughly the same extent as the longest K15 isoform (figure 13 A). Therefore, 
sequences encoded by K15 exons 2-5 may contribute to intracellular signaling by providing 
sites for post-translational modification, by interacting with other intracellular components or 
be crucial for correct membrane insertion. 
The LMP1-K15 chimeric protein was incorporated into lipid rafts (figure 13 D) as was 
described for wildtype LMP1 (see 1.3.1.1), indicating that incorporation into lipid rafts was 
not responsible for the fact that the LMP1-K15 chimera differed in the ability to initiate 
intracellular signaling compared to the K15 ex1-8 isoform. The notion that lipid raft 
association is not sufficient for efficient signaling is further supported by data obtained by 
Kaykas et al. (2001). When they targeted the LMP1 C-terminal domain to lipid rafts by 
tagging it with the 10 aa myristoylation sequence from the Yes Src family PTK, this molecule 
activated NF-κB less efficiently than full length LMP1. 
In contrast to the K15 ex1-8 and K15 ex1/6-8 isoforms, the 34 and 26 kDa proteins derived 
from splice variants K15 ex1 as/6-8 and K15 ex1 as/4-8, which show an alternative start 
codon and splice donor in exon 1 and therefore contain only 6 amino acids derived from the 
first exon in a different reading frame (figure 5), were not incorporated into lipid rafts (figure 
13 B and C). This might point to an important role of exon 1 for lipid raft targeting. As shown 
in table 3, the K15-P variant contains four potential caveolin-binding sites (exon 1: 
F6FWNLWLW, exon 3: W148IFFPISF, exon 6: F227LWCLYVW, W279CLYVWQSF; Couet et 
al., 1997). Splice variants K15 ex1 as/4-8 and K15 ex1 as/6-8 lack the potential caveolin-1-
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binding site in exon 1 due to the use of a different reading frame in exon 1 (M1ALGPT6 
compared to M1KTLIF6FWNLWLW……PSSWHLGII72 for K15 ex1-8 and K15 ex1/6-8). 
Further, the protein derived from the recombinant K15 ex6-8 construct, which lacks the 
putative caveolin-binding sites in exon 1, 3 and 6, did not localise to lipid rafts as well. 
Notably, the K15-M variant also contains a potential caveolin-binding site in exon 1 
(Y3KKYLWGTW). Analysis of the cellular localisation of the protein derived from the K15 
transcript identified by RT-PCR in Jsc-1 cells encoding the alternative 6 aa in exon 1 
followed by exons 2-8 (figure 29) might reveal whether the caveolin-binding motif in exon 1 
plays a role in lipid raft targeting. 
 
Caveolin-1 is a major component of caveolae, which appear as rounded plasma membrane 
invaginations of 50-80 nm in diameter. The lipid composition of caveolae corresponds to that 
of lipid rafts, i.e. caveolae are rich in cholesterol and sphingolipids (reviewed in Simons & 
Toomre 2000, Brown & London 1998). Caveolae seem to be used by cells to internalize 
membrane components that are enriched in rafts. In Ptk2 cells transiently expressing full 
length K15 and GFP-tagged Caveolin-1, we did not observe co-localisation of these two 
proteins by immunofluorescence microscopy (figure 17 I). This may have several reasons: (i) 
K15 expression in co-transfected cells was very low, and only very few cells were found 
positive for expression of both proteins. (ii) The GFP protein fused to Caveolin-1 may 
influence the intercation between the two proteins. To overcome these limitations, the 
subcellular localisation could be determined with an antibody to endogenous Caveolin-1. 
However, in order to further address the possible interaction of K15 with Caveolin-1, co-
immunoprecipitation experiments will be performed. 
 
The LMP1 transmembrane domains, as well as those of LMP2A, do not show a region 
reminiscent of a putative caveolin-binding site. Both, LMP1 and LMP2A, have been shown to 
be palmitoylated, but palmitoylation was not crucial for lipid raft localisation of LMP1 and 
LMP2A or signaling activity of LMP1 (Higuchi et al., 2001). It has been shown that the first 
two transmembrane domains of LMP1 are sufficient for lipid raft association, but they do 
support NF-κB signaling less potently compared to wildtype LMP1 (Coffin et al., 2003). 
Gurezka et al. (1999) have found that proteins with clusters within their membrane spanning 
domains similar to the sequence LLXXLLXLLXXLLXL can self assemble and identified 
LMP1 to have this “leucine” pattern. Substitutions of leucines in the LMP1 leucine-motif 
yields a derivative which forms multimeres as wildtype LMP1, but cannot activate the NF-κB 
transcription factor (Kaykas et al., 2002). This provides further evidence for the crucial role of 
transmembrane domains in signaling. However, K15 does not show such a leucine motif as 
LMP1 in its transmembrane domains. 
However, our immunofluorescence microscopy studies with the LMP1-K15 chimera 
showed a distribution pattern different from wildtype LMP1 (compare figures 15 A and C). 
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Whereas LMP1 showed a punctate expression pattern distributed over the entire cell, similar 
to K15 ex1-8 (figure 14 A), the LMP1-K15 chimera partially formed distinct patches in the 
plasma membrane similar to Caveolin-1-GFP (figure 14 C), localised to the ER and a 
perinuclear region. The patches in the plasma membrane observed with LMP1-K15 and 
Caveolin-1 are reminiscent of clustered lipid rafts. Lipid rafts can be visualised with 
fluorescently labeled cholera toxin B subunit, that binds glycosphingolipids, which then is 
cross-linked into distinct patches with anti-cholera toxin B subunit antibody (Janes et al., 
1999). With this method we will further address the subcellular localisation of LMP1, LMP1-
K15 and K15 ex1-8 by immunofluorescence microscopy. 
 
Coffin et al. (2003) further showed that LMP1 chimeric proteins composed of either the first 
and second or the fifth and sixth transmembrane domain fused to the cytoplasmic domain 
were not able to bind to TRAFs. TRAFs are crucial effectors molecules for LMP1 signaling 
(see figure 35). We have shown binding of TRAFs -1, -2 and -3 to the C-terminal domain of 
K15 fused to the six transmembrane domains of LMP1 (Brinkmann et al., 2003), but have not 
proven yet whether K15 ex1-8 and K15 splice variants interacted with TRAFs. If the K15 
splice variants were not able to interact with TRAFs, this may in part explain their impaired 
signaling capabilities. However, since the LMP1-K15 chimera was impaired in signaling 
compared to full length K15 (figures 21 and 22). TRAF binding seems not to be the only 
factor critical for efficient signaling. One interesting aspect for future experiments would be 
to identify further interaction partners of K15, with focus on its membrane domains or loop 
regions. Since K15 localises to lipid rafts, co-immunoprecipitations could be performed from 
lipid raft fractions containing the K15 ex1-8 protein. LMP1 expression for example results in 
the recruitment of TRAF-3 to lipid rafts, but not of TRAF-1 and -2 (Higuchi et al., 2001, 
Kaykas et al., 2001). 
 
When fused to the cytoplasmic domain of the CD40 receptor, the N-terminus and six 
transmembrane domains of LMP1 could mediate constitutive signaling of this chimeric 
protein in the absence of CD40 ligand (Floettmann & Rowe 1997, Gires et al., 1997, 
Hatzivassiliou et al., 1998). Interestingly, constitutive signaling of the KSHV K1 protein is 
attributed to its extracellular domain, since this domain can mediate constitutive signaling 
when transferred to other cytoplasmic domains containing an ITAM motif (Lagunoff et al., 
1999). It would be of interest whether the K15 transmembrane domains would also be able to 
mediate constitutive signaling when fused to cytoplasmic domains involved in signaling, as 
for example to that of the CD40 receptor which induces NF-κB and binds TRAFs (see 
1.3.1.1). 
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Figure 35: LMP1 signal transduction. The EBV LMP1 oncoprotein activates the NF-κB transcription factor 
via the canonical and non-canonical pathway. In addition, LMP1 activates the AP-1 transcription factor via 
MAPKs JNK1 and p38. TRADD and TRAFs are key effectors and mediators of LMP1 signaling. For details see 
1.3.1.1. 
Is there a functional role for the smaller K15 isoforms? The study by Choi et al. (2000a) 
suggests that a signaling-inactive K15 variant could inhibit intracellular signaling pathways. It 
is therefore conceivable that the smaller K15 isoforms may play a role in modulating the 
effect of the 8-exon isoform on the activation of the pathways reported here. This would 
represent a parallel to the presumed role of the LMP2 splice variant LMP2B, which is devoid 
of the amino-terminal intracellular domain of LMP2A, but could modify LMP2A-induced 
signaling by affecting the clustering of LMP2A molecules in the cell membrane (see 1.3.1.2). 
Another parallel comes from studies with lytic LMP1, which is expressed during the late lytic 
viral life cycle. Lytic LMP1 encodes the C-terminal 258 aa of LMP1 and thus is comprised of 
TMs 5 and 6 and the cytoplasmic domain (Hudson et al., 1985). This lytic form of LMP1, as 
well as an LMP1 mutant lacking the N-terminal 25 aa (Rothenberger et al., 2002, Brennan et 
al., 2001), have a dominant negative effect on full length LMP1 signaling. Lytic LMP1, 
which neither binds TRAFs nor shows signaling activity (Baichwal & Sugden 1989, Erickson 
& Martin 2000, Huen et al., 1995, Mitchell & Sugden 1995, Wang et al. 1988a, b), inhibits 
NF-κB and JNK1 signaling by full length LMP1 when the two isoforms are coexpressed 
(Erickson & Martin 1997, 2000). 
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Lytic LMP1 protein does not form patches as full length LMP1, but shows a diffuse staining 
pattern and localises to intracellular membranes in B-cells, and does not localise to lipid rafts 
(Wang et al., 1988a, b, Higuchi et al., 2001). This is reminiscent of splice variant K15 ex1 
as/4-8 (figure 16 A), which showed an immunostaining very different from splice variant K15 
ex1/6-8 (figure 16 E) or full length K15 ex1-8 (figure 14 A). We are currently collecting 
reagents to perform co-localisation studies to further elucidate the subcellular localisation of 
splice variant K15 ex1 as/4-8. Interestingly, lytic LMP1 was reported to localise to 
extracellular EBV virions (Erickson & Martin 1997), and also in intracellular enveloped 
virions (Vazirabadi et al., 2003) which would suggest a possible role in virus assembly. So 
far, we have not systematically analysed KSHV virions for the presence of K15 protein. 
 
RT-PCR studies on PEL cell lines (Glenn et al., 1999, Choi et al., 2000a) suggest that the 
transcript encoding the longest K15 isoform is more strongly expressed than those for the 
smaller isoforms. This is confirmed by our RT-PCR experiments on the Jsc-1 cell line (figure 
29), although we also found abundant incompletely spliced transcripts whose translation and 
functional importance (if any) remains to be studied. A recent report (Sharp et al., 2002) 
attributed the presence of an approximately 23 kDa K15-derived protein in PEL cell lines to 
internal proteolytic processing of the ~45 kDa (exon 1-8) K15 precursor protein (see 1.3.6). 
We have seen proteins of a similar size in PEL cells which were not associated with cellular 
membranes in contrast to the 21 kDa proteins translated from splice variants K15 ex1 as/4-8 
and K15 ex1 as/6-8, that have been shown to associate with lipid rafts (figure 13 B and C). 
Whether the balance in virus-infected cells is therefore in favour of the 45 kDa ‘activating’ 
K15 protein, or in favour of the smaller ‘non-activating’ forms, is currently unclear and may 
be difficult to predict from the relative abundance of individual transcripts. 
 
We have shown in this study that the full length K15 isoform, K15 ex1-8, activates the AP-1 
transcription factor via the classical Ras-Raf-MEK-Erk pathway, via the MAPK JNK1 but not 
via MAPK p38 (summarised in figure 36). In this respect, K15 resembles LMP2A which has 
recently been reported to activate Erk2 and JNK1, but not p38, when stably expressed in 293 
cells (Chen et al., 2002), although others have not seen an activation of Ras/MAPK by 
LMP2A in epithelial cells (Scholle et al., 2000). We have clearly shown that K15 induces the 
activity of the MAPK Erk2 via Ras, Raf-1 and MEK1/2 by using dominant negative mutants 
and chemical inhibitors, and that TRAF-2 seems to play a role possibly by linking K15 
signaling to the Ras-Raf-MEK1/2 cascade. It has not been shown yet which cellular effector 
molecules link LMP2A signaling to Erk2. 
One effect of stably expressed LMP2A in 293 cells was increased stability of c-jun (Chen et 
al., 2002). We found a moderately increased JNK1 activity following transfection of K15 in in 
vitro kinase assays (figure 23), but have not investigated whether K15 expression resulted in 
increased c-jun stability in vivo. It remains a possibility that the activation of the JNK1 
pathway by K15 occurs indirectly, perhaps as a consequence of the activation of other 
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pathways, such as Ras/MAPK. Our preliminary studies on cDNA arrays also indicate that the 
expression of c-jun might be increased at the transcriptional level following K15 transfection 
(not shown). There may therefore be multiple routes for LMP2A and K15 to increase the 
activity of the JNK/c-jun pathway, which would contribute to the increased activity of the AP-
1 transcription factor following K15 expression, as reported here. Gene array studies of 
different LMP2A expressing cell systems indicate that LMP2A has multiple effects on global 
cellular gene expression (Portis et al., 2003, Portis & Longnecker 2003). K15 gene arrays are 
planned. 
It is a contentious issue whether LMP1 activates the MAPK Erk1/2. One group found that 
LMP1 activated Erk1/2 by Ras in Rat-1 fibroblasts, and a dominant negative Ras mutant was 
able to impair the ability of LMP1 to induce transformation (Roberts & Cooper 1998). 
However, Erk2 activation by LMP1 in 293 epithelial cells was not observed by us (not 
shown) and others (Kieser et al., 1997). The Herpesvirus saimiri oncoprotein StpC directly 
interacts with cellular Ras and activates the Ras signaling pathway, which seems to be an 
important factor for the oncogenecity of the StpC protein (Jung & Desrosiers 1994, 1995, Guo 
et al., 1998). Furthermore, the K1 protein was shown to activate the AP-1 transcription factor 
via Ras (Lagunoff et al., 2001). 
 
Since the two KSHV terminal membrane proteins K1 and K15 are both expressed during 
the lytic viral life cycle at the transcript level, we wondered whether these two viral proteins 
would co-localise. Initial experiments with Ptk2 cells transiently expressing K1 and K15 
showed significant co-localisation (figure 17 C). This is reminiscent of the EBV LMP1 and 
LMP2A (but not LMP2B) proteins that co-localise in latently EBV infected B lymphocytes 
(Longnecker et al., 1991, Longnecker & Kieff 1990). Interestingly, LMP2A (but not LMP2B) 
seems to augment signaling of LMP1 by prolonging its half-life (Dawson et al., 2001). 
However, the co-localisation studies with K1 and K15 need to be extended to cell types more 
relevant for KSHV, as for example human epithelial cells, B-cells or endothelial cells. 
 
K15 shares several features with the LMP1 protein regarding its signaling activity (see 
figures 35 and 36). The NF-κB transcription factor plays a key role in the oncogenic potential 
of LMP1, and is activated by LMP1 via the canonical and, as recently described, the non-
canonical pathway (see 1.3.1.1 and figure 35). We have shown that K15 was an inducer of the 
NF-κB pathway, less potent than LMP1, but have not yet analysed the pathway K15 uses to 
activate NF-κB. Viral TMPs K1 (KSHV), Tip (HVS), and StpC (HVS) have also been shown 
to activate NF-κB in some cell systems (see table 1 and figure 6). As mentioned in 1.3.1.1, the 
activation of the NF-κB transcription factor does not seem to be the only factor crucial for the 
transforming activities of the LMP1 oncoprotein. TRAF-2, which plays a major role in LMP1 
signaling to NF-κB, was also shown to be the key mediator of LMP1 signaling to the MAPKs 
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p38 and JNK1 together with TRAF-1 and TRAF-6 (Kaye et al., 1996, Eliopoulos & Young 
1998, Kieser et al., 1999). 
Our results suggest an involvement of TRAF-2 in the K15-induced activation of the 
Ras/MAPK pathway, since a dominant negative TRAF-2 mutant inhibited the activity of Erk2 
and AP-1 in K15-transfected cells (figures 24 and 25). We observed weak binding of TRAF-2 
to the cytoplasmic domain of K15, which was abolished by deleting the last 17 aa including 
the Y481EEV motif, as well as the sequence ATQPTDD which appears distantly related to the 
TRAF binding consensus site PxQxS/T (residues identical with the CTAR1 of LMP1 are 
underlined) (Brinkmann et al., 2003, see figure 36). Interaction of K15 with TRAF-1 and -3 
seems to occur through a more membrane-proximal region of K15 (Brinkmann et al., 2003, 
see figure 36). LMP1 binds TRAF-2 indirectly via its CTAR-2 region, most probably via the 
TRADD protein (figure 35), and it is possible that the interaction of the K15 cytoplasmic 
domain with TRAF-2 occurs in an indirect manner. Experiments with a dominant negative 
TRAF-2 mutant have shown that TRAF-2 is involved in NF-κB signaling of the StpC protein 
in Rat-1 fibroblasts (Lee et al., 1999). Interestingly, despite being capable of binding to 
TRAFs, the StpA and StpB proteins of HVS strain A and B are not activating NF-κB (Lee et 
al., 1999, Choi et al., 2000b), which may explain their reduced oncogenic potential compared 
to StpC. 
As depicted in figure 35, the effect on the MAPKs p38 and JNK1 by LMP1 also involves 
TRAF-6 downstream of TRAF-2 (Schultheiss et al., 1999), and TRAF-6 has recently been 
shown to be involved in the IL-1 induced activation of p38/MAPK via Ras (McDermott & 
O´Neill 2002) and in the CD40-induced activation of Erk via a Ras-independent pathway 
(Kashiwada et al., 1998). However, K15-induced AP-1 activity was not affected by co-
expressing a dominant-negative TRAF-6 mutant (figure 25), suggesting that other cellular 
factors may link the cytoplasmic domain of K15, phosphorylated on Y481, to the activation of 
the Ras/MAPK pathway. This issue, and the identity of cellular and viral genes affected by 
K15-induced Ras/MAPK activation, is currently under investigation. 
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Figure 36: K15 signal transduction. The full length K15 protein, composed of up to 12 transmembrane 
domains, localised to the plasma membrane and intracellular membranes, as well as to lipid rafts. K15 splice 
variants were shown not to be able to activate the NF-κB and AP-1 pathway as full length K15 did via MAPKs 
Erk2 and JNK1. K15 was shown to interact with and to be phosphorylated at Y481 by members of the Src kinase 
family of non-receptor tyrosine kinases (PTKs). 
Transient expression in cos7, 293-T or Vero cells of the K15 ex1-8 expression construct 
gave rise to a major protein of ~45 kDa, and two minor protein species of 34 and 23 kDa 
(figure 10 A). Sharp et al. (2002) described strongly expressed proteins of 35 and 23 kDa and 
a weakly expressed 50 kDa protein derived from a K15 ex1-8 construct and suggested that the 
smaller proteins were derived by cleavage from the 50 kDa precursor protein. However, we 
believe that the smaller proteins were derived from internal initiation at in frame ATG codons 
in exon 4 or exon 6 (figure 10 C). In 293 cells transiently transfected with K15, Sharp et al. 
(2002) observed a cytoplasmic and strong perinuclear immunolabelling pattern, which differs 
from the immunolabelling we observed with our K15 ex1-8 expression construct (figure 14 
A). Since the 23 kDa protein derived from K15 ex6-8, which initiates at the in frame ATG 
codon in exon 6, did not localise to lipid rafts (figure 12 B) and showed an immunolabelling 
that differed from the full length K15 ex1-8 protein (figure 16 C and D), we postulate that the 
subcellular localisation of K15 observed by Sharp et al. (2002) by microscopy does not 
correspond to the 45/50 kDa protein, but rather to the 34 and 23 kDa proteins. This is further 
supported by the observation by Sharp et al. (2002) who described ER localisation of K15 in 
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Hela cells treated with the ER dye DiOC6. In our hands, the K15 ex1-8 protein did clearly not 
colocalise with the ER marker protein Calnexin (figure 17 D-F). 
The role of the two smaller proteins derived from K15 ex1-8 (34 and 23 kDa) is not yet 
clear. Both proteins were membrane associated, but did not localise to lipid rafts (data not 
shown). Whether they could act as dominant negative K15 forms, as already discussed for the 
K15 splice isoforms, was not investigated. 
 
In summary, we have shown that the K15 ORF of KSHV encoded a protein of 45 kDa that 
associated with the cellular plasma membrane, intracellular membranes and lipid rafts, and 
showed signaling activities reminiscent of its positional equivalent in the EBV genome 
LMP2A, as well as of terminal membrane proteins K1 of KSHV, LMP1 of EBV, StpA, B and 
C and Tip of HVS, R1 of RRV and Tio of HVA. Remarkably, although LMP2A, the two K15 
variants K15-P and K15-M, and the putative R15 protein share only little amino acid identity, 
they show striking structural similarities. Comparative studies between these “right end side” 
terminal membrane proteins may help to further understand their role in viral infection. 
4.2 K15 in vivo expression and the viral lytic life cycle 
In vivo expression of K15 
RT-PCR studies indicate that K15 may be expressed during the latent viral life cycle, but 
K15 transcripts are clearly upregulated upon TPA induction, which is a characteristic for lytic 
genes (Glenn et al., 1999, Choi et al., 2000a). In addition, gene array studies indicate that K15 
is predominantly expressed during the lytic cycle in PEL cell lines upon TPA induction 
(Paulose-Murphy et al., 2001) or ectopic expression of the viral lytic switch protein RTA 
(Nakamura et al., 2003). 
We detected a protein of 23 kDa in latently infected PEL cell lines with a polyclonal K15 
antibody raised against the cytoplasmic domain of K15 (figure 27), and its expression was 
found to be slightly upregulated after lytic cycle induction with TPA, which would 
correspond to the RT-PCR data. However, when we characterised the 23 kDa protein by 
cellular fractionation, it was found to localise to the cytosolic fraction (figure 28). In contrast 
to our data, expression of the 23 kDa protein observed by Sharp et al. (2002) in the latently 
infected PEL cell line Jsc-1 decreased upon TPA treatment. According to Sharp et al. (2002), 
immunolabelling of Jsc-1 cells with a monoclonal antibody raised against the K15 C-terminus 
showed a cytoplasmic staining pattern, which supports our observation that the 23 kDa 
protein in Jsc-1 cells probably is a soluble protein. The LMP1 protein can be cleaved near the 
beginning of the C-terminal cytoplasmic domain at leucine residue L242, which results in a 
soluble C-terminal domain of 25 kDa (Moorthy & Thorley-Lawson 1990, 1993b). However, 
when we analysed an expression construct encompassing the cytoplasmic domain of K15 by 
Western blotting, this protein clearly migrated faster than the 23 kDa Jsc-1 protein (figure 28). 
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In some latently infected Burkitt´s lymphoma cells, LMP1 expression can be induced during 
the lytic phase (Laux et al., 1988, Boos et al., 1987). The promoter for full length LMP1 
expression in lytic infection has not been characterized, but in late lytic infection, a promoter 
in the third exon drives transcription of an alternative LMP1 transcript encoding the last two 
transmembrane domains and the C-terminal cytoplasmic domain (Hudson et al., 1985). This 
smaller protein (lytic LMP1) localises to cytoplasmic membranes but does not patch and is 
not transforming (Mann et al., 1985, Liebowitz et al., 1987, 1992). In theory, the 23 kDa K15 
protein in Jsc-1 cells may be derived from alternative splice events that have not been 
characterised so far. Regarding the multiple splicing events described so far for ORF K15 
(Glenn et al., 1999, Choi et al., 2000a, figures 5 and 29), further alternative splicing events 
could potentially result in a protein with low hydrophobicity, although we could not identify 
such a transcript (figure 29). 
 
The most prominent transcript identified in this work and by Glenn et al. (1999), Choi et al. 
(2000a) and Poole et al. (1999) in PEL cell lines Jsc-1, BCP-1 and BCBL-1 was completely 
spliced and contained all exons, which gave rise to a major protein of 45 kDa when transiently 
expressed in cos7, 293-T or Vero cells (figure 10 A). We did not detect a protein of this size 
in PEL cell lines (figure 27) or endothelial cell lines T24 rKSHV.152, DU145 rKSHV.152 or 
Vero rKSHV.219 (figure 30) with our polyclonal or monoclonal K15 antibodies. This may be 
due to low in vivo expression or a short half life of the 45 kDa K15 protein. The EBV 
LMP2A protein interacts with members of the Nedd4-like ubiquitin protein ligase family via 
the two PPPPY motifs of its cytoplasmic domain (see 1.3.1.2). This interaction results in 
ubiquitination and degradation of LMP2A and LMP2A-associated proteins such as Lyn and 
Syk (Longnecker et al., 2000, Ikeda et al., 2000, 2001, 2002, Winberg et al., 2000). Although 
K15 contains a proline rich motif in its cytoplasmic domain (PP387PLPP, table 3, figure 18) 
similar to those of LMP2A, these do not correspond to the PPY consensus of Nedd4 binding 
proteins, and a function of this K15 motif has not been adressed yet. 
 
The regulation of K15 gene expression is not well understood, but we have evidence that the 
K15 promoter is located within the terminal repeat (TR) region based on primer extension 
analysis (L. Rainbow, personal communication). When one subunit of the terminal repeat 
region (803 bp) was cloned upstream of a luciferase gene in a vector lacking promoter 
elements, this element showed strong promoter activity (A. Tittel, diploma thesis). The 
latency-associated antigen 1 (LANA-1) of KSHV is expressed during latency and tethers viral 
episomes to host chromatin by binding to two motifs of 16 nucleotides within the terminal 
repeat subunits (LANA binding sites 1 and 2) via its C-terminus, and to heterochromatin via 
its N-terminus (reviewed in Viejo-Borbolla & Schulz 2003). Lana-1 has been shown to 
function as a transcriptional repressor as well as transactivator (see 1.2, latent replication). 
When Lana-1 was co-expressed with the TR reporter plasmid, the promoter activity of the TR 
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was significantly downregulated (A. Tittel, diploma thesis). Hence, during the latent viral life 
cycle, LANA-1 might repress K15 gene expression, but this needs further investigation. 
 
KSHV infection of primary human B-cells in vitro has been reported by one group (Kliche 
et al., 1998), but another group reported that de novo infection of human B-cells such as Raji 
(EBV positive, KSHV negative) with KSHV obtained from induced PEL cell lines failed 
(Bechtel et al., 2003). Our attempts to de novo infect the human B-cell lines BJAB and Raji 
and the PEL cell line BCBL-1 with recombinant rKSHV.219 did not succeed. In contrast, we 
could de novo infect human epithelial cell lines 293 and 293-T as well as the African green 
monkey epithelial cell line Vero with rKSHV.219 (figure 31 B). 
When we analysed the expression of K15 after de novo infection of 293-T cells with 
rKSHV.219, we detected K15 transcripts by RT-PCR at timepoints 24, 48 and 72 h post 
infection (figure 32 B). However, K15 protein was not detected in 293-T lysates collected at 
24, 48 and 72 h post infection with our polyclonal K15 antibody by Western blotting (figure 
32 C), suggesting that K15 protein is expressed at levels too low to be detected with our 
antibody. 
 
The present study is the first documenting K15 gene expression after de novo infection with 
recombinant KSHV.219 of human epithelial cells. A very recent study investigated the 
expression kinetics of KSHV genes immediately after primary KSHV infection of primary 
human dermal microvascular endothelial (HMVEC-d) and human foreskin fibroblast (HFF) 
cells by real time RT-PCR and whole genome array (Krishnan et al., 2004). 
Upon entry into the in vitro target cells, members of α-, β-, and γ-herpesviruses have been 
shown to enter the lytic replicative cycle, which is characterised by a cascade of gene 
expression (reviewed in Kieff & Rickinson 2002, Mocarski & Courcelle 2002, Roizman & 
Knipe 2002 and Roizman & Pellett 2002). Unlike many members of α-, β-, and γ-
herpesviruseses, lytic γ1-herpesvirus EBV replication has not been demonstrated during in 
vitro infection of susceptible primary human B-cells. Instead, EBV establishes a latent 
infection in these cells, resulting in the transformation and establishment of LCLs (see 1.3.1). 
Like EBV, KSHV has so far not been shown to initiate a lytic gene expression cascade and 
formation of progeny virus from the input KSHV in vitro, but KSHV establishes a latent 
infection in many in vitro systems and lytic replication can be supported by activation with 
TPA or the lytic switch protein ORF50/RTA. 
KSHV gene expression analyses by whole genome arrays published so far were conducted 
with latently infected B-cells and lytic gene expression was induced with RTA or TPA 
(Paulose-Murphy et al., 2001, Nakamura et al., 2003). The study by Krishnan et al. (2004) is 
the first that adresses KSHV gene expression following a primary infection of target cells. 
They have shown that early during infection (2 h p.i.), KSHV expresses the lytic ORF50/RTA 
gene and the latent ORF73/LANA-1 gene concurrently, with ORF50 expression rapidly 
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declining 24 h p.i. and ORF73 expression being maintained up to 120 h p.i.. In addition, they 
found a limited number of lytic genes being expressed immediately after infection, most of 
which decline sharply or were undetectable during the course of infection (8 h p.i. in 
HMVEC-d, 24 h p.i. in HFF). The study by Krishnan et al. (2004) suggests that lytic gene 
expression of KSHV is initiated soon after the infection, but this initial lytic activation is not 
enough to proceed to a complete lytic replication and progeny virus development. 
According to their gene array data, K15 did not belong to the lytic genes expressed after de 
novo infection. Notably, K15 expression was analysed by whole genome array and not by 
RT-PCR as in our study, and they analysed K15 expression at timepoints 2 h and 8 h post 
infection for HMVEC-d and 8 and 24 h p.i. for HFF cells, whereas we analysed K15 
expression at timepoints 24, 48 and 72 h post infection. Hence, Krishnan et al. (2004) looked 
for K15 transcripts at earlier timepoints. Furthermore, they used KSHV prepared from TPA-
induced BCBL-1 cells, whereas we used recombinant KSHV.219 obtained from the Vero 
rKSHV.219 cell line induced with n-butyrate and Baculovirus ORF50/RTA for our infection 
studies. Notably, early during infection, lytic KSHV genes were found to be expressed that 
have a role in immune modulation and have an anti-apoptotic function (Krishnan et al., 2004). 
This observation together with our results that K15 was expressed during de novo infection 
might point at a hypothetical immunmodulatory or anti-apoptotic function for K15. 
K15 and the lytic viral life cycle 
What might be the role of K15 signaling during KSHV infection? K15 does not seem to 
have oncogenic properties (unpublished results) as viral TMPs LMP1, K1, R1, Stp and Tip. 
Studies on EBV gene regulation have defined several AP-1 binding elements in various EBV 
lytic gene promoters. These AP-1 elements respond to both AP-1 and the EBV transactivator 
ZTA and therefore play important roles in the regulation of these promoters (Lieberman et al., 
1990). We have shown in this study that K15 activated the AP-1 transcription factor via the 
Ras-Raf-MEK1/2-Erk2 signaling cascade involving TRAF-2, and have also shown that K15 
can activate the MAPK JNK1. Further, we showed that K15 activated the promoter of the 
lytic switch protein ORF50/RTA, which contains several putative AP-1 binding sites (figure 
33 A). Luciferase reporter assays with dominant negative mutants of Ras, TRAF-2 and Erk2 
revealed that Ras and Erk2 and, to a lesser extent, TRAF-2 play a role in the activation of the 
ORF50 promoter by K15 (figure 33 B). TPA is thought to induce lytic gene expression in B-
cells by the induction of AP-1 activity via the Ras-Raf-MEK-Erk pathway and via JNK. We 
therefore asked whether K15 was also able to induce the viral lytic life cycle in vivo. 
In cells latently infected with KSHV, overexpression of RTA can activate the KSHV 
immediate early/early (K8, K5, K2, K12, Nut1, ORF6, K3) and late (K1, K8.1, ORF21) lytic 
cycle genes, either alone or in synergy with other viral regulatory genes such as K8 and 
ORF57 (Dourmishev et al., 2003, reviewed in Moore & Chang 2001, Sun et al., 1999, West & 
Wood 2003). Activation of the lytic cycle by RTA results in the production of virus progeny 
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(Bechtel et al., 2003, Dourmishev et al., 2003, West & Wood 2003, Sun et al., 1999). We 
could show that in an epithelial cell line infected with recombinant rKSHV.219, Vero 
rKSHV.219, the lytic viral life cycle could be induced by ectopic expression of RTA (figure 
31 A, 34 C) and infectious virus progeny was obtained as monitored by the appearance of 
GFP expressing 293, 293-T or Vero cells 48 hours after de novo infection with rKSHV.219 
(figure 31 B). Addition of n-butyrate further enhanced the induction of the lytic cycle in Vero 
rKSHV.219 cells as monitored by expression of RFP and the late lytic K8.1 protein (figure 34 
D). 
The major mechanism by which n-butyrate as well as trichostatin A are thought to activate 
viral lytic gene expression is by blocking histone deacetylases. Acetylation of the N-terminal 
domain of histones (at lysine residues) tends to destabilise chromatin structure, which allows 
transcription to take place, whereas histone deacetylation decreases the accessibility of DNA 
in the affected chromatin. Hence, in the presence of n-butyrate, RTA and other transcription 
factors involved in lytic gene expression may better access viral DNA to initiate transcription. 
This would be reminiscent of the immediate early protein IE86 of human cytomegalovirus 
that activates viral early gene expression by directly interacting with histone 
acetyltransferases (Bryant et al., 2000). 
 
When we transiently expressed the K15 ex1-8 expression construct in Vero rKSHV.219 
cells, RFP expression was not observed (figure 34 B). Hence, although K15 was shown to 
activate the ORF50 promoter in luciferase reporter assays, it seemed not to enhance 
expression of ORF50/RTA of recombinant KSHV.219, which would subsequently drive lytic 
gene expression resulting in virus progeny production. Notably, Krishnan et al. (2004) 
observed high levels of ORF50/RTA expression soon after infection, but only a subset of 
ORF50/RTA target genes were activated during the early stage of infection, and these were 
not sustained at later times of infection. This implies that expression of ORF50/RTA alone is 
not sufficient to completely activate the lytic cycle during the early time of infection. 
Assuming that transiently expressed K15 does activate RTA expression in Vero rKSHV.219 
cells, posttranslational modifications of ORF50/RTA synthesized from the genome may 
potentially differ from the ORF50/RTA provided in trans. Furthermore, host cell factors and 
other viral factors may influence the activation of the lytic life cycle such that K15 expression 
alone does not result in lytic cycle induction. The transcriptional transactivator protein ICP-4 
of herpes simplex virus type I undergoes multiple modifications including phosphorylation, 
poly-ADP ribosylation and nucleotidylation. Whether ORF50 undergoes such modifications 
has not been investigated so far. 
 
Furthermore, the KSHV genome, that is associated with host chromatin during latency, may 
be modified. Methylation is common among γ-herpesvirus genomes such as EBV and HVS 
(Karlin et al., 1994). Interestingly, the KSHV genome is not significantly methylated with the 
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exception of the ORF50 promoter region during latency (Chen et al., 2001). Hence, if K15 
was expressed and activated the AP-1 transcription factor, AP-1 could possibly not activate 
ORF50/RTA gene expression due to methylation of the promoter region in Vero rKSHV.219 
cells. The ORF50 promoter reporter plasmid may not be methylated due to non-methylation 
of plasmid DNA prepared in E. coli. The hypermethylated region of the ORF50 promoter 
region was found to be situated between base -315 and -255 (see figure 33) and demethylation 
was shown to be essential for ORF50 expression in vitro (Chen et al., 2001). Treatment of the 
PEL cell line BCBL-1 with 5´azacytidine, a DNA methyltransferase inhibitor that reduces the 
level of DNA methylation, induces the lytic viral life cycle and treatment of BCBL-1 cells 
with TPA resulted in demethylation of the ORF50 promoter (Chen et al., 2001). 
In order to show that methylation of the ORF50 promoter prevents K15 from activating 
ORF50 expression, Vero rKSHV.219 cells could be treated with 5´azacytidine and 
subsequently transfected with K15 ex1-8. Another approach would be a methylation cassette 
assay as described in Chen et al. (2001) and Robertson & Ambinder (1997), in which the 
ORF50 promoter can be in vitro methylated by a methylation enzyme. If K15 could not 
activate the in vitro methylated ORF50 promoter region in luciferase reporter assays (see 
figure 33 B), this could explain why we did not observe RFP expression in Vero rKSHV.219 
cells. 
Little is known about how RTA expression is triggered initially at the earliest stages after 
TPA induction. Treatment with TPA proved to significantly induce AP-1 DNA binding 
activity in EBV immortalised B-cells (Lieberman et al., 1990, Ruf & Rawlins 1995) and in 
KSHV positive PEL cells (Lee et al., 2002). Wang et al. (2004) recently found that co-
transfected c-jun plus c-Fos, both members of the AP-1 family, transactivated the KSHV 
RTA promoter in an AP-1 binding site-dependent manner. When they mutated the AP-1 site 
located at position -86 (see figure 33), they lost RTA promoter transactivation by the c-jun-c-
Fos heterodimer. Exogenously introduced c-jun plus c-Fos was shown to trigger endogenous 
RTA protein expression in PEL cells (Wang et al., 2004). We have shown that K15 ex1-8 
induced the MAP kinase JNK1. JNK1 is known to regulate c-jun activity through 
phosporylation, and we saw a slight upregulation of c-jun in 293-T cells expressing K15 in 
preliminary gene array experiments (not shown). We have not analysed yet whether K15 may 
induce RTA expression in PEL cells, but this will be an aspect to be analysed in the near 
future. 
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